
<html lang="en"     class="pb-page"  data-request-id="a7f12944-10b1-4c48-a7d0-85ee677c42b4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2013.56.issue-1;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm301511h"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Agonists of Cannabinoid Receptor 1 with Restricted Central Nervous System Penetration Aimed for Treatment of Gastroesophageal Reflux Disease" /></meta><meta name="dc.Creator" content="Alleyn T.  Plowright" /></meta><meta name="dc.Creator" content="Karolina  Nilsson" /></meta><meta name="dc.Creator" content="Madeleine  Antonsson" /></meta><meta name="dc.Creator" content="Kosrat  Amin" /></meta><meta name="dc.Creator" content="Johan  Broddefalk" /></meta><meta name="dc.Creator" content="Jörgen  Jensen" /></meta><meta name="dc.Creator" content="Anders  Lehmann" /></meta><meta name="dc.Creator" content="Shujuan  Jin" /></meta><meta name="dc.Creator" content="Stephane  St-Onge" /></meta><meta name="dc.Creator" content="Mirosław J.  Tomaszewski" /></meta><meta name="dc.Creator" content="Maxime  Tremblay" /></meta><meta name="dc.Creator" content="Christopher  Walpole" /></meta><meta name="dc.Creator" content="Zhongyong  Wei" /></meta><meta name="dc.Creator" content="Hua  Yang" /></meta><meta name="dc.Creator" content="Johan  Ulander" /></meta><meta name="dc.Description" content="Agonists of the cannabinoid receptor 1 (CB1) have been suggested as possible treatments for a range of medical disorders including gastroesophageal reflux disease (GERD). While centrally acting can..." /></meta><meta name="Description" content="Agonists of the cannabinoid receptor 1 (CB1) have been suggested as possible treatments for a range of medical disorders including gastroesophageal reflux disease (GERD). While centrally acting can..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 24, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm301511h" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm301511h" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm301511h" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm301511h" /></link>
        
    
    

<title>Discovery of Agonists of Cannabinoid Receptor 1 with Restricted Central Nervous System Penetration Aimed for Treatment of Gastroesophageal Reflux Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm301511h" /></meta><meta property="og:title" content="Discovery of Agonists of Cannabinoid Receptor 1 with Restricted Central Nervous System Penetration Aimed for Treatment of Gastroesophageal Reflux Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0015.jpeg" /></meta><meta property="og:description" content="Agonists of the cannabinoid receptor 1 (CB1) have been suggested as possible treatments for a range of medical disorders including gastroesophageal reflux disease (GERD). While centrally acting cannabinoid agonists are known to produce psychotropic effects, it has been suggested that the CB1 receptors in the periphery could play a significant role in reducing reflux. A moderately potent and highly lipophilic series of 2-aminobenzamides was identified through focused screening of GPCR libraries. Development of this series focused on improving potency and efficacy at the CB1 receptor, reducing lipophilicity and limiting the central nervous system (CNS) exposure while maintaining good oral absorption. Improvement of the series led to compounds having excellent potency at the CB1 receptor and high levels of agonism, good physical and pharmacokinetic properties, and low penetration into the CNS. A range of compounds demonstrated a dose-dependent inhibition of transient lower esophageal sphincter relaxations in a dog model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm301511h"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm301511h">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm301511h&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm301511h&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm301511h&amp;href=/doi/10.1021/jm301511h" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 220-240</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm301501k" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm301539x" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Agonists of Cannabinoid Receptor 1 with Restricted Central Nervous System Penetration Aimed for Treatment of Gastroesophageal Reflux Disease</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alleyn+T.++Plowright">Alleyn T. Plowright</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karolina++Nilsson">Karolina Nilsson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Madeleine++Antonsson">Madeleine Antonsson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kosrat++Amin">Kosrat Amin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Johan++Broddefalk">Johan Broddefalk</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%B6rgen++Jensen">Jörgen Jensen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anders++Lehmann">Anders Lehmann</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shujuan++Jin">Shujuan Jin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephane++St-Onge">Stephane St-Onge</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Miros%C5%82aw+J.++Tomaszewski">Mirosław J. Tomaszewski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maxime++Tremblay">Maxime Tremblay</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Walpole">Christopher Walpole</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhongyong++Wei">Zhongyong Wei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hua++Yang">Hua Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Johan++Ulander">Johan Ulander</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">AstraZeneca Research and Development, Pepparedsleden 1, Mölndal, 43183, Sweden</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">AstraZeneca Research and Development, 7171 Frederick-Banting, Saint-Laurent, Quebec, H4S 1Z9, Canada</span></div><div class="corresp-info"><strong>*</strong>Phone: +46 31 7761572. Fax: +44 31 7763868. E-mail: <a href="/cdn-cgi/l/email-protection#f7969b9b928e99d9879b9880859e909f83b796848385968d9299929496d994989a"><span class="__cf_email__" data-cfemail="99f8f5f5fce0f7b7e9f5f6eeebf0fef1edd9f8eaedebf8e3fcf7fcfaf8b7faf6f4">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm301511h&amp;href=/doi/10.1021%2Fjm301511h" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 220–240</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 10, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 October 2012</li><li><span class="item_label"><b>Published</b> online</span>24 December 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 January 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm301511h" title="DOI URL">https://doi.org/10.1021/jm301511h</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D220%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAlleyn%2BT.%2BPlowright%252C%2BKarolina%2BNilsson%252C%2BMadeleine%2BAntonsson%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D1%26contentID%3Djm301511h%26title%3DDiscovery%2Bof%2BAgonists%2Bof%2BCannabinoid%2BReceptor%2B1%2Bwith%2BRestricted%2BCentral%2BNervous%2BSystem%2BPenetration%2BAimed%2Bfor%2BTreatment%2Bof%2BGastroesophageal%2BReflux%2BDisease%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D240%26publicationDate%3DJanuary%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm301511h"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2256</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm301511h" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Agonists of Cannabinoid Receptor 1 with Restricted Central Nervous System Penetration Aimed for Treatment of Gastroesophageal Reflux Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Alleyn&quot;,&quot;last_name&quot;:&quot;T. Plowright&quot;},{&quot;first_name&quot;:&quot;Karolina&quot;,&quot;last_name&quot;:&quot;Nilsson&quot;},{&quot;first_name&quot;:&quot;Madeleine&quot;,&quot;last_name&quot;:&quot;Antonsson&quot;},{&quot;first_name&quot;:&quot;Kosrat&quot;,&quot;last_name&quot;:&quot;Amin&quot;},{&quot;first_name&quot;:&quot;Johan&quot;,&quot;last_name&quot;:&quot;Broddefalk&quot;},{&quot;first_name&quot;:&quot;Jörgen&quot;,&quot;last_name&quot;:&quot;Jensen&quot;},{&quot;first_name&quot;:&quot;Anders&quot;,&quot;last_name&quot;:&quot;Lehmann&quot;},{&quot;first_name&quot;:&quot;Shujuan&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Stephane&quot;,&quot;last_name&quot;:&quot;St-Onge&quot;},{&quot;first_name&quot;:&quot;Mirosław&quot;,&quot;last_name&quot;:&quot;J. Tomaszewski&quot;},{&quot;first_name&quot;:&quot;Maxime&quot;,&quot;last_name&quot;:&quot;Tremblay&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Walpole&quot;},{&quot;first_name&quot;:&quot;Zhongyong&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Hua&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Johan&quot;,&quot;last_name&quot;:&quot;Ulander&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;220-240&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm301511h&quot;},&quot;abstract&quot;:&quot;Agonists of the cannabinoid receptor 1 (CB1) have been suggested as possible treatments for a range of medical disorders including gastroesophageal reflux disease (GERD). While centrally acting cannabinoid agonists are known to produce psychotropic effects, it has been suggested that the CB1 receptors in the periphery could play a significant role in reducing reflux. A moderately potent and highly lipophilic series of 2-aminobenzamides was identified through focused screening of GPCR libraries. Development of this series focused on improving potency and efficacy at the CB1 receptor, reducing lipophilicity and limiting the central nervous system (CNS) exposure while maintaining good oral absorption. Improvement of the series led to compounds having excellent potency at the CB1 receptor and high levels of agonism, good physical and pharmacokinetic properties, and low penetration into the CNS. A range of compounds demonstrated a dose-dependent inhibition of transient lower esophageal sphincter relaxations in a d&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301511h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301511h" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301511h&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301511h" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301511h&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301511h" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm301511h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301511h&amp;href=/doi/10.1021/jm301511h" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm301511h" /></input><a href="/doi/pdf/10.1021/jm301511h" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm301511h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm301511h%26sid%3Dliteratum%253Aachs%26pmid%3D23227781%26genre%3Darticle%26aulast%3DPlowright%26date%3D2013%26atitle%3DDiscovery%2Bof%2BAgonists%2Bof%2BCannabinoid%2BReceptor%2B1%2Bwith%2BRestricted%2BCentral%2BNervous%2BSystem%2BPenetration%2BAimed%2Bfor%2BTreatment%2Bof%2BGastroesophageal%2BReflux%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D1%26spage%3D220%26epage%3D240%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292610" title="Antibiotic resistance">Antibiotic resistance</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=290703" title="Pyridines">Pyridines</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jmcmar.2013.56.issue-1/production/jmcmar.2013.56.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Agonists of the cannabinoid receptor 1 (CB1) have been suggested as possible treatments for a range of medical disorders including gastroesophageal reflux disease (GERD). While centrally acting cannabinoid agonists are known to produce psychotropic effects, it has been suggested that the CB1 receptors in the periphery could play a significant role in reducing reflux. A moderately potent and highly lipophilic series of 2-aminobenzamides was identified through focused screening of GPCR libraries. Development of this series focused on improving potency and efficacy at the CB1 receptor, reducing lipophilicity and limiting the central nervous system (CNS) exposure while maintaining good oral absorption. Improvement of the series led to compounds having excellent potency at the CB1 receptor and high levels of agonism, good physical and pharmacokinetic properties, and low penetration into the CNS. A range of compounds demonstrated a dose-dependent inhibition of transient lower esophageal sphincter relaxations in a dog model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04154" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04154" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The cannabinoid receptor 1 (CB1) is a GPCR that is located both in the central nervous system (CNS) and on peripheral neurons.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Activation of CB1 receptors reduces calcium flux through voltage dependent calcium channels, resulting in reduced neurotransmitter release. The endogenous ligand for the CB1 receptor, anandamide (<b>1</b>), has been shown to block the N-type calcium channel (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> As a consequence of these effects, agonists of the CB1 receptor have been suggested as possible medical treatments for a range of disorders including pain, inflammation, spasticity, neurodegenerative disorders, glaucoma, and gastroesophageal reflux disease (GERD).<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7 ref8 ref9">(3-9)</a> In healthy adults, the large majority of all reflux episodes results from transient lower esophageal sphincter relaxation (TLESR) and is hence the single most important motility event as a cause of reflux in all GERD patients.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> TLESRs are equally common in both healthy individuals and GERD patients. However, TLESRs in GERD patients are more frequently associated with acid reflux than those in healthy people. The centrally acting mixed CB1/cannabinoid receptor 2 (CB2) agonists, WIN 55,212-2 (<b>2</b>) and Δ<sup>9</sup>-tetrahydrocannabinol (<b>3</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), have been shown to dose-dependently inhibit TLESRs in dogs.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> Marinol, of which the active ingredient is <b>3</b>, has been shown to reduce TLESRs in healthy human volunteers.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The effect of <b>2</b> on TLESRs in dog could be reversed by the selective CB1 antagonist rimonabant<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> but not by the selective CB2 antagonist 5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-<i>N</i>-[(1<i>S</i>,2<i>S</i>,4<i>R</i>)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1<i>H</i>-pyrazole-3-carboxamide (SR144528),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> indicating that CB1 alone mediates the action of <b>2</b>, and thereby CB1 agonists rather than CB2 agonists were desired.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Although the exact location of CB1 receptors involved in the inhibition of TLESRs is still uncertain, it has been suggested that the CB1 receptors in the periphery could play a significant role.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Centrally acting CB1 receptor agonists are known to produce psychotropic events that are not a viable therapeutic option for GERD patients, and therefore, targeting CB1 receptors in the periphery would be required.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> While a number of cannabinoid ligands, particularly CB1 receptor antagonists, targeting peripheral restriction have recently been reported,<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16-19)</a> potent CB1 or CB1/CB2 agonists that combine low CNS penetration together with good physicochemical, pharmacokinetic, and in vivo efficacy characteristics are more scarce.<a onclick="showRef(event, 'ref5 ref20'); return false;" href="javascript:void(0);" class="ref ref5 ref20">(5, 20)</a></div><div class="NLM_p">Herein, a novel CB1 receptor agonist series is reported with high in vitro binding affinities and full agonism, good ligand lipophilicity efficiency (LLE)<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and physicochemical properties, and low ratios of unbound concentration of compound in brain versus plasma (<i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub>). Compounds in this series inhibit TLESRs in a dose dependent manner in an in vivo dog model.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of CB1 receptor agonists: anandamide (<b>1</b>), WIN 55,212-2 (<b>2</b>), and Δ<sup>9</sup>-tetrahydrocannabinol (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78551" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78551" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Design and Identification of the Hit Series</h3><div class="NLM_p">The driver for biological response is the concentration of the drug available to interact with the target receptor in the required effect compartments.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> In general, the amount of nonspecific binding differs between brain and plasma and the pharmacologically relevant ratio is the unbound brain-to-plasma concentration ratio <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub>.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> The brain is separated from the systemic circulation by the BBB and the blood cerebrospinal fluid barrier. The CNS endothelial cells differ from their peripheral counterparts by having tighter junctions, limited pinocytic transport, and no fenestrations.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The net permeation across the BBB is a combination between permeability and efflux properties, and any substance with a finite permeability can maintain asymmetry of unbound concentration only by active-transport. One of the more prominent efflux transporters is P-gp.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> P-gp transporters are expressed both in the BBB and in the gut, and it has been reported that most marketed CNS drugs are not PGP substrates.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The X-ray structure of apo P-gp has shed some light on putative mechanisms for P-gp mediated transport.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The crystal structure reveals a large flexible cavity of 6000 Å<sup>3</sup>, making structure-based attempts to model P-gp specificity highly challenging. In addition, P-gp is just one of several potential transporters. The transporter breast cancer resistance protein (BCRP) has been shown to have, along with P-gp, the highest expression in human brain microvessels.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Therefore, while one strategy in the present molecular design was to achieve a high level of efflux from the CNS, it was not confined only to P-gp mediation. The extent of efflux (efflux ratio) was measured using Caco-2 cells.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> P-gp and BCRP are both expressed in the Caco-2 cell line.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Brain exposure was described as the steady-state unbound brain-to-plasma concentration ratio <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> measured in rats where the compounds were administered as 4 h constant-rate intravenous infusions (both unbound and total ratios are reported on key compounds for comparison).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> shows the <i>C</i><sub>br</sub>/<i>C</i><sub>pl</sub> and <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratios for 258 compounds from a variety of AstraZeneca projects where the coloring is based on measured Caco-2 efflux ratios.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The relevance of the efflux ratio is demonstrated by a clear shift in the plot where compounds with higher efflux generally have lower <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratios.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Experimental data showing total (<i>C</i><sub>br</sub>/<i>C</i><sub>pl</sub>) versus unbound (<i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub>) ratios for 258 compounds from a variety of AstraZeneca projects and marketed drugs.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The coloring is based on experimental Caco-2 efflux data. The relevance of the efflux ratio is demonstrated by a clear shift in the plot where compounds with higher efflux generally have lower <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratios.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Much attention has recently been given to lipophilicity and in particular the consequences of making very lipophilic compounds in the search for highly potent compounds.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Lipophilicity influences permeability and is an important parameter in the design of peripheral compounds. However, lipophilicity alone is not expected to influence the asymmetry of unbound concentration directly, and the lipophilicity of non-CNS drugs is not expected to differ from that of CNS drugs by default.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> LLE (pIC<sub>50</sub> – log <i>D</i> or pIC<sub>50</sub> – clogP) is one simple measure of the degree to which the potency is driven by forces other than hydrophobicity.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> As the lead compounds in this study were highly lipophilic, LLE was a key parameter driving the design. Two human CB1 (hCB1) assays were used for estimation of CB1 potency, one competitive receptor binding assay (IC<sub>50</sub>)<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> and one assay for stimulation of [<sup>35</sup>S]guanosine 5′-<i>O</i>-(3-thiotriphosphate) (GTPγ[<sup>35</sup>S]) binding assay (EC<sub>50</sub>).<a onclick="showRef(event, 'ref36 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref38">(36, 38)</a> A corresponding competitive receptor binding assay was also utilized for the estimation of human CB2 (hCB2) potency.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">Screening a set of targeted GPCR libraries (75 000 compounds) led to the identification of the aminobenzamide derivative <b>4</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Compound <b>4</b> displayed reasonable in vitro potency, as measured in the competitive receptor binding assay, but was highly lipophilic<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and displayed partial agonism (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Initial CB1 receptor agonist lead (<b>4</b>) identified from screening a set of targeted GPCR libraries (75 000 compounds).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemical Synthesis</h3><div class="NLM_p">The syntheses of the pyridyl and pyrazinyl derivatives are described in general in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Introduction of the amide functional groups into the 2- and 3-position of the heterocyclic core structure was performed by two methods. Coupling 3-aminopyridine-2-carboxylic acid <b>5a</b>, 3-amino-6-methoxypyridine-2-carboxylic acid <b>5b</b> (synthesized from 3-(acetylamino)-6-methoxypyridine-2-carboxylic acid<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a>), or 3-aminopyrazine-2-carboxylic acid <b>5c</b> to the required acid chloride followed by heating in the presence of <i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyl-<i>O</i>-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (HATU) gave the oxazin-4-one derivatives <b>6a</b>–<b>e</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Alternatively, the required amine was first coupled to <b>5a</b>–<b>c</b> using HATU mediated coupling conditions to give amides <b>7a</b>,<b>b</b>. The oxazin-4-one derivatives <b>6a</b>–<b>e</b> then underwent ring opening upon treatment with the required amine, or the amides <b>7a</b>,<b>b</b> underwent a second acid coupling with the required substituted carboxylic acid to give the dicarboxamide derivatives <b>8a</b>–<b>o</b>. Some compounds were derivatized further. For example, where R<sup>3</sup> was a 4-substituted-1-naphthoic acid group, the acid was reduced via the mixed anhydride to the alcohol, which was subsequently converted to a mesylate. The mesylate was then displaced with a variety of nucleophiles to provide derivatives <b>9a</b>–<b>f</b>. A methoxy group in the 6-position of the pyridyl ring also provided a handle for further derivatization. Treatment of <b>8n</b>, where R<sup>1</sup> was a methoxy group, with pyridine hydrochloride at 160 °C gave the pyridone which was subsequently O-alkylated either using a variety of electrophiles in the presence of silver(I) carbonate at 130 °C or using Mitsunobu reaction conditions with the required alcohol to give the products <b>10a</b>,<b>b</b>.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Substituted Pyridine and Pyrazine Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) R<sup>3</sup>C(O)Cl, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), DMF, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (ii) DIPEA, HATU, 50 °C; (b) R<sup>2</sup>NH<sub>2</sub>, DIPEA, DMF; (c) R<sup>2</sup>NH<sub>2</sub>, HATU, DIPEA, DMF; (d) R<sup>3</sup>COOH, HATU, DIPEA, DMF; (e) (i) oxalyl chloride, DCE, 70 °C; (ii) NaBH<sub>4</sub>, I<sub>2</sub>; (f) CH<sub>3</sub>SO<sub>2</sub>Cl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (g) nucleophile (R<sup>4</sup>H) (e.g., pyrrole for <b>9c</b>), KI, DMF, 80 °C; (h) pyridine hydrochloride, 160 °C; (i) Ag<sub>2</sub>CO<sub>3</sub>, R<sup>5</sup>Cl, DMF, 130 °C or R<sup>5</sup>OH, diisopropyl azodicarboxylate, Ph<sub>3</sub>P, THF, 50 °C. The structures of R<sup>1</sup>–R<sup>5</sup> and the molecule cores are presented in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>.</p></p></figure><div class="NLM_p">Further manipulation of the naphthalene ring led to the introduction of triazole and sulfur containing functionality into the 4-position. The triazole derivatives were synthesized by first coupling <b>5a</b>–<b>c</b> with 4-methyl-1-naphthalenecarbonyl chloride and then trapping the resultant acid with methyl iodide to give the esters <b>11a</b>–<b>c</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). The methyl substituted naphthalene was then brominated under radical conditions to give the bromomethyl intermediate, which then underwent a S<sub>N</sub>2 reaction upon treatment with 1,2,3-triazole to give <b>12a</b>–<b>c</b>. Finally the amide was introduced at the 2-position of the heterocyclic core by treating <b>12a</b>–<b>c</b> with the required amine to give the triazoles <b>13a</b>–<b>e</b>. Treatment of <b>13c</b>, where R<sup>1</sup> was a methoxy group, with pyridine hydrochloride at 160 °C gave the pyridone which was subsequently O-alkylated using silver(I) carbonate and 3,3,3-trifluoropropylsulfonyl chloride to give <b>14</b>.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Triazole Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) 4-methyl-1-naphthalenecarbonyl chloride, DIPEA, DMF, 50 °C; (ii) MeI, K<sub>2</sub>CO<sub>3</sub>; (b) (i) NBS, benzoyl peroxide, CCl<sub>4</sub>; (ii) 1,2,3-triazole, DMF; (c) R<sup>2</sup>NH<sub>2</sub>, DMF, 80 °C; (d) pyridine hydrochloride, 160 °C; (e) Ag<sub>2</sub>CO<sub>3</sub>, R<sup>5</sup>Cl, DMF, 130 °C. The structures of R<sup>1</sup>, R<sup>2</sup>, and R<sup>5</sup> are presented in Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</p></p></figure><div class="NLM_p">The sulfur containing derivatives were synthesized by two methods (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). Treatment of <b>5b</b>,<b>c</b> with HCl in methanol gave the methyl esters <b>15a</b>,<b>b</b>, which were then reacted with 4-[(methylthio)methyl]-1-naphthoyl chloride (synthesized from 4-(bromomethyl)-1-naphthoic acid<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a>) to give the amides <b>16a</b>,<b>b</b>. Treatment of <b>16a</b>,<b>b</b> with the required amines gave the thiomethylnaphthalene intermediates <b>17b</b> and <b>17d</b>–<b>e</b>. Alternatively, treatment of intermediates <b>7a</b>,<b>b</b> with 4-[(methylthio)methyl]-1-naphthoyl chloride gave <b>17a</b> and <b>17c</b>. Finally, oxidation of <b>17a</b>–<b>e</b> using <i>m</i>-CPBA gave the sulfoxides <b>18a</b>–<b>g</b> and the sulfone derivative <b>19</b>. The R<sup>1</sup> group was varied by treating <b>17e</b>, where R<sup>1</sup> was a methoxy group, with pyridine hydrochloride to give the pyridone. The pyridone was then oxidized using <i>m</i>-CPBA to give the sulfoxide which was subsequently O-alkylated with silver(I) carbonate and 2-(2-chloroethoxy)ethanol to give <b>20</b>.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Sulfoxide Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HCl, MeOH; (b) 4-[(methylthio)methyl]-1-naphthoyl chloride, pyridine, DMAP, CHCl<sub>3</sub>, 50 °C; (c) R<sup>2</sup>NH<sub>2</sub>, DMF, 80 °C; (d) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (e) pyridine hydrochloride, 160 °C; (f) Ag<sub>2</sub>CO<sub>3</sub>, R<sup>5</sup>Cl, DMF, 130 °C. The structures of R<sup>1</sup>, R<sup>2</sup>, and R<sup>5</sup> are presented in Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Biological Evaluation and Structure–Activity Relationship Study</h3><div class="NLM_p">Explorative chemistry aimed at improving the overall properties showed that the phenyl core in the lead compound <b>4</b> could be replaced with the pyridyl (<b>8a</b>) or pyrazinyl (<b>8b</b>) ring systems and lead to improved potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In the case of the pyridyl-2-carboxamide derivative <b>8a</b>, affinity to the hCB1 receptor was increased greater than 10-fold and full efficacy achieved. The increase in binding affinity for <b>8a</b> and <b>8b</b> is believed to be attributed to the intramolecular hydrogen bond that exists between either the pyridyl or pyrazinyl nitrogen atom and the NH moiety of the 2-carboxamide group which conformationally restricts the structure to provide a planar conformation. In contrast, moving the pyridine nitrogen atom to give the corresponding 3-carboxamide (<b>8c</b>), 4-carboxamide (<b>8d</b>), or 2-amino-3-carboxamide (<b>8e</b>) derivatives gave a significant decrease in potency compared to <b>4</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Binding, Efficacy, and Lipophilicity Data for the Core Variations</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0007.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0008.gif" alt="" id="GRAPHIC-d839e1069-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values against hCB1 and hCB2 were determined using membranes from HEK293S cells expressing the cloned hCB1 receptor or Sf9 cells expressing the cloned hCB2 receptor and <sup>3</sup>H-CP55,940 as the radioligand.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> Curve fitting and IC<sub>50</sub> calculations were performed using Xlfit4 (IDBS, Inc.). IC<sub>50</sub> values were obtained from three independent experiments and are expressed as the mean.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">EC<sub>50</sub> values from GTPγ[<sup>35</sup>S] binding assay were measured on cloned hCB1 receptors in membranes of HEK 293S cells.<a onclick="showRef(event, 'ref36 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref38">(36, 38)</a> Curve fitting and EC<sub>50</sub> calculations were performed using Xlfit4 (IDBS, Inc.). EC<sub>50</sub> values were obtained from three independent experiments and are expressed as the mean.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last"><i>E</i><sub>max</sub> is the maximal effect of the test compounds and expressed as a percentage of that value obtained with <b>2</b>.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Chromatographic log <i>D</i> measurements performed in a similar fashion to that described previously.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The log <i>D</i> was calculated from retention time versus standard curve.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">LLE defined as pIC<sub>50</sub>(hCB1 IC<sub>50</sub>) – log <i>D</i>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></p></div><div class="footnote" id="t1fn6"><sup>Table f</sup><p class="last">ND means not determined.</p></div></div><div></div></div><div class="NLM_p">With the knowledge that good affinity and full agonism could be achieved, the focus shifted toward improving ADMET properties to meet the required peripheral candidate drug profile. The different positions on the core structure were modified to build up knowledge of how different substitution patterns and groups would affect these properties. The 2-carboxamide side chain of the pyridine ring was varied showing that both lipophilicity and molecular weight could be reduced without significant loss of potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). For example, replacement of the cyclohexylmethyl moiety with tetrahydropyranylmethyl (<b>8f</b>) gave a 3-fold reduction in binding affinity with a significant reduction in lipophilicity while replacement with cyclobutylmethyl (<b>8g</b>) gave similar potency compared to <b>8a</b>. Compound <b>8f</b> showed significant CNS exposure (<i>C</i><sub>br</sub>/<i>C</i><sub>pl</sub> = 3), which was comparable to that of <b>2</b> (<i>C</i><sub>br</sub>/<i>C</i><sub>pl</sub> = 2.5), highlighting that significant work was required to achieve peripheral compounds in this series.</div><div class="NLM_p">A large contributing factor to the overall lipophilicity of these compounds was the naphthalene in the 3-position of the pyridine ring. Replacement of the naphthalene ring with alternative bicyclic systems, such as benzodioxane (<b>8h</b>), benzothiazole (<b>8i</b>), or quinoxaline (<b>8j</b>) led to a drop in potency compared with the naphthalene derivative <b>8f</b>. Introduction of a nitrogen atom to give regioisomeric quinoline or isoquinoline derivatives was also explored. The 5-substituted isoquinoline (<b>8k</b>) and 8-substituted quinoline (<b>8l</b>) both showed reduced binding affinity compared with <b>8g</b>. However, the 4-substituted quinoline (<b>8m</b>) displayed greater potency than the other regioisomers and also maintained full efficacy and had no selectivity versus hCB2. Further substitution in the 6-position of the pyridine ring of <b>8m</b> with a methoxy group gave <b>8n</b> which was also well tolerated (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><div class="NLM_p">As a nitrogen atom could be incorporated into the 4-position of the naphthalene ring, this led to an investigation into alternative substitution at this position in an attempt to further enhance potency while reducing lipophilicity. This was also an opportunity to introduce additional polarity, including hydrogen bond donors and acceptors, in an attempt to pick up recognition elements with CNS efflux transporters such as P-gp and also modify molecular properties to restrict brain penetration.<a onclick="showRef(event, 'ref17 ref43'); return false;" href="javascript:void(0);" class="ref ref17 ref43">(17, 43)</a> While acidic side chains such as in <b>8o</b> were not tolerated, it was found that a wide variety of polar substituents could successfully be incorporated into this position to achieve high levels of hCB1 inhibition, including both neutral and basic side chains (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). This included substituents such as methoxymethyl (<b>9a</b>) and dimethylaminomethyl (<b>9b</b>). The pyrrole derivative (<b>9c</b>) lost potency compared to the unsubstituted naphthalene (<b>8g</b>). The imidazole (<b>9d</b>) and pyrazole (<b>9e</b>) derivatives had comparable potency, while the triazole (<b>9f</b>) had excellent subnanomolar binding affinity to hCB1 and full agonism. As expected, <b>9f</b> had reduced lipophilicity relative to <b>8a</b> and hence achieved an improved LLE and also good selectivity over hCB2. This is most likely due to the triazole ring picking up an additional binding interaction with the hCB1 receptor. Alternatively the methylsulfoxide (<b>18a</b>) and methylsulfone (<b>19</b>) were also tolerated with the sulfoxide displaying significantly greater binding affinity and LLE compared with the sulfone <b>19</b>. As a methoxy group was well tolerated in the 6-position of the pyridine ring as shown with <b>8n</b>, additional modifications were made in this position. This is exemplified with the hydroxy ethers (<b>10a</b> and <b>10b</b>) (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). The derivative containing the hydroxyethoxyethoxy side chain (<b>10b</b>) gave the highest affinity for hCB1 and highest LLE. Substitution at the 6-position also had a large effect on the selectivity over hCB2, where increasing the size and length of the substituent from a hydrogen atom to the hydroxyethoxyethoxy side chain in <b>10b</b> increased the selectivity significantly.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Binding, Efficacy, Lipophilicity, and LLE Data for R<sup>2</sup> and R<sup>3</sup> Variations</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0009.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0010.gif" alt="" id="GRAPHIC-d839e1317-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values against hCB1 and hCB2 were determined using membranes from HEK293S cells expressing the cloned hCB1 receptor or Sf9 cells expressing the cloned hCB2 receptor and <sup>3</sup>H-CP55,940 as the radioligand.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> Curve fitting and IC<sub>50</sub> calculations were performed using Xlfit4 (IDBS, Inc.). IC<sub>50</sub> values were obtained from three independent experiments and are expressed as the mean.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">EC<sub>50</sub> values from GTPγ[<sup>35</sup>S] binding assay were measured on cloned human CB1 receptors in membranes of HEK 293S cells.<a onclick="showRef(event, 'ref36 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref38">(36, 38)</a> Curve fitting and EC<sub>50</sub> calculations were performed using Xlfit4 (IDBS, Inc.). EC<sub>50</sub> values were obtained from three independent experiments and are expressed as the mean.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last"><i>E</i><sub>max</sub> is the maximal effect of the test compounds and expressed as a percentage of that value obtained with <b>2</b>.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Chromatographic log <i>D</i> measurements performed in a similar fashion to that described previously.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The log <i>D</i> was calculated from retention time versus standard curve.</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">LLE defined as pIC<sub>50</sub>(hCB1 IC<sub>50</sub>) – log <i>D</i>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></p></div><div class="footnote" id="t2fn6"><sup>Table f</sup><p class="last">ND means not determined.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Binding, Efficacy, Selectivity, and LLE Data for R<sup>1</sup> and R<sup>3</sup> Variations</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0012.gif" alt="" id="GRAPHIC-d839e1421-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values against hCB1 and hCB2 were determined using membranes from HEK293S cells expressing the cloned hCB1 receptor or Sf9 cells expressing the cloned hCB2 receptor and <sup>3</sup>H-CP55,940 as the radioligand.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> Curve fitting and IC<sub>50</sub> calculations were performed using Xlfit4 (IDBS, Inc.). IC<sub>50</sub> values were obtained from three independent experiments and are expressed as the mean.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">EC<sub>50</sub> values from GTPγ[<sup>35</sup>S] binding assay were measured on cloned human CB1 receptors in membranes of HEK 293S cells.<a onclick="showRef(event, 'ref36 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref38">(36, 38)</a> Curve fitting and EC<sub>50</sub> calculations were performed using Xlfit4 (IDBS, Inc.). EC<sub>50</sub> values were obtained from three independent experiments and are expressed as the mean.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last"><i>E</i><sub>max</sub> is the maximal effect of the test compounds and expressed as a percentage of that value obtained with <b>2</b>.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Chromatographic log <i>D</i> measurements performed in a similar fashion to that described previously.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The log <i>D</i> was calculated from retention time versus standard curve.</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">LLE defined as pIC<sub>50</sub>(hCB1 IC<sub>50</sub>) – log <i>D</i>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></p></div><div class="footnote" id="t3fn6"><sup>Table f</sup><p class="last">Compound <b>8o</b> contains tetrahydropyranylmethyl instead of cyclobutylmethyl in the R<sup>2</sup> position.</p></div><div class="footnote" id="t3fn7"><sup>Table g</sup><p class="last">ND means not determined.</p></div></div><div></div></div><div class="NLM_p">With the SAR of the three side chains established, the best substituents were combined to address the overall design criteria including achieving compounds with a very low <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratio (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). The series of 1,4-naphthylmethyltriazoles (<b>13a</b>–<b>d</b>) achieved excellent hCB1 potency and showed a reduction in log <i>D</i> of 3 log units across the series, whereas the drop in potency is less than 1 log unit. Thus, an increase in LLE is achieved where the LLE for <b>13d</b> is the greatest. Other properties including permeability, as measured in Caco-2 cells, and solubility are also improved as log <i>D</i> decreases across this series. The <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratio also decreases from <b>13a</b> to <b>13d</b>. The polar surface area (PSA) is similar between <b>13a</b>–<b>d</b> (PSA = 112 for <b>13a</b> and PSA = 111 for <b>13d</b>), and interestingly the efflux ratio decreases as the <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> decreases. This may be caused by several reasons, including that other transporter mechanisms are involved. The triazole derivatives <b>13a</b>, <b>13c</b>, and <b>13d</b> maintained good selectivity over hCB2, while <b>13d</b> also displayed full efficacy. At the beginning of this investigation it was shown that a pyrazine ring could replace the pyridine core structure. The preferred side chains from the SAR exploration with the pyridine derivatives were applied to the pyrazine core which gave the triazole derivative <b>13e</b>, a potent hCB1 receptor agonist. Further exploration of the 6-position of the pyridine ring led to the discovery of the 1,1,1-trifluoropropylsulfonate containing derivative <b>14</b>,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> which was a highly potent and full agonist of hCB1 with excellent selectivity over hCB2. Compound <b>14</b> had an even lower <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratio compared to <b>13d</b>, most likely reflecting the increased PSA (158) as well as being an efflux substrate as shown in the Caco-2 assay. A set of 1,4-naphthylmethylsulfoxides with different substituents in the 2- and 6-position of the pyridyl ring were also prepared. This set of compounds, including <b>18b</b>,<b>c</b>, again showed that good binding affinity against hCB1 can be achieved with compounds with significantly reduced lipophilicity and hence improved LLEs. Compounds <b>18b</b>,<b>c</b> have good permeability and are efflux substrates in Caco-2 cells, which leads to low <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratios. The enantiomers of the sulfoxide moiety show a significant difference in binding affinity to hCB1 as exemplified by the enantiomers of <b>18c</b>, compounds <b>18d</b> and <b>18e</b>. The more potent enantiomer <b>18d</b> has a high efflux ratio and is peripherally restricted with a low <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratio. Replacement of the pyridine core in <b>18a</b> with a pyrazine ring provided the sulfoxide derivative <b>18f</b>, which had good potency against the hCB1 receptor. The enantiomers of <b>18f</b> were separated, and as with the pyridine core, one sulfoxide enantiomer (<b>18g</b>) showed much greater potency versus hCB1. Analysis of the matched pairs of the pyridine and pyrazine containing compounds showed that the pyrazine compounds were in general 5- to 10-fold less potent versus hCB1 with similar efficacy.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The pyrazines were also less lipophilic and had higher predicted PSA, similar selectivity versus hCB2, and generally improved solubility (3- to 100-fold). Compounds <b>18f</b> and <b>18g</b> were peripherally restricted with low <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratios. Finally, increasing the size of the 6-substituent on the pyridine core, exemplified with compound <b>20</b>, maintained excellent potency and led to excellent selectivity against hCB2.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Binding, Lipophilicity, and Caco-2 Data and <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> Data for the Best R<sup>1</sup>, R<sup>2</sup>, and R<sup>4</sup> Combinations</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0013.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values against hCB1 and hCB2 were determined using membranes from HEK293S cells expressing the cloned hCB1 receptor or Sf9 cells expressing the cloned hCB2 receptor and <sup>3</sup>H-CP55,940 as the radioligand.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> Curve fitting and IC<sub>50</sub> calculations were performed using Xlfit4 (IDBS, Inc.). IC<sub>50</sub> values were obtained from three independent experiments and are expressed as the mean.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">EC<sub>50</sub> values from GTPγ[<sup>35</sup>S] binding assay were measured on cloned human CB1 receptors in membranes of HEK 293S cells.<a onclick="showRef(event, 'ref36 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref38">(36, 38)</a> Curve fitting and EC<sub>50</sub> calculations were performed using Xlfit4 (IDBS, Inc.). EC<sub>50</sub> values were obtained from three independent experiments and are expressed as the mean.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last"><i>E</i><sub>max</sub> is the maximal effect of the test compounds and expressed as a percentage of that value obtained with <b>2</b>.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">Chromatographic log <i>D</i> measurements performed in a similar fashion to that described previously.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The log <i>D</i> was calculated from retention time versus standard curve.</p></div><div class="footnote" id="t4fn5"><sup>Table e</sup><p class="last">LLE defined as pIC<sub>50</sub>(hCB1 IC<sub>50</sub>) – log <i>D</i>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></p></div><div class="footnote" id="t4fn6"><sup>Table f</sup><p class="last">Apparent permeability measurements carried out in Caco-2 cells at pH 7.4 for apical (A) to basolateral (B) transport.</p></div><div class="footnote" id="t4fn7"><sup>Table g</sup><p class="last">Efflux ratio defined as <i>P</i><sub>app</sub>(B to A)/<i>P</i><sub>app</sub>(A to B) where both <i>P</i><sub>app</sub>(A to B) and <i>P</i><sub>app</sub>(B to A) are measured in Caco-2 cells.</p></div><div class="footnote" id="t4fn8"><sup>Table h</sup><p class="last">Calculated by combining the total brain to plasma ratio determined from in vivo samples from Sprague–Dawley rats with estimates of the unbound fraction in the brain from rat brain slices<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and unbound fraction in plasma by equilibrium dialysis.<a onclick="showRef(event, 'ref32 ref46'); return false;" href="javascript:void(0);" class="ref ref32 ref46">(32, 46)</a></p></div><div class="footnote" id="t4fn9"><sup>Table i</sup><p class="last">The total brain to plasma ratio determined from in vivo samples from Sprague–Dawley rats.</p></div><div class="footnote" id="t4fn10"><sup>Table j</sup><p class="last">ND means not determined.</p></div><div class="footnote" id="t4fn11"><sup>Table k</sup><p class="last">Compounds contain pyrazine core.</p></div><div class="footnote" id="t4fn12"><sup>Table l</sup><p class="last">The two enantiomers of <b>18c</b>.</p></div><div class="footnote" id="t4fn13"><sup>Table m</sup><p class="last">Most active enantiomer of <b>18f</b>.</p></div></div><div></div></div><div class="NLM_p">Now that compounds displaying good potency and efficacy versus hCB1 and low <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratios had been identified, the concept of inhibition of TLESRs through CB1 receptor agonism was tested in an in vivo dog model.<a onclick="showRef(event, 'ref9 ref48'); return false;" href="javascript:void(0);" class="ref ref9 ref48">(9, 48)</a> Prior to testing in vivo, it was confirmed that compounds in this series, for example, <b>13c</b>, <b>18b</b>, and <b>20</b>, showed excellent potency at the dog CB1 receptor with EC<sub>50</sub> values that were similar to that shown at the hCB1 receptor (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). The compounds tested in vivo demonstrate a dose-dependent inhibition of TLESRs in the dog, delivering greater than 50% inhibition for most of the compounds tested (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> shows the dose response plots for <b>13c</b> and <b>14</b>. The level of inhibition achieved is comparable in magnitude to what has been shown previously for the more centrally acting CB1 agonists, <b>2</b> and <b>3</b>, in the same animal model.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> In dogs, centrally acting cannabinoids induce a behavioral pattern known as static ataxia, including sedation, prancing, and motor incoordination.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Single behavioral experiments with the CB1 receptor agonists with restricted CNS penetration demonstrated an increased margin (e.g., approximately 5 and 10 times for <b>13c</b> and <b>14</b>, respectively) between plasma concentrations producing 50% inhibition of TLESRs and the plasma concentrations that induce these CNS side effects in comparison with <b>2</b>. Compound <b>2</b> showed no margin between the plasma concentrations required to reach 50% inhibition of TLESRs and CNS side effects. The present data demonstrate the potential for achieving a robust inhibition of TLESRs with CB1 agonists with restricted CNS penetration, reducing the risk for CNS mediated side effects.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Dog CB1 EC<sub>50</sub> Values (GTPγ[<sup>35</sup>S] Binding Assay) and Mean Inhibition of Transient Lower Esophageal Sphincter Relaxations (TLESRs) in the Dog in Vivo Model at Different Doses</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">dog CB1 EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">mean inhibition of TLESRs (%)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">±SEM</th><th class="colsep0 rowsep0" align="center">dose (μmol/kg)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"><i>n</i> <a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">47</td><td class="colsep0 rowsep0" align="left">14.1</td><td class="colsep0 rowsep0" align="left">12.7</td><td class="colsep0 rowsep0" align="left">0.006</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">10.4</td><td class="colsep0 rowsep0" align="left">0.019</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">81.7</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13a</b></td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">43.2</td><td class="colsep0 rowsep0" align="left">16.2</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">81.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13c</b></td><td class="colsep0 rowsep0" align="left">4.1</td><td class="colsep0 rowsep0" align="left">28.9</td><td class="colsep0 rowsep0" align="left">6.9</td><td class="colsep0 rowsep0" align="left">0.05</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">57.2</td><td class="colsep0 rowsep0" align="left">6.8</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">90.4</td><td class="colsep0 rowsep0" align="left">9.6</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13d</b></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">13.5</td><td class="colsep0 rowsep0" align="left">9.6</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">10.7</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13e</b></td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">21.5</td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">38.1</td><td class="colsep0 rowsep0" align="left">16.3</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">28.6</td><td class="colsep0 rowsep0" align="left">4.7</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">33.5</td><td class="colsep0 rowsep0" align="left">12.8</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">58.4</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18b</b></td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">38.6</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">0.05</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">62.2</td><td class="colsep0 rowsep0" align="left">23.4</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">5.9</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">31.7</td><td class="colsep0 rowsep0" align="left">16.8</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">EC<sub>50</sub> values from GTPγ[<sup>35</sup>S] binding assay were measured on cloned dog CB1 receptors in membranes of HEK 293S cells.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Curve fitting and EC<sub>50</sub> calculations were performed using Xlfit4 (IDBS, Inc.). EC<sub>50</sub> values were obtained from three independent experiments and are expressed as the mean.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Inhibition of TLESRs through CB1 receptor agonism tested in an in vivo dog model.<a onclick="showRef(event, 'ref9 ref48'); return false;" href="javascript:void(0);" class="ref ref9 ref48">(9, 48)</a> The compounds tested demonstrated a dose-dependent inhibition of TLESRs.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Administered intragastrically except <b>2</b>, <b>14</b>, and <b>18b</b>, which were administered by an iv bolus.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last"><i>n</i> = number of experiments for each dose.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">ND means not determined.</p></div></div></div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0014.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compounds <b>13c</b> and <b>14</b> produced dose-dependent inhibition of transient lower esophageal sphincter relaxations (TLESRs) in the dog in vivo.<a onclick="showRef(event, 'ref9 ref48'); return false;" href="javascript:void(0);" class="ref ref9 ref48">(9, 48)</a> The graphs show mean percentage inhibition and SEM (<i>n</i> = number of experiments for each dose).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further profiling of this series revealed that a number of compounds were strong inhibitors of the cytochrome P450 (CYP) isoforms 3A4 and 2C9, in some cases with IC<sub>50</sub> values of around 100 nM (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). These interactions are highly undesirable because of potential drug–drug interactions in the clinic.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The potency versus CYP 2C9 was particularly sensitive to changes in R<sup>1</sup>. Changing a H atom to a methoxy group increased potency at CYP 2C9; for example, compare <b>13d</b> with <b>13c</b> or <b>18c</b> with <b>18b</b>. This effect of the methoxy group on the interactions with CYP 2C9 could be decreased by increasing the size and flexibility of the R<sup>1</sup> substituent, as shown by comparing <b>18b</b> with <b>20</b>. The potency at CYP 3A4 was impacted to some extent by the R<sup>1</sup> substituent. However, it was particularly sensitive to variations on the naphthalene ring (R<sup>4</sup>). For example, while the methyltriazole substituted naphthalene in compound <b>13c</b> significantly increased the hCB1 potency and LLE, it also led to strong inhibition of CYP 3A4. It has been reported that nitrogen atoms in heterocyclic ring systems can bind strongly to the heme moiety within the active site of the CYP enzymes.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Hence, attempts were made to substitute the triazole ring to increase the steric bulk around the triazole nitrogen atoms to reduce the affinity. However, in this case this approach had minimal impact on reducing the interactions. Alternatively, replacement of the triazole ring with a sulfoxide group led to significantly reduced potency at the CYP enzymes; for example, compare <b>13c</b> and <b>18b</b>. Applying the learning from R<sup>1</sup> and R<sup>4</sup> in combination led to significantly reduced CYP interactions and provided compounds with reduced inhibition of both CYP 2C9 and 3A4 isoforms (e.g., <b>18c</b>). Applying the same learning with the pyrazine core also provided compounds, such as <b>18f</b>, with significantly reduced inhibition of the CYP enzymes.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. CYP 3A4 and 2C9 Inhibition Data</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">CYP 3A4</th><th class="colsep0 rowsep0" align="center">CYP 2C9</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13c</b></td><td class="colsep0 rowsep0" align="left">0.36</td><td class="colsep0 rowsep0" align="left">0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13d</b></td><td class="colsep0 rowsep0" align="left">0.61</td><td class="colsep0 rowsep0" align="left">0.66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18b</b></td><td class="colsep0 rowsep0" align="left">8.8</td><td class="colsep0 rowsep0" align="left">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">5.5</td><td class="colsep0 rowsep0" align="left">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18c</b></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18f</b></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Inhibition values show the inhibition of metabolic degradation of the corresponding substrate by human recombinant CYP 3A4 and 2C9 at 37 °C (the percent of inhibition is determined at five different concentrations and is reported as IC<sub>50</sub>). Data were analyzed using nonlinear regression analysis with ActivityBase software.</p></div></div></div><div class="NLM_p">The most promising sulfoxide derivatives <b>18b</b>, <b>18c</b>, and <b>18f</b> were profiled further (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). As well as showing good permeability in Caco-2 cells and having low <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratios, these compounds display good solubility and low inhibition of the hERG encoded potassium channel.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> These compounds were also tested in in vivo rat PK studies and show moderate clearance and moderate to good oral bioavailability. For example, despite efflux properties contributing to very low concentrations in the CNS, <b>18b</b> showed acceptable oral bioavailability and clearance while the pyrazine derivative <b>18f</b> had similar clearance but good oral bioavailability.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub>, Rat PK, hERG, and Solubility Data for Leading Derivatives</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> <a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>br</sub>/<i>C</i><sub>pl</sub> <a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">rat <i>F</i> <a class="ref internalNav" href="#t7fn3" aria-label="c">c</a> (%)</th><th class="colsep0 rowsep0" align="center" char=".">rat CL <a class="ref internalNav" href="#t7fn3" aria-label="c">c</a>(mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">hERG IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">solubility (μM)<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13c</b></td><td class="colsep0 rowsep0" align="char" char=".">0.044</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td><td class="colsep0 rowsep0" align="left">5.8</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18b</b></td><td class="colsep0 rowsep0" align="char" char=".">0.026</td><td class="colsep0 rowsep0" align="char" char=".">0.031</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">>32</td><td class="colsep0 rowsep0" align="char" char=".">93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18c</b></td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">0.018</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">>33</td><td class="colsep0 rowsep0" align="char" char=".">79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18f</b></td><td class="colsep0 rowsep0" align="char" char=".">0.030</td><td class="colsep0 rowsep0" align="char" char=".">0.022</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">87</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Calculated by combining the total brain to plasma ratio determined from in vivo samples from Sprague–Dawley rats with estimates of the unbound fraction in the brain from rat brain slices<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and unbound fraction in plasma by equilibrium dialysis.<a onclick="showRef(event, 'ref32 ref46'); return false;" href="javascript:void(0);" class="ref ref32 ref46">(32, 46)</a></p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">The total brain to plasma ratio determined from in vivo samples from Sprague–Dawley rats.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">Compounds <b>18b</b>, <b>18c</b>, and <b>18f</b> were dosed at 2 μmol/kg (iv) and 10 μmol/kg (po), and <b>13c</b> was dosed at 1 μmol/kg (iv) and 15 μmol/kg (po) to Sprague–Dawley rats.</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last">Patch clamp assay using IonWorks technology in hERG-expressing CHO cells.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></p></div><div class="footnote" id="t7fn5"><sup>e</sup><p class="last">Solubility determined by adding Hank’s balanced saline solution (pH 7.4) to a solution of the compound in DMSO and shaking for 24 h. The mixtures were then filtered and analyzed to give an estimate of the solubility.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80567" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80567" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The design of efficient orally bioavailable yet peripherally restricted compounds involves optimizing properties that are often in conflict with each other. Sufficient bioavailability is required; thus, permeability across the intestinal membrane is needed, while permeation across the BBB needs to be minimized. This can be achieved, as the concentration of the compound is much higher in the intestine, potentially leading to saturation of efflux transporters.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> A moderately potent and highly lipophilic series of 2-aminobenzamides was identified through focused screening of GPCR libraries. Opportunities were found to vary the core structure to pyridine or pyrazine to increase potency at the hCB1 receptor by restricting the conformation through an intramolecular hydrogen bond. The series was developed further focusing on improving potency and efficacy at the hCB1 receptor and reducing lipophilicity to improve compound properties. Design strategies were applied to limit CNS exposure, including increasing PSA and introducing polar functionality in an attempt to increase recognition by CNS efflux transporters while simultaneously maintaining properties for good oral absorption. A rewarding strategy to achieve the required criteria was to introduce polar functionality, particularly triazole or sulfoxide groups, into the 4-position of the naphthalene ring located in the 3-position of the heterocyclic scaffold. This led to compounds with excellent potency at the hCB1 receptor, lipophilicity values in the preferred range for oral drug-like compounds, and hence, significantly improved LLEs. These modifications also gave compounds with low <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratios. Changes were tolerated in the 6-position of the core heterocyclic ring structure, allowing further modification of compound properties as well as increasing selectivity versus hCB2. In general, the sulfoxide derivatives such as <b>18b</b> and <b>18f</b> gave higher efflux ratios than the triazoles and also better properties including less inhibition of the CYP enzymes and good in vivo rat PK profiles.</div><div class="NLM_p last">The ultimate goal for this series was to demonstrate that CB1 agonists with restricted CNS penetration are efficacious in inhibition of TLESRs. The in vivo data presented demonstrate that compounds from this series, such as <b>18b</b>, dose dependently inhibit TLESRs in dogs in a way comparable to what has previously been reported for the centrally acting compounds <b>2</b> and <b>3</b>. This suggests that the peripheral concept of CB1 receptor agonism can deliver high efficacy while minimizing CNS-related side effects and have a potential benefit for the treatment of GERD.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77874" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77874" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry</h3><div class="NLM_p last">All solvents and reagents were obtained from commercially available sources and used without further purification. Reactions were carried out under nitrogen atmosphere unless otherwise stated. Reactions carried out using a microwave reactor were performed using a Biotage initiator or Personal Chemistry [Biotage] Emrys optimizer. Flash chromatography was carried out on prepacked silica gel columns supplied by Biotage and using Horizon/Biotage systems. Analytical HPLC/MS was conducted on a Waters Zevo QTof or Waters LCT Premiere mass spectrometer using an Acquity PDA (Waters) UV detector monitoring either at (a) 210 nm with an Acquity BEH C18 column (2.1 mm × 100 mm, 1.7 μm, 0.7 mL/min flow rate), using a gradient of 2% v/v CH<sub>3</sub>CN in H<sub>2</sub>O (ammonium carbonate buffer, pH 10) to 98% v/v CH<sub>3</sub>CN in H<sub>2</sub>O or (b) 230 nm with an Acquity HSS C18 column (2.1 mm × 100 mm, 1.8 μm, 0.7 mL/min flow rate), using a gradient of 2% v/v CH<sub>3</sub>CN in H<sub>2</sub>O (ammonium formate buffer, pH 3) to 98% v/v CH<sub>3</sub>CN in H<sub>2</sub>O. Preparative HPLC was conducted using a Waters Fraction Lynx purification system using either (i) Xbridge Prep C18 5 μm OBD, 19 mm × 150 mm columns. The mobile phase used was varying gradients of CH<sub>3</sub>CN and 0.2% NH<sub>3</sub> buffer at flow rate of 30 mL/min or (ii) Kromasil, C8, 10 μm, 50.8 mm × 300 mm columns. The mobile phase used was varying gradients of CH<sub>3</sub>CN and 0.1 M NH<sub>4</sub>OAc buffer at flow rate of 30 mL/min or (iii) Kromasil, C8, 10 μm, 20 mm × 50 mm columns. The mobile phase used was varying gradients of CH<sub>3</sub>CN and 0.1 M HCO<sub>2</sub>H buffer at flow rate of 30 mL/min. MS-triggered fraction collection was used for (a)–(c). All tested compounds were determined to be >95% pure using the analytical method (a) or (b) described above based on the peak area percentage. <sup>1</sup>H NMR spectra were generated on a Varian 300 MHz, Varian 400 MHz, Varian 500 MHz, or Varian 600 MHz instrument as indicated. Chemical shifts (δ) are given in parts per million (ppm), with the residual solvent signal used as a reference. Coupling constants (<i>J</i>) are reported as Hz. NMR abbreviations are used as follows: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>N</i>-[4-Chloro-2-[[(cyclohexylmethyl)amino]carbonyl]phenyl]-1-naphthalene-carboxamide (<b>4</b>)</h3><div class="NLM_p">1-Cyclohexylmethanamine (6.8 g, 60 mmol) was added to a solution of 6-chloro-2<i>H</i>-3,1-benzoxazine-2,4(1<i>H</i>)-dione (6.0 g, 30 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA, 3.8 g, 30 mmol) in DMF (50 mL) at room temperature. After 2 h, the reaction mixture was quenched with H<sub>2</sub>O (100 mL) and Et<sub>2</sub>O (50 mL). The precipitate was collected to provide 2- amino-5-chloro-<i>N</i>-(cyclohexylmethyl)benzamide (7.0 g, 87%).</div><div class="NLM_p last">A solution of 1-naphthoyl chloride (296 mg, l.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added to a mixture of DIPEA (190 mg, 1.5 mmol) and 2-amino-5-chloro-<i>N</i>-(cyclohexylmethyl)benzamide (270 mg, 1.0 mmol) in DMF (10 mL) at 0 °C. The reaction mixture was then stirred for 2 h at room temperature and then quenched with H<sub>2</sub>O (20 mL). The precipitate was collected to provide the title compound (178 mg, 43%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.99 (m, 2H), 1.22 (m, 3H), 1.56 (m, 1H), 1.75 (m, 5H), 3.23 (d, <i>J</i> = 6.4, 2H), 6.21 (brs, 1H), 7.46 (m, 1H), 7.53 (m, 4H), 7.84 (dd, <i>J</i> = 7.2, 1.2, 1H), 7.89 (m, 1H), 7.97 (d, <i>J</i> = 8.0, 1H), 8.52 (m, 1H), 8.88 (d, <i>J</i> = 9.2, 1H), 11.53 (brs, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 421.1683; found 421.168.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 3-Amino-6-methoxypyridine-2-carboxylic Acid (<b>5b</b>)</h3><div class="NLM_p last">A mixture of 3-(acetylamino)-6-methoxypyridine-2-carboxylic acid<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> (8.0 g, 37.9 mmol) and a 2.5 M aqueous solution of NaOH (80 mL) was refluxed for 80 min. The solution was cooled to 0 °C and 4 M aqueous HCl was added until the solution was pH 4. The precipitate was collected and washed with cold H<sub>2</sub>O to give the title compound as a solid (5.7 g, 89%). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 3.87 (s, 3H), 6.86 (d, <i>J</i> = 9.0, 1H), 7.25 (d, <i>J</i> = 9.0 Hz, 1H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 3-Amino-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-ylmethyl)pyridine-2-carboxamide (<b>7a</b>)</h3><div class="NLM_p last">HATU (2.63 g, 6.93 mmol) and 1-(tetrahydro-2<i>H</i>-pyran-4-yl)methanamine (0.80 g, 6.94 mmol) were added to a solution of 3-amino-2-pyridinecarboxylic acid (<b>5a</b>, 0.91 g, 6.60 mmol) and DIPEA (1.26 mL, 7.26 mmol) in DMF (120 mL) at 0 °C. The reaction mixture was warmed to room temperature and heated to 50 °C for 3 h. The solvent was concentrated in vacuo, and the residue was partitioned between EtOAc and water. The organic phase was washed with saturated aqueous NaHCO<sub>3</sub> solution, saturated aqueous NaCl solution, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The residue was purified by flash column chromatography (Et<sub>3</sub>N 0.1%, MeOH 3%, and acetone 5% in CH<sub>2</sub>Cl<sub>2</sub>) to give the title compound as a white solid (1.40 g, 90%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.34–1.48 (m, 2H), 1.66–1.77 (m, 2H), 1.82–1.96 (m, 1H), 3.34 (t, <i>J</i> = 6.6, 2H), 3.37–3.45 (m, 2H), 4.01 (dd, <i>J</i> = 11.2, 4.0, 2H), 5.96 (s, 2H), 7.03 (d, <i>J</i> = 11.2, 1H), 7.17 (dd, <i>J</i> = 8.3, 4.3, 1H), 7.81–7.91 (m, 1H), 8.25 (s, 1H).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 3-Amino-<i>N</i>-(cyclobutylmethyl)pyridine-2-carboxamide (<b>7b</b>)</h3><div class="NLM_p last"><i>O</i>-(Benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium tetrafluoroborate (2.32 g, 7.24 mmol) and DIPEA (2.02 mL, 11.6 mmol) were added to a solution of <b>5a</b> (1.00 g, 7.24 mmol) in DMF (5 mL), and after 15 min 1-cyclobutylmethanamine (0.62 g, 7.24 mmol) was added. The reaction mixture was stirred at room temperature for 1 h and was then partitioned between EtOAc and H<sub>2</sub>O. The organic phase was washed with H<sub>2</sub>O, saturated aqueous solution of NaHCO<sub>3</sub>, and saturated solution of NaCl. The combined aqueous phases were extracted with EtOAc. The combined organic phases was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The residue was purified by flash column chromatography (heptane/EtOAc 1:1) to give the title compound as a clear oil (1.05 g, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.68–1.81 (m, 2H), 1.83–1.97 (m, 2H), 2.01–2.15 (m, 2H), 2.46–2.65 (m, 1H), 3.34–3.5 (m, 2H), 5.93 (s, 2H), 6.96 (dd, <i>J</i> = 8.3, 1.3, 1H), 7.12 (dd, <i>J</i> = 8.4, 4.3, 1H), 7.82 (dd, <i>J</i> = 4.3, 1.3, 1H), 8.07 (s, 1H).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>N</i>-(Cyclohexylmethyl)-3-[(1-naphthalenylcarbonyl)amino]-2-pyridinecarboxamide (<b>8a</b>)</h3><div class="NLM_p">1-Naphthalenecarbonyl chloride (400 mg, 2.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added to a solution of 3-aminopyridine-2-carboxylic acid (<b>5a</b>, 280 mg, 2.0 mmol) and DIPEA (280 mg, 2.2 mmol) in DMF (10 mL) at 0 °C. The reaction mixture was stirred for 16 h at room temperature, and then DIPEA (280 mg, 2.2 mmol) and HATU (0.84 g, 2.2 mmol) were added. After being stirred for 1 h at room temperature, the reaction mixture was heated at 50 °C to provide 2-(1-naphthalenyl)-<i>H</i>-pyrido[3,2-<i>d</i>][1,3]oxazin-4-one (<b>6a</b>) which was used in the next step with no further purification.</div><div class="NLM_p last">A solution of 1-cyclohexylmethanamine (0.261 g, 2.3 mmol) in MeOH (0.5 mL) was added to a solution of <b>6a</b> (130 mg, 0.47 mmol) in DMF (2 mL) at 0 °C. The reaction mixture was stirred for 18 h at room temperature and then concentrated in vacuo to leave a residue, which was purified by flash chromatography (hexane/EtOAc 9:1) to provide the title compound as a solid (172 mg, 95%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 0.90–1.00 (m, 2H), 1.13–1.28 (m, 3H), 1.52–1.75 (m, 6H), 3.16 (d, <i>J</i> = 6.83, 2H), 7.55–7.61 (m, 4H), 7.88–7.90 (m, 1H), 7.94–7.96 (m, 1H), 8.05–8.07 (m, 1H), 8.36 (dd, <i>J</i> = 4.5, 1.6, 1H), 8.41–8.43 (m, 1H), 9.29 (dd, <i>J</i> = 8.6, 1.4, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 388.2025; found 388.2014.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-(Cyclohexylmethyl)-3-(1-naphthoylamino)pyrazine-2-carboxamide (<b>8b</b>)</h3><div class="NLM_p last">Following the procedure for <b>8a</b>, using 3-aminopyrazine-2-carboxylic acid (<b>5c</b>, 139 mg, 1.0 mmol) in place of <b>5a</b> gave 2-(naphthalen-1-yl)-4<i>H</i>-pyrazino[2,3-<i>d</i>][1,3]oxazin-4-one (<b>6b</b>). Treatment of <b>6b</b> (69 mg, 0.25 mmol) with 1-cyclohexylmethanamine (113 mg, 1.0 mmol) provided the title compound as its TFA salt after purification by reversed-phase HPLC (6 mg, 5%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 0.96 (m, 2H), 1.22 (m, 3H), 1.72 (m, 6H), 3.19 (m, 2H), 7.55 (m, 3H), 7.95 (m, 2H), 8.06 (m, 1H), 8.48 (m, 3H); MS (ESI) <i>m</i>/<i>z</i> C<sub>23</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> found 389.0.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-(Cyclohexylmethyl)-4-[(naphthalen-1-ylcarbonyl)amino]pyridine-3-carboxamide (<b>8c</b>)</h3><div class="NLM_p last">Following the procedure for <b>8a</b>, using 4-aminopyridine-3-carboxylic acid (138 mg, 1.0 mmol) in place of <b>5a</b> gave 2-(naphthalen-1-yl)-4<i>H</i>-pyrido[4,3-<i>d</i>][1,3]oxazin-4-one (<b>6c</b>). Treatment of <b>6c</b> (0.137 mg, 0.5 mmol) with 1-cyclohexylmethanamine (226 mg, 2.0 mmol) provided the title compound as its TFA salt after purification by reversed-phase HPLC (39 mg, 16%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.99 (m, 2H), 1.23 (m, 3H), 1.63 (m, 1H), 1.76 (m, 5H), 3.22 (d, <i>J</i> = 6.8, 2H), 7.61 (m, 3H), 7.98 (m, 2H), 8.14 (d, <i>J</i> = 8.4, 1H), 8.53 (m, 1H), 8.72 (m, 1H), 9.05 (s, 1H), 9.22 (d, <i>J</i> = 6.8, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 388.2025; found 388.2064.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-(Cyclohexylmethyl)-3-[(naphthalen-1-ylcarbonyl)amino]pyridine-4-carboxamide (<b>8d</b>)</h3><div class="NLM_p last">Following the procedure for <b>8a</b>, using 3-aminopyridine-4-carboxylic acid (138 mg, 1.0 mmol) in place of <b>5a</b> gave 2-(naphthalen-1-yl)-4<i>H</i>-pyrido[3,4-<i>d</i>][1,3]oxazin-4-one (<b>6d</b>). Treatment of <b>6d</b> (137 mg, 0.5 mmol) with 1-cyclohexylmethanamine (226 mg, 2.0 mmol) provided the title compound as its TFA salt after purification by reversed-phase HPLC (55 mg, 22%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 0.99 (m, 2H), 1.22 (m, 3H), 1.70 (m, 6H), 3.22 (d, <i>J</i> = 7.2, 2H), 7.59 (m, 3H), 7.90 (dd, <i>J</i> = 7.2, 1.2, 1H), 7.96 (m, 1H), 7.99 (brs, 1H), 8.08 (d, <i>J</i> = 8.4, 1H), 8.47 (m, 1H), 8.64 (brs, 1H), 10.1 (brs, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 388.2025; found 388.2064.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N</i>-(Cyclohexylmethyl)-2-[(naphthalen-1-ylcarbonyl)amino]pyridine-3-carboxamide (<b>8e</b>)</h3><div class="NLM_p last">Following the procedure for <b>8a</b>, using 2-aminopyridine-3-carboxylic acid in place of <b>5a</b> gave 2-(naphthalen-1-yl)-4<i>H</i>-pyrido[2,3-<i>d</i>][1,3]oxazin-4-one (<b>6e</b>). Treatment of <b>6e</b> (100 mg, 0.36 mmol) with 1-cyclohexylmethanamine (226 mg, 2.0 mmol) provided the title compound as its TFA salt after purification by reversed-phase HPLC (89 mg, 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.76–0.93 (m, 2H), 0.99–1.14 (m, 3H), 1.39–1.79 (m, 6H), 3.02 (t, <i>J</i> = 6.3, 2H), 7.30 (dd, <i>J</i> = 7.6, 4.9, 1H), 7.49–7.64 (m, 3H), 7.80 (dd, <i>J</i> = 7.2, 1.0, 1H), 7.94–8.10 (m, 3H), 8.33–8.39 (m, 1H), 8.48 (dd, <i>J</i> = 4.9, 1.8, 1H), 8.60 (brs, 1H), 11.24 (brs, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 388.2025; found 388.2051.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 3-[(1-Naphthalenylcarbonyl)amino]-<i>N</i>-[(tetrahydro-2<i>H</i>-pyran-4-yl)methyl]-2-pyridinecarboxamide (<b>8f</b>)</h3><div class="NLM_p last">Following the procedure for <b>8a</b>, treating <b>6a</b> (122 mg, 0.446 mmol) with 1-(tetrahydro-2<i>H</i>-pyran-4-yl)methanamine (62 mg, 0.535 mmol) in place of 1-cyclohexylmethanamine provided the title compound as a solid (139 mg, 90%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.98 (m, 2H), 1.23 (m, 3H), 1.56 (m, 1H), 1.76 (m, 5H), 3.25 (t, <i>J</i> = 6.4, 2H), 7.54 (m, 4H), 7.90 (m, 2H), 7.98 (d, <i>J</i> = 8.0, 1H), 8.28 (dd, <i>J</i> = 8.4, 1.6, 1H), 8.53 (m, 2H), 9.41 (dd, <i>J</i> = 8.4, 0.8, 1H), 12.87 (s, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 390.1818; found 390.1812.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-(Cyclobutylmethyl)-3-[(1-naphthalenylcarbonyl)amino]-2-pyridinecarboxamide (<b>8g</b>)</h3><div class="NLM_p last">Following the procedure for <b>8a</b>, treating <b>6a</b> (100 mg, 0.37 mmol) with 1-cyclobutylmethanamine (45 mg, 0.53 mmol) in place of 1-cyclohexylmethanamine provided the title compound as a solid (160 mg, 83%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.69–1.78 (m, 2H), 1.81–1.91 (m, 2H), 1.99–2.07 (m, 2H), 2.51–2.62 (m, 1H), 3.34 (d, <i>J</i> = 7.0, 2H), 7.52–7.59 (m, 4H), 7.87–7.89 (m, 1H), 7.92–7.96 (m, 1H), 8.03–8.05 (m, 1H), 8.30–8.35 (m, 1H), 8.42–8.45 (m, 1H), 9.27 (dd, <i>J</i> = 8.6, 1.2, 1H). MS (ESI) <i>m</i>/<i>z</i> C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> found 360.0.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 3-[(2,3-Dihydro-1,4-benzodioxin-5-ylcarbonyl)amino]-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-ylmethyl)pyridine-2-carboxamide (<b>8h</b>)</h3><div class="NLM_p last">A mixture of <b>7a</b> (125 mg, 0.53 mmol), crude 1,4-benzodioxan-5-carboxylic acid chloride (0.88 mmol, prepared from 1,4-benzodioxan-5-carboxylic acid and oxalyl chloride), and DIPEA (0.15 mL, 0.88 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was stirred for 16 h. A saturated aqueous solution of NaHCO<sub>3</sub> was added, and the phases were separated. The organic phase was dried (phase separator) and concentrated in vacuo. The residue was purified by preparative reversed phase HPLC to give the title compound as a solid (150 mg, 71%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.34–1.47 (m, 2H), 1.68–1.81 (m, 2H), 1.89–2.01 (m, 1H), 3.31–3.40 (m, 2H), 3.41–3.51 (m, 2H), 3.95–4.04 (m, 2H), 4.37–4.44 (m, 2H), 4.52–4.57 (m, 2H), 6.98 (t, <i>J</i> = 7.9, 1H), 7.09 (dd, <i>J</i> = 1.6, 8.0, 1H), 7.5–7.62 (m, 2H), 8.36 (dd, <i>J</i> = 1.3, 4.4, 1H), 9.26 (dd, <i>J</i> = 1.3, 8.6, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>24</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup> 398.1716; found 398.1725.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-{2-[(Tetrahydro-2<i>H</i>-pyran-4-ylmethyl)carbamoyl]pyridin-3-yl}-1,3-benzothiazole-6-carboxamide (<b>8i</b>)</h3><div class="NLM_p last">Following the procedure for <b>8h</b>, treating <b>7a</b> (71 mg, 0.30 mmol) with 1,3-benzothiazole-6-carboxylic acid chloride (1.0 mmol, prepared from 1,3-benzothiazole-6-carboxylic acid and oxalyl chloride) in place of 1,4-benzodioxan-5-carboxylic acid chloride provided the title compound as a solid (54 mg, 45%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.35–1.49 (m, 2H), 1.71 (brd, 2H), 1.84–1.98 (m, 1H), 3.34–3.44 (m, 4H), 3.99 (dd, 2H), 7.50 (dd, 1H), 8.17–8.28 (m, 3H), 8.67 (brt, 1H), 8.71 (s, 1H), 9.14 (s, 1H), 9.34 (d, 1H), 13.30 (s, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 397.1334; found 397.1313.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-{2-[(Tetrahydro-2<i>H</i>-pyran-4-ylmethyl)carbamoyl]pyridin-3-yl}quinoxaline-5-carboxamide (<b>8j</b>)</h3><div class="NLM_p last">Following the procedure for <b>8h</b>, treating <b>7a</b> (125 mg, 0.53 mmol) with quinoxaline-5-carboxylic acid chloride (0.883 mmol, prepared from quinoxaline-5-carboxylic acid and oxalyl chloride) in place of 4-benzodioxan-5-carboxylic acid chloride provided the title compound as a solid (63 mg, 30%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.33–1.48 (m, 2H), 1.68–1.80 (m, 2H), 1.87–2.01 (m, 1H), 3.33–3.38 (m, 2H), 3.39–3.49 (m, 2H), 3.93–4.04 (m, 2H), 7.56–7.68 (m, 1H), 7.98–8.09 (m, 1H), 8.3–8.46 (m, 2H), 8.65 (dd, <i>J</i> = 1.3, 7.4, 1H), 9.06 (d, <i>J</i> = 1.6, 1H), 9.13 (d, <i>J</i> = 1.6, 1H), 9.29 (dd, <i>J</i> = 1.3, 8.6, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 392.1722; found 392.1708.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-[2-[[(Cyclobutylmethyl)amino]carbonyl]-3-pyridinyl]-5-isoquinolinecarboxamide (<b>8k</b>)</h3><div class="NLM_p last">DIPEA (0.17 mL, 0.97 mmol) was added to a solution of <b>7b</b> (100 mg, 0.49 mmol) and isoquinoline-5-carboxylic acid (168 mg, 0.97 mmol) in DMF (20 mL) at 0 °C. The mixture was stirred for 20 min, and then HATU (369 mg, 0.97 mmol) was added. The reaction mixture was stirred for 24 h at room temperature and was then quenched with water and extracted with EtOAc. The combined organic phases were combined and concentrated in vacuo to leave a residue which was purified by reversed-phase HPLC to provide the title compound as its TFA salt (97 mg, 42%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.47–1.96 (m, 4H), 2.02–2.10 (m, 2H), 2.58–2.65 (m, 1H), 3.39 (d, <i>J</i> = 7.2, 2H), 7.62 (dd, <i>J</i> = 8.6, 4.6, 1H), 8.10 (dd, <i>J</i> = 8.3, 7.3, 1H), 8.39 (dd, <i>J</i> = 4.6, 1.4, 1H), 8.59–8.64 (m, 3H), 8.98–8.90 (m, 1H), 9.26 (dd, <i>J</i> = 8.6, 1.4, 1H), 9.73–9.80 (brs, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 361.1664; found 361.1643.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-{2-[(Cyclobutylmethyl)carbamoyl]pyridin-3-yl}quinoline-8-carboxamide (<b>8l</b>)</h3><div class="NLM_p">A solution of methyl 3-aminopyridine-2-carboxylate (0.62 g, 4.06 mmol), pyridine (0.7 mL, 8.1 mmol), and DMAP (15 mg, 0.12 mmol) in CHCl<sub>3</sub> (6 mL) was added to a suspension of quinoline-8-carbonyl chloride (1.16 g, 6.08 mmol) in CHCl<sub>3</sub> (10 mL), and the reaction mixture was heated at reflux for 14 h. The reaction mixture was then diluted with CH<sub>2</sub>Cl<sub>2</sub> and was washed with saturated aqueous solution of Cu(II)SO<sub>4</sub>, 1 M aqueous NaOH, and a saturated aqueous solution of NaCl. The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to leave a residue which was purified by flash column chromatography (toluene/EtOH 15:1) to give methyl 3-[(quinolin-8-ylcarbonyl)amino]pyridine-2-carboxylate as a solid (0.50 g, 40%).</div><div class="NLM_p last">Methyl 3-[(quinolin-8-ylcarbonyl)amino]pyridine-2-carboxylate (50 mg, 0.16 mmol), dissolved in DMF (1.5 mL), was added to 1-cyclobutylmethanamine (36 mg, 0.42 mmol). The reaction mixture was stirred at 80 °C for 16 h. Additional 1-cyclobutylmethanamine (28 mg) was added, and the reaction mixture was stirred for 5 h at 80 °C. The reaction mixture was concentrated in vacuo and then purified by HPLC to give the title compound (8 mg, 14%) as a solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.74–1.86 (m, 2H), 1.88–1.99 (m, 2H), 2.07–2.20 (m, 2H), 2.55–2.68 (m, 1H), 3.43–3.55 (m, 2H), 7.47 (dd, <i>J</i> = 4.4, 8.6, 1H), 7.54 (dd, <i>J</i> = 4.2, 8.3, 1H), 7.68 (t, <i>J</i> = 7.7, 1H), 7.97–8.04 (m, 1H), 8.23–8.34 (m, 3H), 8.66 (dd, <i>J</i> = 1.4, 7.3, 1H), 9.18 (dd, <i>J</i> = 1.8, 4.2, 1H), 9.42 (dd, <i>J</i> = 1.4, 8.6, 1H), 14.34 (s, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 361.1659; found 361.1658.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-[2-[[(Cyclobutylmethyl)amino]carbonyl]-3-pyridinyl]-4-quinolinecarboxamide (<b>8m</b>)</h3><div class="NLM_p last">Following the procedure for <b>8k</b>, treating <b>7b</b> (50 mg, 0.24 mmol) with quinoline-4-carboxylic acid (50 mg, 0.29 mmol) in place of isoquinoline-5-carboxylic acid provided the title compound as its TFA salt (9 mg, 8%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.71–1.93 (m, 4H), 2.02–2.10 (m, 2H), 2.57–2.64 (m, 1H), 3.38 (d, <i>J</i> = 7.2, 2H), 7.64 (m, 1H), 7.76–7.78 (m, 1H), 7.82–7.96 (m, 2H), 8.17–8.19 (d, 1H), 8.41 (dd, <i>J</i> = 4.6, 1.5, 1H), 8.50–8.52 (m, 1H), 9.10 (d, <i>J</i> = 4.7, 1H), 9.27 (dd, <i>J</i> = 8.6, 1.5, 1H); MS (ESI) <i>m</i>/<i>z</i> C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> found 361.2.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-{2-[(Cyclobutylmethyl)carbamoyl]-6-methoxypyridin-3-yl}quinoline-4-carboxamide (<b>8n</b>)</h3><div class="NLM_p">A solution of quinoline-4-carbonyl chloride (16.5 mmol, prepared from quinoline-4-carboxylic acid and oxalyl chloride) and pyridine (7.8 mL, 97 mmol) in CHCl<sub>3</sub> (20 mL) was added to a solution of <b>15a</b> (2.00 g, 11.0 mmol), DMAP (0.302 g, 2.47 mmol), and pyridine (1.0 mL, 12 mmol) in CHCl<sub>3</sub> (10 mL) at 70 °C, and the reaction mixture was stirred at 70 °C for 1 h. The reaction mixture was then partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated aqueous solution of NaHCO<sub>3</sub>. The organic phase was washed with saturated aqueous solution of NaHCO<sub>3</sub>, dried (phase separator), and concentrated in vacuo to give crude methyl 6-methoxy-3-[(quinolin-4-ylcarbonyl)amino]pyridine-2-carboxylate (2.19 g, 59%).</div><div class="NLM_p last">A mixture of crude methyl 6-methoxy-3-[(quinolin-4-ylcarbonyl)amino]pyridine-2-carboxylate (56 mg, 0.17 mmol) and crude 1-cyclobutylmethanamine (50 mg, 0.50 mmol) in DMF (2 mL) was heated at 80 °C for 5 h and at room temperature for 16 h. The reaction mixture was concentrated in vacuo and the residue was purified by flash column chromatography (heptane/EtOAc 4:1 → 1:1) to give the title compound as a white solid (52 mg, 80%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 1.69–1.81 (m, 2H), 1.85–1.98 (m, 2H), 2.05–2.15 (m, 2H), 2.52–2.65 (m, 1H), 3.39–3.45 (m, 2H), 3.95 (s, 3H), 7.04 (d, <i>J</i> = 9.1, 1H), 7.59–7.65 (m, 1H), 7.71 (d, <i>J</i> = 4.3, 1H), 7.74–7.80 (m, 1H), 8.12–8.20 (m, 2H), 8.47 (d, <i>J</i> = 8.0, 1H), 9.04 (d, <i>J</i> = 4.3, 1H), 9.30 (d, <i>J</i> = 9.1, 1H), 12.82 (bs, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 391.177; found 391.1762.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 4-{[(2-{[(Tetrahydro-2<i>H</i>-pyran-4-ylmethyl)amino]carbonyl}pyridin-3-yl)amino]carbonyl}-1-naphthoic Acid (<b>8o</b>)</h3><div class="NLM_p last">A solution of <b>7a</b> (67 mg, 0.28 mmol) and DIPEA (1 mL, 5.74 mmol) in DCE (2 mL) was added to a solution of naphthalene-1,4-dicarbonyl dichloride (1.15 mmol, prepared from naphthalene 1,4-dicarboxylic acid and thionyl chloride) in DCE (20 mL). The reaction mixture was stirred for 3 h at room temperature and then quenched with H<sub>2</sub>O. The organic phase was separated and dried (Na<sub>2</sub>SO<sub>4</sub>). The solvent was concentrated in vacuo and the residue was purified by preparative HPLC to provide the title compound as its TFA salt (20 mg, 16%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.49 (dd, <i>J</i> = 12.9, 2.2, 2H), 2.07 (d, <i>J</i> = 3.9, 2H), 3.12 (m, 2H), 3.19 (m, 2H), 3.32 (s, 2H), 3.78 (dd, <i>J</i> = 10.7, 3.3, 2H), 3.89 (s, 1H), 7.67 (t, <i>J</i> = 7.7, 1H), 7.73 (dd, <i>J</i> = 8.6, 4.7, 2H), 7.92 (d, <i>J</i> = 7.4, 1H), 8.19 (d, <i>J</i> = 7.6, 1H), 8.35 (d, <i>J</i> = 8.2, 1H), 8.42 (dd, <i>J</i> = 4.5, 1.4, 1H), 8.85 (d, <i>J</i> = 8.4, 1H), 9.20 (dd, <i>J</i> = 8.5, 1.3, 1H), 13.0 (s, 1H); MS (ESI) <i>m</i>/<i>z</i> for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub> (M + H)<sup>+</sup> 434.0</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-(Cyclobutylmethyl)-3-{[4-(methoxymethyl)-1-naphthoyl]amino}pyridine-2-carboxamide (<b>9a</b>)</h3><div class="NLM_p">A solution of <b>7b</b> (3.0 g, 14.6 mmol) and Et<sub>3</sub>N (2.6 mL, 14.6 mmol) in MeCN (50 mL) was added to a solution of naphthalene-1,4-dicarbonyl dichloride (4.7 g, 18.5 mmol, prepared from naphthalene 1,4-dicarboxylic acid and thionyl chloride) in MeCN (700 mL) at 0 °C, and the reaction mixture was stirred for 2 h. NaOH (0.1 M aqueous solution, 0.44 mL) was then added. The reaction mixture was stirred for 1 h, and then an excess of NaOH (0.1 M aqueous solution) was added. The reaction mixture was concentrated in vacuo to leave a residue which was taken up in H<sub>2</sub>O. The precipitate was filtered, and the filtrate was acidified with concentrated HCl. The resulting precipitate was then filtered and taken up in CH<sub>2</sub>Cl<sub>2</sub> and dried (Na<sub>2</sub>SO<sub>4</sub>). The solvent was concentrated in vacuo to provide the naphthoic acid product as a solid (5.43 g, 92%).</div><div class="NLM_p">Oxalyl chloride (0.015 mL, 0.18 mmol) was added to a mixture of 4-{[(2-{[(cyclobutylmethyl)amino]carbonyl}pyridin-3-yl)amino]carbonyl}-1-naphthoic acid (50 mg, 0.11 mmol) and DCE (20 mL) at 0 °C. The reaction mixture was warmed to room temperature, heated to 70 °C for 1 h, and then cooled to 0 °C. Sodium borohydride (22 mg, 0.57 mmol) and iodine (one crystal) were added, and the reaction mixture was stirred for 1 h at 0 °C. Then EtOAc was added. The mixture was washed with H<sub>2</sub>O and then concentrated in vacuo to leave the alcohol as an oil (41 mg, 67%).</div><div class="NLM_p">Methanesulfonyl chloride (0.24 mL, 3.11 mmol) was added to a solution of <i>N</i>-(cyclobutylmethyl)-3-{[4-(hydroxymethyl)-1-naphthoyl]amino}pyridine-2-carboxamide (1.01 g, 2.59 mmol) and Et<sub>3</sub>N (0.45 mL, 3.23 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (150 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 3 h. The reaction mixture was washed with a saturated aqueous solution of NaHCO<sub>3</sub>, H<sub>2</sub>O, and then brine and then dried (Na<sub>2</sub>SO<sub>4</sub>). The mixture was concentrated in vacuo to leave a residue which was purified using flash column chromatography to provide the mesylate as a colorless oil (340 mg, 28%).</div><div class="NLM_p last">A mixture of (4-{[(2-{[(cyclobutylmethyl)amino]carbonyl}pyridin-3-yl)amino]carbonyl}-1-naphthyl)methyl methanesulfonate (60 mg, 0.13 mmol) in NaOMe (20% in MeOH, 15 mL) was heated at 70 °C for 1 h. The reaction mixture was concentrated in vacuo to leave a residue which was taken up in EtOAc. The solution was washed with a saturated aqueous solution of NaHCO<sub>3</sub>, H<sub>2</sub>O, and then brine and then dried (Na<sub>2</sub>SO<sub>4</sub>). The solution was concentrated in vacuo to leave a residue which was purified by preparative HPLC to provide the title compound as its TFA salt (30 mg, 44%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.68–1.81 (m, 2H), 1.83–1.99 (m, 2H), 2.03–2.16 (m, 2H), 2.52–2.64 (m, 1H), 3.42 (t, <i>J</i> = 6.1, 2H), 3.47 (s, 3H), 4.92–4.99 (m, 2H), 7.52 (dd, <i>J</i> = 3.1, 1.4, 1H), 7.59 (dd, <i>J</i> = 6.6, 2.7, 3H), 7.87 (d, <i>J</i> = 7.2, 1H), 8.14 (dd, <i>J</i> = 6.6, 2.9, 1H), 8.28 (s, 1H), 8.43 (s, 1H), 8.56 (dd, <i>J</i> = 6.6, 2.9, 1H), 9.40 (d, <i>J</i> = 8.2, 1H), 12.9 (s, 1H); MS (ESI) <i>m</i>/<i>z</i> for C<sub>24</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 404.0.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>-(Cyclobutylmethyl)-3-({4-[(dimethylamino)methyl]-1-naphthoyl}amino)pyridine-2-carboxamide (<b>9b</b>)</h3><div class="NLM_p last">Intermediate (4-{[(2-{[(cyclobutylmethyl)amino]carbonyl}pyridin-3-yl)amino]carbonyl}-1-naphthyl)methyl methanesulfonate (prepared in <b>9a</b>) (60 mg, 0.13 mmol), dimethylamine hydrochloride (0.20 g, 2.45 mmol), potassium iodide (138 mg, 0.84 mmol), and DMF (2 mL) were mixed and heated at 70 °C for 1 h. The reaction mixture was concentrated in vacuo to leave a residue which was taken up in EtOAc. The solution was washed with a saturated aqueous solution of NaHCO<sub>3</sub>, H<sub>2</sub>O, and then brine and then dried (Na<sub>2</sub>SO<sub>4</sub>). The solution was concentrated in vacuo to leave a residue which was purified by preparative HPLC to provide the title compound as its TFA salt (30 mg, 44%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.69–1.80 (m, 2H), 1.85–1.98 (m, 2H), 2.05–2.16 (m, 2H), 2.53–2.64 (m, 1H), 2.84 (s, 6H), 3.38–3.45 (m, 2H), 4.73–4.79 (m, 2H), 7.55 (dd, <i>J</i> = 8.5, 4.6, 1H), 7.63–7.74 (m, 2H), 7.85 (dd, <i>J</i> = 6.4, 7.3, 2H), 8.17 (d, <i>J</i> = 7.8, 1H), 8.3 (dd, <i>J</i> = 4.5, 1.4, 1H), 8.46 (t, <i>J</i> = 5.7, 1H), 8.56 (dd, <i>J</i> = 8.4, 1.2, 1H), 9.38 (dd, <i>J</i> = 8.6, 1.6, 1H), 12.99 (s, 1H); MS (ESI) <i>m</i>/<i>z</i> for C<sub>25</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 417.3.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-(Cyclobutylmethyl)-3-{[4-(1<i>H</i>-pyrrol-1-ylmethyl)-1-naphthoyl]amino}pyridine-2-carboxamide (<b>9c</b>)</h3><div class="NLM_p last">Intermediate (4-{[(2-{[(cyclobutylmethyl)amino]carbonyl}pyridin-3-yl)amino]carbonyl}-1-naphthyl)methyl methanesulfonate (prepared in <b>9a</b>) (85 mg, 0.18 mmol), pyrrole (624 mg, 9.30 mmol), potassium iodide (33 mg, 0.20 mmol), and DMF (2 mL) were mixed and heated at 80 °C for 1 h. The reaction mixture was concentrated in vacuo to leave a residue which was taken up in EtOAc. The solution was washed with a saturated aqueous solution of NaHCO<sub>3</sub>, H<sub>2</sub>O, and then brine and then dried (Na<sub>2</sub>SO<sub>4</sub>). The solution was concentrated in vacuo to leave a residue which was purified by preparative HPLC to provide the title compound as its TFA salt (29 mg, 28%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.67–1.84 (m, 3H), 1.85–1.97 (m, 2H), 2.04–2.17 (m, 2H), 2.52–2.64 (m, 1H), 3.42 (dd, <i>J</i> = 7.1, 6.2, 2H), 4.45–4.50 (m, 2H), 6.06–6.11 (m, 1H), 6.18 (q, <i>J</i> = 2.7, 1H), 6.62–6.68 (m, 1H), 7.38 (d, <i>J</i> = 7.4, 1H), 7.48–7.61 (m, 3H), 7.84 (d, <i>J</i> = 7.2, 1H), 8.09–8.15 (m, 1H), 8.28 (dd, <i>J</i> = 4.5, 1.6, 1H), 8.45 (t, <i>J</i> = 5.8, 1H), 8.54–8.59 (m, 1H), 9.40 (dd, <i>J</i> = 8.6, 1.6, 1H), 12.9 (s, 1H); MS (ESI) C<sub>24</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> found 439.0.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>-(Cyclobutylmethyl)-3-{[4-(1<i>H</i>-imidazol-1-ylmethyl)-1-naphthoyl]amino}pyridine-2-carboxamide (<b>9d</b>)</h3><div class="NLM_p last">Following the procedure for <b>9c</b>, using imidazole in place of pyrrole provided the title compound as its TFA salt (50 mg, 18%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.68–1.81 (m, 2H), 1.83–1.99 (m, 2H), 2.04–2.16 (m, 2H), 2.52–2.64 (m, 1H), 3.37–3.45 (m, 2H), 5.83 (s, 2H), 7.04 (s, 1H), 7.36 (s, 1H), 7.46 (d, <i>J</i> = 7.4, 1H), 7.54 (dd, <i>J</i> = 8.6, 4.5, 1H), 7.60–7.69 (m, 2H), 7.82–7.92 (m, 2H), 8.31 (dd, <i>J</i> = 4.5, 1.4, 1H), 8.47 (t, <i>J</i> = 6.0, 1H), 8.55–8.62 (m, 1H), 8.98 (s, 1H), 9.38 (dd, <i>J</i> = 8.6, 1.4, 1H), 13.00 (s, 1H); MS (ESI) <i>m</i>/<i>z</i> for C<sub>26</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 440.2066.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N</i>-(Cyclobutylmethyl)-3-{[4-(1<i>H</i>-pyrazol-1-ylmethyl)-1-naphthoyl]amino}pyridine-2-carboxamide (<b>9e</b>)</h3><div class="NLM_p last">Following the procedure for <b>9c</b>, using pyrazole in place of pyrrole provided the title compound as its TFA salt (33 mg, 32%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.67–1.81 (m, 2H), 1.84–1.98 (m, 2H), 2.04–2.16 (m, 2H), 2.52–2.64 (m, 1H), 3.42 (dd, <i>J</i> = 7.2, 6.3 Hz, 2H), 5.85 (s, 2H), 6.30 (s, 1H), 7.22–7.28 (m, 1H), 7.33 (s, 1H), 7.52 (dd, <i>J</i> = 8.6, 4.5, 1H), 7.56–7.61 (m, 2H), 7.61–7.65 (m, 1H), 7.85 (d, <i>J</i> = 7.4, 1H), 7.98–8.06 (m, 1H), 8.28 (dd, <i>J</i> = 4.5, 1.6, 1H), 8.44 (t, <i>J</i> = 5.8, 1H), 8.53–8.61 (m, 1H), 9.39 (dd, <i>J</i> = 8.6, 1.4, 1H), 12.90 (s, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 440.2086; found 440.2066.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i>-(Cyclobutylmethyl)-3-{[4-(1<i>H</i>-1,2,3-triazol-1-ylmethyl)-1-naphthoyl]amino}pyridine-2-carboxamide (<b>9f</b>)</h3><div class="NLM_p last">Following the procedure for <b>9c</b>, using 1,2,3-triazole in place of pyrrole provided the title compound as its TFA salt (63 mg, 64%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.68–1.81 (m, 2H), 1.85–1.98 (m, 2H), 2.05–2.16 (m, 2H), 2.52–2.65 (m, 1H), 3.42 (dd, <i>J</i> = 7.1, 6.2, 2H), 6.08 (s, 2H), 7.43 (s, 1H), 7.48 (d, <i>J</i> = 7.2, 1H), 7.54 (dd, <i>J</i> = 8.6, 4.5, 1H), 7.57–7.66 (m, 2H), 7.76 (s, 1H), 7.88 (d, <i>J</i> = 7.4, 1H), 7.95–8.02 (m, 1H), 8.30 (dd, <i>J</i> = 4.5, 1.4, 1H), 8.48 (t, <i>J</i> = 5.8, 1H), 8.52–8.59 (m, 1H), 9.39 (dd, <i>J</i> = 8.6, 1.6, 1H), 12.95 (s, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 441.2039; found 441.2044.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N</i>-{2-[(Cyclobutylmethyl)carbamoyl]-6-(2-hydroxyethoxy)pyridin-3-yl}quinoline-4-carboxamide (<b>10a</b>)</h3><div class="NLM_p">Pyridine hydrochloride (31.4 g, 0.27 mol) was added to compound <b>8n</b> (1.06 g, 2.72 mmol), and the mixture was heated at 180 °C for 25 min. The mixture was then cooled to room temperature, and a saturated aqueous solution of NaHCO<sub>3</sub> was added. The pH of the mixture was made basic by addition of solid NaHCO<sub>3</sub>. The precipitated material was filtered and washed with H<sub>2</sub>O. The solid material was then suspended in CH<sub>2</sub>Cl<sub>2</sub> and a mixture of saturated aqueous NaHCO<sub>3</sub> and saturated aqueous NaCl. The CH<sub>2</sub>Cl<sub>2</sub> phase was discarded and the solid material filtered, washed with H<sub>2</sub>O and Et<sub>2</sub>O, and dried to give <i>N</i>-{2-[(cyclobutylmethyl)carbamoyl]-6-hydroxypyridin-3-yl}quinoline-4-carboxamide (0.71 g, 69%).</div><div class="NLM_p last">Silver(I) carbonate (0.220 g, 0.798 mmol) was added to a solution of the hydroxypyridine (112 mg, 0.266 mmol) in DMF (4 mL), and the mixture was stirred at 90 °C for 5 min. 3-Bromo-1-propanol (0.145 mL, 1.60 mmol) was then added, and the reaction mixture was stirred at 90 °C for 45 min. The reaction mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated aqueous NaHCO<sub>3</sub>. The organic phase was dried (phase separator) and concentrated in vacuo to leave a residue. The residue was purified by preparative HPLC to give the title compound as a solid (49 mg, 44%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.70–1.80 (m, 2H), 1.84–2.00 (m, 2H), 2.05–2.15 (m, 2H), 2.52–2.69 (m, 1H), 3.38–3.45 (m, 2H), 3.99–4.06 (m, 2H), 4.39–4.45 (m, 2H), 7.06 (dd, <i>J</i> = 2.0, 9.1, 1H), 7.60–7.66 (m, 1H), 7.70–7.74 (m, 1H), 7.75–7.81 (m, 1H), 8.06–8.15 (m, 1H), 8.18 (d, <i>J</i> = 8.5, 1H), 8.48 (d, <i>J</i> = 8.5, 1H), 9.01–9.09 (m, 1H), 9.31 (dd, <i>J</i> = 2.0, 9.1, 1H), 12.83 (s, 1H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>24</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 421.1876; found 421.1881.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>N</i>-{2-[(Cyclobutylmethyl)carbamoyl]-6-[2-(2-hydroxyethoxy)ethoxy]pyridin-3-yl}quinoline-4-carboxamide (<b>10b</b>)</h3><div class="NLM_p last">Intermediate <i>N</i>-{2-[(cyclobutylmethyl)carbamoyl]-6-hydroxypyridin-3-yl}quinoline-4-carboxamide (prepared in <b>10a</b>) (115 mg, 0.31 mmol), diethylene glycol (162 mg, 1.528 mmol), and triphenylphosphine (480 mg, 1.83 mmol) were dissolved in THF (10 mL), and diisopropyl azodicarboxylate (370 mg, 1.83 mmol) was added. The reaction mixture was heated at 50 °C for 30 min. CH<sub>2</sub>Cl<sub>2</sub> and a saturated aqueous solution of NaHCO<sub>3</sub> were added, and the phases were separated. The organic layer was dried (phase separator) and concentrated in vacuo to leave a residue which was purified by flash column chromatography (EtOAc in heptane 10% → 100%) to give the title compound as a solid (73 mg, 51%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.66–1.80 (m, 2H), 1.82–1.96 (m, 2H), 2.03–2.14 (m, 2H), 2.44 (s, 1H), 2.49–2.64 (m, 1H), 3.40 (t, <i>J</i> = 6.6, 2H), 3.63–3.71 (m, 2H), 3.74–3.81 (m, 2H), 3.84–3.92 (m, 2H), 4.38–4.48 (m, 2H), 7.05 (d, <i>J</i> = 9.2, 1H), 7.58–7.64 (m, 1H), 7.69 (d, <i>J</i> = 4.4, 1H), 7.72–7.79 (m, 1H), 8.08 (t, <i>J</i> = 5.6, 1H), 8.16 (d, <i>J</i> = 8.4, 1H), 8.46 (d, <i>J</i> = 7.9, 1H), 9.02 (d, <i>J</i> = 4.4, 1H), 9.28 (d, <i>J</i> = 9.2, 1H), 12.80 (s, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup> 465.2138; found 465.2152.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Methyl 3-{[(4-Methylnaphthalen-1-yl)carbonyl]amino}pyridine-2-carboxylate (<b>11a</b>)</h3><div class="NLM_p last">A solution of 4-methyl-1-naphthalenecarbonyl chloride (0.65 g, 3.16 mmol) in CHCl<sub>3</sub> (2 mL) was added to a solution of <b>5a</b> (0.321 g, 2.11 mmol), DMAP (8 mg, 0.06 mmol), and pyridine (0.34 mL, 4.2 mmol) in CHCl<sub>3</sub> (4 mL), and the reaction mixture was heated at reflux for 5 h. The reaction mixture was cooled to room temperature, diluted with CH<sub>2</sub>Cl<sub>2</sub>, and washed with a saturated aqueous solution of copper(II) sulfate, a 1 M aqueous solution of NaOH, and a saturated aqueous solution of NaCl. The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to leave a residue, which was purified by flash column chromatography (toluene/EtOAc 20:1) to give the title compound (0.65 g, 96%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.77 (s, 3H), 4.00 (s, 3H), 7.42 (d, <i>J</i> = 7.2, 1H), 7.55–7.66 (m, 3H), 7.80 (d, <i>J</i> = 7.2, 1H), 8.03–8.14 (m, 1H), 8.49 (dd, <i>J</i> = 4.4, 1.3, 1H), 8.53–8.6 (m, 1H), 9.42 (dd, <i>J</i> = 8.6, 1.2, 1H), 11.59 (s, 1H).</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Methyl 3-{[(4-Methylnaphthalen-1-yl)carbonyl]amino}pyrazine-2-carboxylate (<b>11c</b>)</h3><div class="NLM_p">A solution of 4-methyl-1-naphthalenecarbonyl chloride (1.50 g, 7.31 mmol) in CHCl<sub>3</sub> (3 mL) was added to a suspension of methyl 3-aminopyrazine-2-carboxylate<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> (<b>15b</b>, 0.224 g, 1.46 mmol) and DMAP (18 mg, 0.15 mmol) in pyridine (5 mL), and the reaction mixture was stirred at 50 °C for 20 h. The reaction mixture was cooled to room temperature. NaHCO<sub>3</sub> (614 mg, 7.31 mmol) was carefully added, and the mixture was then concentrated in vacuo. The residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and H<sub>2</sub>O, and the organic phase was washed with a saturated aqueous solution of NaHCO<sub>3</sub>, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The residue was purified by flash column chromatography (toluene/EtOH 30:1; toluene/EtOH 10:1) to give methyl 3-{bis[(4-methyl-naphthalen-1-yl)carbonyl]amino}pyrazine-2-carboxylate (0.69 g, 97%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.47 (s, 6H), 3.99 (s, 3H), 6.98 (d, <i>J</i> = 7.4, 2H), 7.41–7.52 (m, 4H), 7.76–7.84 (m, 2H), 7.98 (d, <i>J</i> = 7.3, 2H), 8.26–8.33 (m, 2H), 8.52 (d, <i>J</i> = 2.3, 1H), 8.57 (d, <i>J</i> = 2.3, 1H).</div><div class="NLM_p last">2-Propanol (5 mL) and hydrazine monohydate (0.067 mL, 1.39 mmol) were added to a solution of methyl 3-{bis[(4-methylnaphthalen-1-yl)carbonyl]amino}pyrazine-2-carboxylate (0.680 g, 1.38 mmol) in dioxane (5 mL) at 100 °C. The reaction mixture was heated at reflux for 30 min and concentrated in vacuo. The residue was purified by flash column chromatography (toluene/EtOH 15:1) to give the title compound (0.44 g, 99%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.75 (s, 3H), 4.01 (s, 3H), 7.40 (d, <i>J</i> = 7.3, 1H), 7.54–7.63 (m, 2H), 7.81 (d, <i>J</i> = 7.3, 1H), 8.02–8.09 (m, 1H), 8.44 (d, <i>J</i> = 2.3 Hz, 1H), 8.58–8.66 (m, 1H), 8.72 (d, <i>J</i> = 2.3, 1H), 11.22 (s, 1H).</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Methyl 3-({[4-(1<i>H</i>-1,2,3-Triazol-1-ylmethyl)naphthalen-1-yl]carbonyl}amino)pyridine-2-carboxylate (<b>12a</b>)</h3><div class="NLM_p last">NBS (0.418 g, 2.35 mmol) and benzoyl peroxide (0.54 g, 0.22 mmol) were added to a mixture of <b>11a</b> (1.80 g, 5.14 mmol) in carbon tetrachloride (50 mL), and the reaction mixture was heated at reflux for 80 min. 1,2,3-Triazole (1.30 mL, 22.4 mmol) was added, and the reaction mixture was heated at reflux for 16 h. The reaction mixture was concentrated in vacuo to leave a residue which was purified by preparative HPLC to provide the title compound (0.20 g, 23%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.83 (s, 3H), 6.21 (s, 2H), 7.44 (d, <i>J</i> = 7.4, 1H), 7.66–7.74 (m, 3H), 7.77 (s, 1H), 7.85 (d, <i>J</i> = 7.3, 1H), 8.23 (s, 1H), 8.32 (dd, <i>J</i> = 6.8, 2.6, 1H), 8.38 (dd, <i>J</i> = 6.9, 2.8, 1H), 8.46–8.52 (m, 2H), 11.06 (s, 1H).</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N</i>-(Cyclohexylmethyl)-6-methoxy-3-{[4-(1<i>H</i>-1,2,3-triazol-1-ylmethyl)-1-naphthoyl]amino}pyridine-2-carboxamide (<b>13a</b>)</h3><div class="NLM_p">DIPEA (11.1 mL, 63.6 mmol) and 4-methyl-1-naphthalenecarbonyl chloride (2.65 g, 13.0 mmol) were added to a solution of <b>5b</b> (1.78 g, 10.6 mmol) in DMF (30 mL). The reaction mixture was stirred for 1 h at room temperature and then for 1 h at 50 °C. The reaction mixture was cooled to room temperature, and K<sub>2</sub>CO<sub>3</sub> (2.2 g, 15.9 mmol) was added followed by the addition of MeI (3.3 mL, 53 mmol). The reaction mixture was stirred for 16 h and then concentrated in vacuo to leave a residue, which was taken up in H<sub>2</sub>O. The mixture was filtered to leave a solid that was washed with H<sub>2</sub>O and then EtOH. The solid was suspended in a mixture of EtOAc and MeOH and then filtered, washed with MeOH and Et<sub>2</sub>O to give methyl 6-methoxy-3-[(4-methyl-1-naphthoyl)amino]pyridine-2-carboxylate (<b>11b</b>, 2.0 g, 54%), which was used directly in the next step.</div><div class="NLM_p">NBS (0.96 g, 5.39 mmol) and benzoyl peroxide (0.13 g, 0.51 mmol) were added to a mixture of <b>11b</b> (1.8 g, 5.14 mmol) in carbon tetrachloride (100 mL), and the reaction mixture was refluxed for 1.5 h. DMF (2.5 mL) and 1,2,3-triazole (3.0 mL, 51.4 mmol) were added, and the reaction mixture was refluxed for 16 h. The reaction mixture was concentrated in vacuo to leave a residue which was taken up in cold H<sub>2</sub>O to leave a precipitate. The mixture was filtered to leave a solid, which was washed with H<sub>2</sub>O and then purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 100:0 → 100:1) to give methyl 6-methoxy-3-{[4-(<i>1H</i>-1,2,3-triazol-1-ylmethyl)-1-naphthoyl]amino}pyridine-2-carboxylate (<b>12b</b>, 1.55 g, 72%) as a solid.</div><div class="NLM_p last">A solution of <b>12b</b> (0.5 g, 1.2 mmol) and 1-cyclohexylmethanamine (0.41 g, 3.6 mmol) in DMF (3 mL) was heated at 80 °C for 40 min. The reaction mixture was then concentrated in vacuo to leave a residue, which was dissolved in CH<sub>2</sub>Cl<sub>2</sub>. H<sub>2</sub>O (50 mL) and 2 M aqueous HCl (13 mL) were added, and the organic phase was separated, washed with a saturated aqueous solution of NaHCO<sub>3</sub> and then saturated aqueous solution of NaCl, and then dried (MgSO<sub>4</sub>). The organic phase was concentrated in vacuo to leave a residue, which was purified by preparative HPLC to give the title compound (520 mg, 86%) as a white solid. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 0.93–1.02 (m, 2H), 1.09–1.27 (m, 3H), 1.50–1.58 (m, 1H), 1.62–1.78 (m, 5H), 3.22 (t, <i>J</i> = 6.7, 2H), 3.94 (s, 3H), 6.04 (s, 2H), 7.01 (d, <i>J</i> = 9.1, 1H), 7.36 (s, 1H), 7.41 (d, <i>J</i> = 7.2, 1H), 7.53–7.60 (m, 2H), 7.66 (s, 1H), 7.83 (d, <i>J</i> = 7.2, 1H), 7.98 (d, <i>J</i> = 7.8, 1H), 8.23 (t, <i>J</i> = 6.5, 1H), 8.53 (d, <i>J</i> = 8.5, 1H), 9.31 (d, <i>J</i> = 9.1, 1H), 12.62 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.6, 166.8, 157.7, 136.2, 134.2, 133.1, 132.8, 131.5, 130.9, 129.7, 127.8, 127.6, 126.7, 126.6, 124.8, 123.4, 123.0, 115.7, 53.5, 52.1, 45.3, 38.0, 30.8, 26.3, 25.8; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>30</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup> 499.2458; found 499.2468.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 6-Methoxy-<i>N</i>-(cyclobutylmethyl)-3-{[4-(1<i>H</i>-1,2,3-triazol-1-ylmethyl)-1-naphthoyl]-amino}pyridine-2-carboxamide (<b>13b</b>)</h3><div class="NLM_p last"><b>13b</b> was prepared using essentially the same procedure as described for <b>13a</b>, using 1-cyclobutylmethanamine in place of 1-cyclohexylmethanamine to give the product (980 mg, 87%) as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.64–1.82 (m, 2H), 1.83–2.00 (m, 2H), 2.02–2.19 (m, 2H), 2.46–2.67 (m, 1H), 3.29–3.53 (m, 2H), 3.94 (s, 3H), 6.05 (s, 2H), 7.02 (d, <i>J</i> = 9.2, 1H), 7.35–7.46 (m, 2H), 7.51–7.64 (m, 2H), 7.67 (s, 1H), 7.85 (d, <i>J</i> = 7.3, 1H), 7.94–8.07 (m, 1H), 8.1–8.25 (m, 1H), 8.44–8.69 (m, 1H), 9.32 (d, <i>J</i> = 9.2, 1H), 12.63 (s, 1H); MS (ESI) (M + H)<sup>+</sup><i>m</i>/<i>z</i> C<sub>26</sub>H<sub>26</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup> found 471.04.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 6-Methoxy-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-ylmethyl)-3-{[4-(1<i>H</i>-1,2,3-triazol-1-ylmethyl)-1-naphthoyl]amino}pyridine-2-carboxamide (<b>13c</b>)</h3><div class="NLM_p last"><b>13c</b> was prepared using essentially the same procedure as described for <b>13a</b> using 1-(tetrahydro-2<i>H</i>-pyran-4-yl)methanamine in place of 1-cyclohexylmethanamine to give the product (470 mg, 79%) as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.30–1.41 (m, 2H), 1.60–1.70 (m, 2H), 1.80–1.94 (m, 1H), 3.26–3.43 (m, 4H), 3.96 (s, 3H), 3.96–4.02 (m, 2H), 6.06 (s, 2H), 7.04 (d, <i>J</i> = 9.2, 1H), 7.39 (d, <i>J</i> = 0.8, 1H), 7.43 (d, <i>J</i> = 7.2, 1H), 7.54–7.64 (m, 2H), 7.69 (d, <i>J</i> = 0.8, 1H), 7.85 (d, <i>J</i> = 7.2, 1H), 7.96–8.04 (m, 1H), 8.27 (t, <i>J</i> = 6.2, 1H), 8.51–8.59 (m, 1H), 9.33 (d, <i>J</i> = 9.1, 1H), 12.6 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.6, 167.0, 157.8, 136.2, 134.2, 133.2, 133.2, 132.9, 131.5, 130.9, 129.4, 127.8, 127.6, 126.6, 126.6, 124.8, 123.5, 123.0, 115.9, 67.5, 53.5, 52.1, 44.8, 35.4, 30.6; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>28</sub>N<sub>6</sub>O<sub>4</sub> [M + H]<sup>+</sup> 501.225; found 501.2228.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-[(Tetrahydro-2<i>H</i>-pyran-4-yl)methyl]-3-[[[4-(1<i>H</i>-1,2,3-triazol-1-ylmethyl)-1-naphthalenyl]carbonyl]amino]-2-pyridinecarboxamide (<b>13d</b>)</h3><div class="NLM_p last">A solution of <b>12a</b> (0.20 g, 0.51 mmol) and 1-(tetrahydro-2<i>H</i>-pyran-4-yl)methanamine (0.153 g, 1.33 mmol) in DMF (3 mL) was heated at 80 °C for 4 h. The reaction mixture was then concentrated in vacuo to leave a residue which was purified by preparative HPLC to provide the title compound as a solid (0.19 g, 80%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.37–1.51 (m, 2H), 1.66–1.70 (m, <i>J</i> = 12.7, 2H), 1.81–1.92 (m, 1H), 3.31 (t, <i>J</i> = 6.6, 2H), 3.36–3.42 (m, 2H), 3.98–4.02 (m, 2H), 6.09 (s, 2H), 7.44–7.46 (m, 1H), 7.48 (d, <i>J</i> = 7.2, 1H), 7.56 (dd, <i>J</i> = 8.6, 4.5, 1H), 7.61–7.65 (m, 2H), 7.79 (s, 1H), 7.88 (d, <i>J</i> = 7.2, 1H), 7.98–7.80 (m, 1H), 8.31 (dd, <i>J</i> = 4.5, 1.4, 1H), 8.54–8.56 (m, 1H), 8.60–8.64 (m, 1H), 9.40 (dd, <i>J</i> = 8.6, 1.6, 1H), 12.86 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 168.1, 167.2, 142.4, 138.3, 135.9, 134.3, 133.3, 133.1, 131.5, 130.8, 128.8, 127.9, 127.7, 127.6, 126.6, 126.6, 124.9, 123.5, 123.1, 67.5, 52.1, 44.9, 35.3, 30.6; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>26</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup> 471.2144; found 471.2135.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-(Cyclobutylmethyl)-3-{[4-(1<i>H</i>-1,2,3-triazol-1-ylmethyl)-1-naphthoyl]amino}pyrazine-2-carboxamide (<b>13e</b>)</h3><div class="NLM_p last">Following the procedure for <b>13a</b>, using <b>11c</b> (139 mg, 1.0 mmol) in place of <b>11b</b> gave methyl 3-({[4-(1<i>H</i>-1,2,3-triazol-1-ylmethyl)naphthalen-1-yl]carbonyl}amino)pyrazine-2-carboxylate (<b>12c</b>, 1.44 g, 58%). Treatment of <b>12c</b> (0.620 g, 1.60 mmol) with 1-cyclobutylmethanamine (316 mg, 3.71 mmol) in place of 1-cyclohexylmethanamine provided the title compound as a solid (0.47 mg, 66%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.62–1.85 (m, 4H), 1.86–2.02 (m, 2H), 2.48–2.58 (m, 1H), 3.23–3.39 (m, 2H), 6.21 (s, 2H), 7.40 (d, <i>J</i> = 7.3, 1H), 7.61–7.73 (m, 2H), 7.78 (s, 1H), 7.87 (d, <i>J</i> = 7.3, 1H), 8.23 (s, 1H), 8.30 (d, <i>J</i> = 8.0, 1H), 8.41 (d, <i>J</i> = 8.4, 1H), 8.47 (d, <i>J</i> = 2.1, 1H), 8.66 (d, <i>J</i> = 2.1, 1H), 9.15 (t, <i>J</i> = 5.6, 1H), 12.21 (brs, 1H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.9, 165.3, 147.9, 145.8, 138.3, 135.2, 134.8, 133.8, 133.0, 131.0, 130.1, 127.5, 127.4, 126.1, 126.0, 125.6, 125.4, 124.0, 50.7, 44.2, 34.6, 25.3, 17.9; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 442.1991; found 442.1997.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 6-{[(Tetrahydro-2<i>H</i>-pyran-4-ylmethyl)amino]carbonyl}-5-{[4-(l<i>H</i>-1,2,3-triazolylmethyl)-1-naphthoyl]amino}pyridin-2-yl-3,3,3-trifluoropropane-1-sulfonate (<b>14</b>)</h3><div class="NLM_p">A mixture of <b>13c</b> (145 mg, 0.3 mmol) and pyridine hydrochloride (3.8 g, 32.9 mmol) was heated at 150 °C for 30 min. Water was added at room temperature and the formed precipitate was collected, washed with water, dried, and purified by preparative HPLC to give 6-hydroxy-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-ylmethyl)-3-{[4-(<i>1H</i>-1,2,3-triazol-1-ylmethyl)-1-naphthoyl]amino}pyridine-2-carboxamide (113 mg, 80%).</div><div class="NLM_p last">Silver(I) carbonate (0.40 g, 1.45 mmol) was added to a solution of the hydroxypyridine (50 mg, 0.10 mmol) and 3,3,3-trifluoropropylsulfonyl chloride (40 mg, 0.21 mmol) in CH<sub>3</sub>CN (20 mL), and the mixture was heated at reflux for 2.5 h. A mixture of CH<sub>2</sub>Cl<sub>2</sub>/MeOH was then added, and the mixture was filtered. The filtrate was concentrated in vacuo to leave a residue which was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated aqueous solution of NaHCO<sub>3</sub>. The organic phase was washed with a saturated aqueous solution of NaCl, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo to leave a residue. The residue was purified by flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 100:1.5) to give the title compound as a solid (260 mg, 78%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 1.34–1.40 (m, 2H), 1.60–1.66 (m, 2H), 1.78–1.88 (m, 1H), 2.88–2.98 (m, 2H), 3.28–3.40 (m, 4H), 3.65–3.71 (m, 2H), 3.95–4.01 (m, 2H), 6.08 (s, 2H), 7.40–7.45 (m, 3H), 7.59–7.66 (m, 2H), 7.71 (s, 1H), 7.86 (d, <i>J</i> = 7.3, 1H), 7.94–7.99 (m, 1H), 8.02–8.08 (m, 1H), 8.52–8.57 (m, 1H), 9.64 (d, <i>J</i> = 9.0, 1H), 12.81 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 168.0, 165.8, 148.7, 138.1, 135.2, 134.3, 134.2, 133.7, 131.6, 131.1, 130.8, 128.0, 127.9, 126.4, 125.2 (q, <i>J</i> = 276), 125.1, 123.6, 123.2, 120.4, 67.5, 52.0, 45.4 (q, <i>J</i> = 3), 45.1, 35.2, 30.5, 29.2 (q, <i>J</i> = 32); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>29</sub>F<sub>3</sub>N<sub>6</sub>O<sub>6</sub>S [M + H]<sup>+</sup> 647.1899; found 647.1904.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Methyl 3-Amino-6-methoxypyridine-2-carboxylate (<b>15a</b>)</h3><div class="NLM_p last">Compound <b>4b</b> (15.1g, 89.8 mmol) was treated with saturated methanolic solution of HCl (300 mL) for 60 h at room temperature. The reaction mixture was concentrated in vacuo to leave a residue, and the residue was suspended in Et<sub>2</sub>O. The solid material was filtered, washed with Et<sub>2</sub>O, and dried (Na<sub>2</sub>SO<sub>4</sub>) to give the title compound as the corresponding HCl salt (19.5g, 99%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.74 (s, 3H), 3.78 (s, 3H), 6.87 (d, <i>J</i> = 8.9, 1H), 7.28 (d, <i>J</i> = 8.9, 1H); MS (ESI) <i>m</i>/<i>z</i> for C<sub>8</sub>H<sub>11</sub>N<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup> 183.0.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Methyl 6-Methoxy-3-[({4-[(methylsulfanyl)methyl]naphthalen-1-yl}carbonyl)amino]pyridine-2-carboxylate (<b>16a</b>)</h3><div class="NLM_p">Sodium methanethiolate (5.6 g, 80.5 mmol) was added in portions to a solution of 4-(bromomethyl)-1-naphthoic acid<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (19.9 g, 75.2 mmol) in THF (140 mL) at 0 °C, and the reaction mixture was stirred at room temperature for 2 h. The mixture was cooled to 0 °C, H<sub>2</sub>O was added, and the pH was adjusted to ∼4 with the aid of a 4 M aqueous solution of HCl to give a precipitate. The precipitate was filtered and washed with cold H<sub>2</sub>O to give 4-[(methylthio)methyl]-1-naphthoic acid (16.1g, 92%).</div><div class="NLM_p">Oxalyl chloride (10.5 mL, 124 mmol) was added slowly to a suspension of 4-[(methylthio)methyl]-1-naphthoic acid (2.89 g, 12.4 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL), and the resulting mixture was stirred at room temperature for 16 h. The reaction mixture was then concentrated in vacuo to leave a residue, which was taken up in toluene and concentrated in vacuo to leave 4-[(methylthio)methyl]-1-naphthoyl chloride (3.06 g, 98%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.06 (s, 3H), 4.15 (s, 2H), 7.48 (d, <i>J</i> = 7.6, 1H), 7.61–7.73 (m, 2H), 8.21 (d, <i>J</i> = 8.2, 1H), 8.48 (d, <i>J</i> = 7.7, 1H), 8.79 (d, <i>J</i> = 8.7, 1H).</div><div class="NLM_p last">A solution of 4-[(methylthio)methyl]-1-naphthoyl chloride (690 mg, 2.74 mmol) in CHCl<sub>3</sub> (4 mL) was added to a solution of <b>15a</b> (400 mg, 1.83 mmol), pyridine (0.59 mL, 7.3 mmol), and DMAP (7.0 mg, 0.06 mmol) in CHCl<sub>3</sub> (6 mL), and the reaction mixture was stirred at 50 °C for 16 h. The mixture was then diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with a saturated aqueous solution of copper(II) sulfate, a 1 M aqueous solution of NaOH, and a saturated aqueous solution of NaCl. The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to leave a residue, which was purified by flash column chromatography (toluene/EtOAc 20:1) to give the title compound (550 mg, 76%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.09 (s, 3H), 3.95 (s, 3H), 4.00 (s, 3H), 4.17 (s, 2H), 7.08 (d, <i>J</i> = 9.2, 1H), 7.46 (d, <i>J</i> = 7.3, 1H), 7.56–7.7 (m, 2H), 7.78 (d, <i>J</i> = 7.3, 1H), 8.13–8.27 (m, 1H), 8.46–8.62 (m, 1H), 9.28 (d, <i>J</i> = 9.2, 1H), 11.36 (s, 1H); MS (ESI) <i>m</i>/<i>z</i> C<sub>21</sub>H<sub>21</sub>N<sub>2</sub>O<sub>4</sub>S (M + H)<sup>+</sup> 397.1.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>N</i>-(Cyclobutylmethyl)-3-({4-[(methylthio)methyl]-1-naphthoyl}amino)pyridine-2-carboxamide. (<b>17a</b>)</h3><div class="NLM_p last">Compound <b>7b</b> (80 mg, 0.39 mmol) was added to a solution of 4-[(methylthio)methyl]-1-naphthoyl chloride (prepared in <b>16a</b>) (143 mg, 0.57 mmol), pyridine (0.32 mL, 3.9 mmol), and DMAP (0.5 mg, 0.004 mmol) in CHCl<sub>3</sub> (1 mL). The reaction mixture was heated at reflux for 2 h. H<sub>2</sub>O and CH<sub>2</sub>Cl<sub>2</sub> were added and the organic phase was filtered through a phase separator and concentrated in vacuo to leave a residue. The residue was purified by flash column chromatography (EtOAc in heptane 0% → 40%) to give the title compound (140 mg, 86%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.66–1.79 (m, 2H), 1.82–1.98 (m, 2H), 2.05 (s, 3H), 2.03–2.13 (m, 2H), 2.49–2.65 (m, 1H), 3.36–3.44 (m, 2H), 4.14 (s, 2H), 7.43 (d, <i>J</i> = 7.3, 1H), 7.49 (dd, <i>J</i> = 8.6, 4.5, 1H), 7.53–7.63 (m, 2H), 7.80 (d, <i>J</i> = 7.2, 1H), 8.14–8.21 (m, 1H), 8.25 (dd, <i>J</i> = 4.5, 1.3, 4.5, 1H), 8.36–8.47 (m, 1H), 8.51–8.59 (m, 1H), 9.38 (dd, <i>J</i> = 8.6, 1.3, 1H), 12.82 (s, 1H); MS (ESI) <i>m</i>/<i>z</i> for C<sub>24</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub>S (M + H)<sup>+</sup> 420.1.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 6-Methoxy-3-({4-[(methylthio)methyl]-1-naphthoyl}amino)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-ylmethyl)pyridine-2-carboxamide (<b>17b</b>)</h3><div class="NLM_p last">1-(Tetrahydro-2<i>H</i>-pyran-4-yl)methanamine (8.72 g, 75.7 mmol) was added to a solution of <b>16a</b> (5.0 g, 12.6 mmol) in DMF (50 mL). The reaction mixture was stirred at 80 °C for 3 h and then cooled to room temperature. H<sub>2</sub>O and CH<sub>2</sub>Cl<sub>2</sub> were added, and the phases were separated. The organic phase was washed with H<sub>2</sub>O and a saturated aqueous solution of NaCl and then dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to leave a residue. The residue was recrystallized using CH<sub>2</sub>Cl<sub>2</sub>/EtOH to give the title compound (5.5 g, 91%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.30–1.51 (m, 2H), 1.54–1.73 (m, 2H), 1.75–1.95 (m, 1H), 2.08 (s, 3H), 3.24–3.45 (m, 4H), 3.95 (s, 3H), 3.96–4.02 (m, 2H), 4.16 (s, 2H), 7.03 (d, <i>J</i> = 9.2, 1H), 7.44 (d, <i>J</i> = 7.3, 1H), 7.52–7.68 (m, 2H), 7.79 (d, <i>J</i> = 7.3, 1H), 8.14–8.35 (m, 2H), 8.49–8.62 (m, 1H), 9.34 (d, <i>J</i> = 9.2, 1H), 12.47 (s, 1H); MS (ESI) <i>m</i>/<i>z</i> C<sub>26</sub>H<sub>30</sub>N<sub>3</sub>O<sub>4</sub>S (M + H)<sup>+</sup> 480.0.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>N</i>-(Cyclobutylmethyl)-3-({4-[(methylsulfinyl)methyl]-1-naphthoyl}amino)pyridine-2-carboxamide (<b>18a</b>)</h3><div class="NLM_p last"><i>m</i>-CPBA (82 mg, ∼70%, 0.33 mmol) was added to a solution of <b>17a</b> (140 mg, 0.33 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 10 min. A saturated aqueous solution of NaHCO<sub>3</sub> was then added, and the organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to leave a residue. The residue was purified by flash column chromatography (EtOAc in toluene 20% → 100%) to give the title compound (51 mg, 35%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.67–1.78 (m, 2H), 1.82–1.95 (m, 2H), 2.02–2.13 (m, 2H), 2.50 (s, 3H), 2.51–2.53 (m, 1H), 3.34–3.43 (m, 2H), 4.33 (d, <i>J</i> = 12.9, 1H), 4.69 (d, <i>J</i> = 12.9, 1H), 7.10–7.17 (m, 1H), 7.47–7.54 (m, 1H), 7.58–7.66 (m, 2H), 7.85 (d, <i>J</i> = 7.3, 1H), 8.09–8.15 (m, 1H), 8.24–8.28 (m, 1H), 8.39–8.46 (m, 1H), 8.51–8.58 (m, 1H), 9.33–9.39 (m, 1H), 12.89 (s, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 436.1695; found 436.1701.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 6-Methoxy-3-({4-[(methylsulfinyl)methyl]-1-naphthoyl}amino)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-ylmethyl)pyridine-2-carboxamide (<b>18b</b>)</h3><div class="NLM_p last">A solution of <i>m</i>-CPBA (120 mg, ∼70%, 0.49 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added to a solution of <b>17b</b> (220 mg, 0.46 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (7 mL) at 0 °C, and the reaction mixture was stirred at 0 °C for 2.5 h. The reaction mixture was then diluted with CH<sub>2</sub>Cl<sub>2</sub>, washed with a saturated aqueous solution of NaHCO<sub>3</sub> and a saturated aqueous solution of NaCl, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo to leave a residue. The residue was purified by flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 50:1 → 25:1) to give the title compound (166 mg, 73%) as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.29–1.45 (m, 2H), 1.60–1.69 (m, 2H), 1.78–1.91 (m, 1H), 2.54 (s, 3H), 3.27–3.42 (m, 4H), 3.92–4.01 (m, 2H), 3.95 (s, 3H), 4.38 (d, <i>J</i> = 12.9, 1H), 4.71 (d, <i>J</i> = 12.9, 1H), 7.03 (d, <i>J</i> = 9.2, 1H), 7.54 (d, <i>J</i> = 7.3, 1H), 7.57–7.67 (m, 2H), 7.84 (d, <i>J</i> = 7.3, 1H), 8.09–8.15 (m, 1H), 8.23–8.29 (m, 1H), 8.52–8.58 (m, 1H), 9.32 (d, <i>J</i> = 9.2, 1H), 12.54 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.7, 167.0, 157.7, 135.5, 133.2, 133.2, 132.2, 130.9, 129.7, 129.4, 128.1, 127.5, 127.4, 126.6, 125.0, 123.8, 115.8, 67.5, 59.0, 53.5, 44.8, 38.2, 35.4, 30.6; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>29</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup> 496.1906; found 496.1925.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 3-({4-[(Methylsulfinyl)methyl]-1-naphthoyl}amino)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-ylmethyl)pyridine-2-carboxamide (<b>18c</b>)</h3><div class="NLM_p">4-Methyl-1-naphthalenecarbonyl chloride (6.14 g, 30.0 mmol) was added to a solution of <b>7a</b>, (2.90 g, 12.3 mmol), pyridine (3.0 mL, 37 mmol), and DMAP (45 mg, 0.37 mmol) in CHCl<sub>3</sub> (160 mL), and the reaction mixture was heated at reflux for 1.5 h. The reaction mixture was then partitioned between CH<sub>2</sub>Cl<sub>2</sub> and H<sub>2</sub>O. The organic phase was dried (phase separator) and concentrated in vacuo to leave a residue. The residue was purified by flash column chromatography (heptane/EtOAc 9:1) to give 3-{[(4-methylnaphthalen-1-yl)carbonyl]amino}-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-ylmethyl)pyridine-2-carboxamide (4.24 g, 85%). <sup>1</sup>H NMR (400 MHz, CDCL<sub>3</sub>) δ 1.29–1.42 (m, 2H), 1.61–1.68 (m, 2H), 1.77–1.91 (m, 1H), 2.72 (s, 3H), 3.29 (t, <i>J</i> = 6.6, 2H), 3.31–3.39 (m, 2H), 3.95 (dd, <i>J</i> = 11,2, 3.4, 2H), 7.38 (d, <i>J</i> = 7.2, 1H), 7.49 (dd, <i>J</i> = 8.6, 4.5, 1H), 7.53–7.59 (m, 2H), 7.79 (d, <i>J</i> = 7.2, 1H), 8.02–8.09 (m, 1H), 8.24 (dd, <i>J</i> = 4.5, 1.4, 1H), 8.5–8.61 (m, 2H), 9.38 (dd, <i>J</i> = 8.6, 1.4, 1H), 12.72 (s, 1H).</div><div class="NLM_p">AIBN (15 mg, 0.06 mmol) was added to a solution of 3-{[(4-methylnaphthalen-1-yl)carbonyl]amino}-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-ylmethyl)pyridine-2-carboxamide (400 mg, 0.99 mmol) and NBS (360 mg, 2 mmol) in DCE (20 mL) at room temperature. The solution was heated at 80 °C for 2.5 h, then cooled to room temperature and concentrated in vacuo to leave the crude bromomethylnaphthalene derivative, which was used directly with no further purification. Sodium methanethiolate (1.22 g, 17.4 mmol) was added to a solution of 3-{[4-(bromomethyl)-1-naphthoyl]amino}-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-ylmethyl)pyridine-2-carboxamide (4.20 g, 8.71 mmol) in DMF (50 mL) at 0 °C. The reaction mixture was stirred at room temperature for 3 h, and then H<sub>2</sub>O and EtOAc were added and the phases were separated. The organic phase was washed with H<sub>2</sub>O, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo to leave a residue. The residue was purified by flash column chromatography (EtOAc in heptane 25% → 50%) to give the crude 3-({4-[(methylthio)methyl]-1-naphthoyl}amino)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-ylmethyl)pyridine-2-carboxamide (<b>17c</b>, 1.81 g, 46%) that was used directly in the next step.</div><div class="NLM_p last"><i>m</i>-CPBA (0.99 g, ∼70%, 4.03 mmol) was added to a solution of the crude methylthionaphthyl derivative (<b>17c</b>, 1.81 g, 4.03 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 10 min. A saturated aqueous solution of NaHCO<sub>3</sub> was then added, and the organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to leave a residue. The residue was purified by flash column chromatography (EtOAc in toluene 20% → 60%) to give the title compound as a solid (0.82 g, 44%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.29–1.41 (m, 2H), 1.59–1.68 (m, 2H), 1.78–1.88 (m, 1H), 2.51 (s, 3H), 3.25–3.39 (m, 4H), 3.91–3.99 (m, 2H), 4.36 (d, <i>J</i> = 12.9, 1H), 4.69 (d, <i>J</i> = 12.9, 1H), 7.49–7.55 (m, 2H), 7.58–7.66 (m, 2H), 7.84 (d, <i>J</i> = 7.3, 1H), 8.09–8.15 (m, 1H), 8.24–8.28 (m, 1H), 8.51–8.58 (m, 2H), 9.34–9.39 (m, 1H), 12.81 (s, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 466.1801; found 466.1779.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 3-[(4-{[(<i>R</i>)-Methylsulfinyl]methyl}-1-naphthoyl)amino]-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-ylmethyl)pyridine-2-carboxamide and 3-[(4-{[(<i>S</i>)-Methylsulfinyl]methyl}-1-naphthoyl)amino]-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl-methyl)pyridine-2-carboxamide (<b>18d</b> and <b>18e</b>)</h3><div class="NLM_p last"><b>18d</b> and <b>18e</b> were obtained by separating the enantiomers of <b>18c</b> using chiral chromatography at 40 °C on a ReproSil HPLC column (250 mm × 20 mm, 8 μm) and eluting with MeOH at a flow rate of 18 mL/min and detected at 265 nm. The first eluted compound was collected and evaporated to yield <b>18d</b> (320 mg, 99.6% ee) [α]<sup>20</sup><sub>D</sub> +101 (<i>c</i> 1.0, CH<sub>3</sub>CN) as a solid. The second eluted compound was collected and evaporated to yield <b>18e</b> (340 mg, 99.7% ee) [α]<sup>20</sup><sub>D</sub> −99.7 (<i>c</i> 1.0, CH<sub>3</sub>CN) as a solid.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>N</i>-(Cyclobutylmethyl)-3-({4-[(methylsulfinyl)methyl]-1-naphthoyl}amino)pyrazine-2-carboxamide (<b>18f</b>)</h3><div class="NLM_p">NBS (88 mg, 0.49 mmol) and AIBN (∼2 mg, 0.01 mmol) were added to a solution of <b>11c</b> (155 mg, 0.482 mmol) in CCl<sub>4</sub> (15 mL) at 77 °C, and the reaction mixture was heated at reflux for 2 h. The reaction mixture was then concentrated in vacuo to leave a residue, and the residue was partitioned between EtOAc and H<sub>2</sub>O. The organic phase was washed with a saturated aqueous solution of NaCl, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to give crude methyl 3-{[4-(bromomethyl)-1-naphthoyl]amino}pyrazine-2-carboxylate (193 mg). This crude product was taken to the next synthetic step without further purification.</div><div class="NLM_p">Sodium methanethiolate (29 mg, 0.41 mmol) was added to a solution of crude methyl 3-{[4-(bromomethyl)-1-naphthoyl]amino}pyrazine-2-carboxylate (190 mg) in DMF (3 mL) at 0 °C. The reaction mixture was stirred at room temperature for 4 h and then partitioned between EtOAc and H<sub>2</sub>O. The aqueous phase was extracted with EtOAc and the combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to leave a residue, which was purified using flash chromatography (EtOAc in heptane 50% → 100%) to give crude methyl 3-({4-[(methylthio)methyl]-1-naphthoyl}amino)pyrazine-2-carboxylate (<b>16b</b>, 102 mg).</div><div class="NLM_p last">The final two steps were performed by an analogous method to <b>16a</b> → <b>17b</b> → <b>18b</b> using 1-cyclobutylmethanamine in place of 1-(tetrahydro-2<i>H</i>-pyran-4-yl)methanamine to give crude <i>N</i>-(cyclobutylmethyl)-3-[({4-[(methylsulfanyl)methyl]naphthalen-1-yl}carbonyl)amino]pyrazine-2-carboxamide (<b>17d)</b> and then performing the last oxidation step with <i>m</i>-CPBA to give the title compound as a solid (33 mg, 16% overall yield from <b>11c</b>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.73–1.81 (m, 2H), 1.89–1.99 (m, 2H), 2.10–2.17 (m, 2H), 2.55 (s, 3H), 2.57–2.64 (m, 1H), 3.45–3.48 (m, 2H), 4.39 (d, <i>J</i> = 12.9, 1H), 4.74 (d, <i>J</i> = 12.9, 1H), 7.58 (d, <i>J</i> = 7.3, 1H), 7.63–7.70 (m, 2H), 7.94 (d, <i>J</i> = 7.3, 1H), 8.15–8.20 (m, 2H), 8.31 (d, <i>J</i> = 2.3, 1H), 8.67–8.70 (m, 1H), 8.74 (d, <i>J</i> = 2.3, 1H), 12.75 (s, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 437.1647; found 437.1664.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>N</i>-(Cyclobutylmethyl)-3-[(4-{[(<i>R</i>)-methylsulfinyl]methyl}-1-naphthoyl)amino]pyrazine-2-carbox-amide or <i>N</i>-(Cyclobutylmethyl)-3-[(4-{[(<i>S</i>)-methylsulfinyl]methyl}-1-naphthoyl)amino]pyrazine-2-carboxamide (<b>18g</b>)</h3><div class="NLM_p last"><b>18g</b> was obtained by separating the enantiomers of <b>18f</b> using chiral chromatography at 40 °C on a Chiralpak IA HPLC column (205 mm × 20 mm, 5 μm), eluting with heptane/EtOH 30:70 at a flow rate of 12 mL/min and detected at 265 nm. The first eluted compound was collected and evaporated to yield 18g (310 mg, 99.9% ee) [α]<sup>20</sup><sub>D</sub> +100 (<i>c</i> 1.0, CH<sub>3</sub>CN) as a solid. The second eluted compound was collected and evaporated to yield the second enantiomer (265 mg, 99.9% ee) [α]<sup>20</sup><sub>D</sub> −131 (<i>c</i> 1.0, CH<sub>3</sub>CN) as a solid.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>N</i>-(Cyclobutylmethyl)-3-({4-[(methylsulfonyl)methyl]-1-naphthoyl}amino)pyridine-2-carboxamide (<b>19</b>)</h3><div class="NLM_p last">In the synthesis of <b>18a</b>, the title compound (<b>19</b>, 51 mg, 34%) could also be isolated as a solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.78–1.66 (m, 2H), 1.94–1.83 (m, 2H), 2.12–2.03 (m, 2H), 2.50–2.62 (m, 1H), 2.77 (s, 3H), 3.35–3.43 (m, 2H), 4.79 (s, 2H), 7.17–7.12 (m, 1H), 7.53–7.48 (m, 1H), 7.68–7.58 (m, 2H), 7.88 (d, <i>J</i> = 7.3, 1H), 8.15 (d, <i>J</i> = 8.0, 1H), 8.28–8.26 (m, 1H), 8.46–8.40 (m, 1H), 8.52–8.59 (m, 1H), 9.38–9.34 (m, 1H), 12.9 (s, 1H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 452.1644; found 452.1649.</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> <i>N</i>-(Cyclobutylmethyl)-6-[2-(2-hydroxyethoxy)ethoxy]-3-({4-[(methylsulfinyl)methyl]-1-naphthoyl}amino)pyridine-2-carboxamide (<b>20</b>)</h3><div class="NLM_p">Following the procedure for <b>17b</b>, using <b>16a</b> (1.7 g, 4.19 mmol) and 1-cyclobutylmethanamine (1.0 g, 11.7 mmol) in place of 1-(tetrahydro-<i>2H</i>-pyran-4-yl)methanamine) gave <i>N</i>-(cyclobutylmethyl)-6-methoxy-3-({4-[(methylthio)methyl]-1-naphthoyl}amino)pyridine-2-carboxamide (17e, 1.68 g, 89%).</div><div class="NLM_p">Compound <b>17e</b> (810 mg, 1.80 mmol) was added to melted pyridine hydrochloride (21 g, 0.11 mol) at 160 °C, and the mixture was stirred at 160 °C for 30 min. The reaction mixture was cooled to room temperature, and H<sub>2</sub>O was added. The precipitated material was filtered, washed with H<sub>2</sub>O, and dried to give <i>N</i>-(cyclobutylmethyl)-3-({4-[(methylthio)methyl]-1-naphthoyl}amino)-6-oxo-1,6-dihydropyridine-2-carboxamide (680 mg, 87%).</div><div class="NLM_p">A solution of <i>m</i>-CPBA (2.70 g, ∼70%, 11.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (200 mL) was added slowly to a solution of the thiomethyl intermediate (4.64 g, 10.7 mmol) in CHCl<sub>3</sub> (200 mL) at 0 °C, and the reaction mixture was stirred at 0 °C for 1 h. A second portion of <i>m</i>-CPBA (105 mg, ∼70%, 0.43 mmol) was added, and the reaction mixture was stirred at 0 °C for an additional 10 min. H<sub>2</sub>O was added. The phases were separated, and the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic phases were washed with a saturated aqueous solution of NaCl, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo to leave a residue, which was purified by flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 40:1 → 25:1) to give the hydroxypyridine (4.50 g, 94%).</div><div class="NLM_p last">Silver(I) carbonate (0.74 g, 2.67 mmol) was added to a solution of the hydroxypyridine (400 mg, 0.89 mmol) and 2-(2-chloroethoxy)ethanol (3.30 g, 26.5 mmol) in DMF (8 mL), and the mixture was heated in a microwave at 130 °C for 8 h. A mixture of CH<sub>2</sub>Cl<sub>2</sub>/MeOH was then added, and the mixture was filtered. The filtrate was concentrated in vacuo to leave a residue which was partitioned between EtOAc and H<sub>2</sub>O. The organic phase was washed with a saturated aqueous solution of NaHCO<sub>3</sub> and a saturated aqueous solution of NaCl, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo to leave a residue. The residue was purified by preparative HPLC to give the title compound as a solid (128 mg, 27%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.73–1.82 (m, 2H), 1.84 (s, 1H), 1.89–1.99 (m, 2H), 2.08–2.15 (m, 2H), 2.56 (s, 3H), 2.57–2.64 (m, 1H), 3.42–3.45 (m, 2H), 3.71–3.74 (m, 2H), 3.81–3.83 (m, 2H), 3.92–3.95 (m, 2H), 4.40 (d, <i>J</i> = 12.9, 1H), 4.47–4.49 (m, 2H), 4.77 (d, <i>J</i> = 12.9, 1H), 7.10 (d, <i>J</i> = 9.1, 1H), 7.56 (d, <i>J</i> = 7.3, 1H), 7.62–7.70 (m, 2H), 7.87 (d, <i>J</i> = 7.3, 1H), 8.09–8.12 (m, 1H), 8.15–8.17 (m, 1H), 8.57–8.60 (m, 1H), 9.37 (d, <i>J</i> = 9.1, 1H), 12.64 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.7, 166.9, 157.0, 135.5, 133.4, 133.3, 132.2, 130.9, 129.7, 129.6, 128.1, 127.5, 127.4, 126.6, 125.0, 123.8, 116.0, 72.6, 69.4, 65.4, 61.8, 59.0, 44.2, 38.2, 34.9, 25.6, 18.3; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>33</sub>N<sub>3</sub>O<sub>6</sub>S [M + H]<sup>+</sup> 540.2168; found 540.2157.</div></div><div id="sec4_50_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Biological Evaluation. hCB<sub>1</sub> and hCB<sub>2</sub> Receptor Binding Assay<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h3><div class="NLM_p last">Membranes are produced from either HEK 293S cells expressing the cloned hCBl receptor (clone no. 24) or Sf9 cells, using the baculovirus system, expressing the cloned hCB2 receptor. The membranes are thawed at 37 °C, passed 3 times through a 23 gauge blunt-end needle, and diluted in the cannabinoid binding buffer (50 mM Tris, 2.5 mM EDTA, 5 mM MgCl<sub>2</sub>, and 0.5 mg/mL BSA fatty acid free, pH 7.4), and 80 μL aliquots containing the appropriate amount of protein are distributed in 96-well plates. The IC<sub>50</sub> values of the compounds (150 μL) at hCBl and hCB2 are evaluated from 10-point dose–response curves performed with <sup>3</sup>H-CP55,940 (70 μL) at 20000–25000 dpm per well (0.17–0.21 nM) in a final volume of 300 μL. The total and nonspecific binding are determined in the absence and presence of 0.2 μM of HU210 (150 μL). The plates are vortexed, incubated for 60 min at room temperature, and filtered through Unifilters GF/B (presoaked in 0.1% polyethyleneimine) with the Packard harvester using 3 mL of wash buffer (50 mM Tris, 5 mM MgCl<sub>2</sub>, 0.05% BSA, pH 7.0). The filters are dried for 1 h at 55 °C. The specific binding (SB) is calculated as TB-NS, and the SB in the presence of various ligands is expressed as percentage of control SB. Values of IC<sub>50</sub> and Hill coefficient (<i>n</i><sub>H</sub>) for ligands in displacing specifically bound radioligand are calculated in ActivityBase with Xlfit4 (IDBS, Inc.). The concentration of compounds to use and dilutions are also calculated with ActivityBase. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μL/well Microscint 20 (Packard Biosciences) scintillation fluid.</div></div><div id="sec4_50_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> GTPγ[<sup>35</sup>S] Binding Assay<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h3><div class="NLM_p">GTPγ[<sup>35</sup>S] binding was measured on cloned human CB1 receptors in membranes of HEK 293S cells or cloned human CB2 receptors in membranes of Sf9 cells. The membranes are thawed at 37 °C, passed 3 times through a 23 gauge blunt-end needle, and diluted in the GTPγ[<sup>35</sup>S] binding buffer (50 mM <i>N</i>-2-hydroxyethylpiperazine-<i>N</i>-2-ethanesulfonic acid (Hepes), 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl<sub>2</sub>, pH 7.4, 0.1% BSA, and 15 μM GDP). The EC<sub>50</sub> and <i>E</i><sub>max</sub> of the compounds at hCBl and hCB2 are evaluated from 10-point dose–response curves. The assay, performed in 96-well plates, consisted of 300 μL, containing 150 μL of buffer alone or compound at varying concentrations, 80 μL of membranes (5 μg of protein/well) mixed with 56 μM GDP (15 μM final). Finally, 70 μL of the tracer GTPγ[<sup>35</sup>S] (Dupont/NEN, Mandel Scientific, St-Laurent) (100000–130000 dpm/well) is added to start the reaction. Eight wells were used to define basal (negative control) binding and eight for positive control (maximal binding) using 10 μM <b>2</b>. The plates were then mixed by hand on an orbital mixer and incubated for 1 h at room temperature, filtered on Unifilters GF/B (presoaked in deionized water) with the Packard harvester using 3 mL of wash buffer (50 mM Tris, 5 mM MgCl<sub>2</sub>, 50 mM NaCl, pH 7.4). The filters are dried for 1 h at 55 °C before adding 50 μL of Microscint 20 (Packard Biosciences) scintillation fluid. The radioactivity (cpm) on the filter plates was counted in a TopCount (Packard). The cpm values of GTPγ[<sup>35</sup>S] binding in the eight wells containing GTPγ[<sup>35</sup>S] and membranes were averaged to define basal binding, and the values of the eight wells containing 10 μM <b>2</b> were averaged to define GTPγ[<sup>35</sup>S] maximal binding. The stimulation of GTPγ[<sup>35</sup>S] binding observed for each concentration of compound was expressed as a percentage of maximal effect elicited by 10 μM <b>2</b>. GTPγ[<sup>35</sup>S] specific binding is calculated by subtracting the basal binding. Curve fitting and EC<sub>50</sub> calculations were performed using Xlfit4 (IDBS, Inc.).</div><div class="NLM_p last">Dog CB1 GTPγ[<sup>35</sup>S] binding assays were conducted using cloned dog CB1 receptors stably expressed in HEK 293S cells using the same procedures described for the human CB1 receptors stably expressed in the same cell line.</div></div><div id="sec4_50_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> TLESR Measurements in Vivo in Dogs</h3><div class="NLM_p last">The method applied for the in vivo studies of TLESR in dogs and the definitions of motility parameters have been described previously.<a onclick="showRef(event, 'ref9 ref48'); return false;" href="javascript:void(0);" class="ref ref9 ref48">(9, 48)</a> In brief, a water-perfused Dentsleeve multilumen assembly was introduced to dogs through the esophagostomy for the measurement of gastric, lower esophageal sphincter (LES) and esophageal pressures. A pH electrode above the LES was used to measure acid reflux episodes, and a catheter was placed in the hypopharynx to measure swallows. TLESRs were stimulated by gastric infusion of an acidified liquid nutrient (10% peptone, 5% <span class="smallcaps smallerCapital">d</span>-glucose, 5% Intralipid, pH 3.0; 30 mL/kg; 100 mL/min) followed by air insufflation (500 mL/min) to maintain gastric pressure at 10 ± 1 mmHg. TLESRs were defined as a rapid decrease in LES pressure (>1 mmHg/s) to a pressure of <2 mmHg above gastric pressure and a duration of >1s without any swallowing <2 s before onset. The compounds were administered intragastrically or intravenously 30 or 10 min before start of the experiment, respectively, and the number of TLESRs was measured for 45 min. Each dog served as its own control, and inhibition of TLESRs was calculated with regard to five preceding control experiments for each dog. Data are presented as the mean ± SEM. All procedures were approved by the Ethical Committee for Animal Experiments of the Gothenburg Region.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70"><a href="/doi/suppl/10.1021/jm301511h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81725" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81725" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Experimental methods used to determine dog behavior, solubility, Caco-2 transport and efflux ratios, CYP enzyme inhibition, measurement of unbound brain exposure in the rat, <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub>, and hERG inhibition. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301511h/suppl_file/jm301511h_si_001.pdf">jm301511h_si_001.pdf (108.37 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm301511h" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67318" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67318" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alleyn T. Plowright</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca Research
and Development, Pepparedsleden 1, Mölndal, 43183,
Sweden</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#53323f3f362a3d7d233f3c24213a343b2713322027213229363d3630327d303c3e"><span class="__cf_email__" data-cfemail="a3c2cfcfc6dacd8dd3cfccd4d1cac4cbd7e3c2d0d7d1c2d9c6cdc6c0c28dc0ccce">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karolina Nilsson</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca Research
and Development, Pepparedsleden 1, Mölndal, 43183,
Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Madeleine Antonsson</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca Research
and Development, Pepparedsleden 1, Mölndal, 43183,
Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kosrat Amin</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca Research
and Development, Pepparedsleden 1, Mölndal, 43183,
Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johan Broddefalk</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca Research
and Development, Pepparedsleden 1, Mölndal, 43183,
Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jörgen Jensen</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca Research
and Development, Pepparedsleden 1, Mölndal, 43183,
Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anders Lehmann</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca Research
and Development, Pepparedsleden 1, Mölndal, 43183,
Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shujuan Jin</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
Research
and Development, 7171 Frederick-Banting, Saint-Laurent,
Quebec, H4S 1Z9, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephane St-Onge</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
Research
and Development, 7171 Frederick-Banting, Saint-Laurent,
Quebec, H4S 1Z9, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mirosław J. Tomaszewski</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
Research
and Development, 7171 Frederick-Banting, Saint-Laurent,
Quebec, H4S 1Z9, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maxime Tremblay</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
Research
and Development, 7171 Frederick-Banting, Saint-Laurent,
Quebec, H4S 1Z9, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Walpole</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
Research
and Development, 7171 Frederick-Banting, Saint-Laurent,
Quebec, H4S 1Z9, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhongyong Wei</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
Research
and Development, 7171 Frederick-Banting, Saint-Laurent,
Quebec, H4S 1Z9, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hua Yang</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
Research
and Development, 7171 Frederick-Banting, Saint-Laurent,
Quebec, H4S 1Z9, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johan Ulander</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca Research
and Development, Pepparedsleden 1, Mölndal, 43183,
Sweden</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d839e6609-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30050" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30050" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Christer Alstermark, David Blomberg Saitton, Yantao Chen, Maria Glosax, and Ziping Lui for the synthesis of compounds and Ann Aurell, Anita Fredriksson, Marcus Fridén, Gunilla Jerndal, Erik Ryberg, and Cecilia Wikell for testing of the compounds.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i72" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i72"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i73" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i73"> Abbreviations Used</h2><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">CB1</td><td class="NLM_def"><p class="first last">cannabinoid receptor 1</p></td></tr><tr><td class="NLM_term">CB2</td><td class="NLM_def"><p class="first last">cannabinoid receptor 2</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub></td><td class="NLM_def"><p class="first last">unbound brain-to-plasma concentration ratio</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">GERD</td><td class="NLM_def"><p class="first last">gastroesophageal reflux disease</p></td></tr><tr><td class="NLM_term">GTPγ[<sup>35</sup>S]</td><td class="NLM_def"><p class="first last">[<sup>35</sup>S]guanosine 5′-<i>O</i>-(3-thiotriphosphate)</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyl-<i>O</i>-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hank’s balanced saline solution</p></td></tr><tr><td class="NLM_term">Hepes</td><td class="NLM_def"><p class="first last"><i>N</i>-2-hydroxyethylpiperazine-<i>N</i>-2-ethanesulfonic acid</p></td></tr><tr><td class="NLM_term">hu Caco-2 A–B</td><td class="NLM_def"><p class="first last">human Caco-2 cells apical to basolateral</p></td></tr><tr><td class="NLM_term">hCB1</td><td class="NLM_def"><p class="first last">human cannabinoid receptor 1</p></td></tr><tr><td class="NLM_term">hCB2</td><td class="NLM_def"><p class="first last">human cannabinoid receptor 2</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">ligand lipophilicity efficiency</p></td></tr><tr><td class="NLM_term">LES</td><td class="NLM_def"><p class="first last">lower esophageal sphincter</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability</p></td></tr><tr><td class="NLM_term">TLESR</td><td class="NLM_def"><p class="first last">transient lower esophageal sphincter relaxation</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47421" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47421" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 55 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Howlett, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabral, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casellas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devane, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herkenham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechoulam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1124%2Fpr.54.2.161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=12037135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=161-202&author=A.+C.+Howlettauthor=F.+Barthauthor=T.+I.+Bonnerauthor=G.+Cabralauthor=P.+Casellasauthor=W.+A.+Devaneauthor=C.+C.+Felderauthor=M.+Herkenhamauthor=K.+Mackieauthor=B.+R.+Martinauthor=R.+Mechoulamauthor=R.+G.+Pertwee&title=International+Union+of+Pharmacology.+XXVII.+Classification+of+cannabinoid+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span></div><div class="casAuthors">Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-202</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Two types of cannabinoid receptor have been discovered so far, CB1 (2.1: CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993.  Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type.  Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity.  Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase.  CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels.  These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release.  Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers.  CB2 receptors are present mainly on immune cells.  Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release.  Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether.  It is unclear whether these eicosanoid mols. are the only, or primary, endogenous agonists.  Hence, the authors consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacol. Committee on Receptor Nomenclature and Drug Classification.  Although pharmacol. evidence for the existence of addnl. types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeoe-6izzgsrVg90H21EOLACvtfcHk0liDmcS38P9AAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D&md5=4a8345d34b5724ee3cd999b71956ab54</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.161%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26aulast%3DCabral%26aufirst%3DG.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DDevane%26aufirst%3DW.%2BA.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DHerkenham%26aufirst%3DM.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXVII.%2520Classification%2520of%2520cannabinoid%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D161%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Devane, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breuer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pertwee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandelbaum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etinger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechoulam, R.</span><span> </span><span class="NLM_article-title">Isolation and structure of a brain constituent that binds to the cannabinoid receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">258</span><span class="NLM_x">, </span> <span class="NLM_fpage">1946</span><span class="NLM_x">–</span> <span class="NLM_lpage">1949</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1126%2Fscience.1470919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=1470919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADyaK3sXpvVKntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=1992&pages=1946-1949&author=W.+Devaneauthor=L.+Hanusauthor=A.+Breuerauthor=R.+Pertweeauthor=L.+Stevensonauthor=G.+Griffinauthor=D.+Gibsonauthor=A.+Mandelbaumauthor=A.+Etingerauthor=R.+Mechoulam&title=Isolation+and+structure+of+a+brain+constituent+that+binds+to+the+cannabinoid+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and structure of a brain constituent that binds to the cannabinoid receptor</span></div><div class="casAuthors">Devane, William A.; Hanus, Lumir; Breuer, Aviva; Pertwee, Roger G.; Stevenson, Lesley A.; Griffin, Graeme; Gibson, Dan; Mandelbaum, Asher; Etinger, Alexander; Mechoulam, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">258</span>
        (<span class="NLM_cas:issue">5090</span>),
    <span class="NLM_cas:pages">1946-9</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Arachidonylethanolamide, an arachidonic acid deriv. in the porcine brain, was identified as an endogenous ligand for the cannabinoid receptor.  The structure of this compd., anandamide, was detd. by mass spectrometry and NMR spectroscopy and was confirmed by synthesis.  Anandamide inhibited the specific binding of a radiolabeled cannabinoid probe to synaptosomal membranes in a manner typical of competitive ligands and produced a concn.-dependent inhibition of the elec. evoked twitch responses of the mouse vas deferens, a characteristic effect of psychotropic cannabinoids.  Anandamide may function as a natural ligand for the cannabinoid receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXqh5E4vHczbVg90H21EOLACvtfcHk0lgRps4Ugg2kwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXpvVKntg%253D%253D&md5=13c7aa7316cd687240779f7f192d086b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1470919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1470919%26sid%3Dliteratum%253Aachs%26aulast%3DDevane%26aufirst%3DW.%26aulast%3DHanus%26aufirst%3DL.%26aulast%3DBreuer%26aufirst%3DA.%26aulast%3DPertwee%26aufirst%3DR.%26aulast%3DStevenson%26aufirst%3DL.%26aulast%3DGriffin%26aufirst%3DG.%26aulast%3DGibson%26aufirst%3DD.%26aulast%3DMandelbaum%26aufirst%3DA.%26aulast%3DEtinger%26aufirst%3DA.%26aulast%3DMechoulam%26aufirst%3DR.%26atitle%3DIsolation%2520and%2520structure%2520of%2520a%2520brain%2520constituent%2520that%2520binds%2520to%2520the%2520cannabinoid%2520receptor%26jtitle%3DScience%26date%3D1992%26volume%3D258%26spage%3D1946%26epage%3D1949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">Emerging strategies for exploiting cannabinoid receptor agonists as medicines</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">411</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1111%2Fj.1476-5381.2008.00048.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=19226257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2009&pages=397-411&author=R.+G.+Pertwee&title=Emerging+strategies+for+exploiting+cannabinoid+receptor+agonists+as+medicines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging strategies for exploiting cannabinoid receptor agonists as medicines</span></div><div class="casAuthors">Pertwee, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-411</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Medicines that activate cannabinoid CB1 and CB2 receptor are already in the clinic.  These are Cesamet (nabilone), Marinol (dronabinol; Δ9-tetrahydrocannabinol) and Sativex (Δ9-tetrahydrocannabinol with cannabidiol).  The first two of these medicines can be prescribed to reduce chemotherapy-induced nausea and vomiting.  Marinol can also be prescribed to stimulate appetite, while Sativex is prescribed for the symptomatic relief of neuropathic pain in adults with multiple sclerosis and as an adjunctive analgesic treatment for adult patients with advanced cancer.  One challenge now is to identify addnl. therapeutic targets for cannabinoid receptor agonists, and a no. of potential clin. applications for such agonists are mentioned in this review.  A second challenge is to develop strategies that will improve the efficacy and/or the benefit-to-risk ratio of a cannabinoid receptor agonist.  This review focuses on five strategies that have the potential to meet either or both of these objectives.  These are strategies that involve: (i) targeting cannabinoid receptors located outside the blood-brain barrier; (ii) targeting cannabinoid receptors expressed by a particular tissue; (iii) targeting up-regulated cannabinoid receptors; (iv) targeting cannabinoid CB2 receptors; or (v) 'multi-targeting'.  Preclin. data that justify addnl. research directed at evaluating the clin. importance of each of these strategies are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyRcPADOyxJLVg90H21EOLACvtfcHk0lgRps4Ugg2kwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wlsrk%253D&md5=d38ff0563eedaf74879d56e148840cb1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2008.00048.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2008.00048.x%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DEmerging%2520strategies%2520for%2520exploiting%2520cannabinoid%2520receptor%2520agonists%2520as%2520medicines%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D156%26spage%3D397%26epage%3D411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Di Marzo, V.; De Petrocellis, L.; Bisogno, T.</span><span> </span><span class="NLM_article-title">The Biosynthesis, Fate and Pharmacological Properties of Endocannabinoids</span>. In  <span class="citation_source-book">Cannabinoids. Handbook of Experimental Pharmacology</span>; <span class="NLM_contrib-group">Pertwee, R. G.</span>, Ed.; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">Heidelberg, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">168</span>, pp  <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=147-185&author=V.+Di+Marzo&author=L.+De+Petrocellis&author=T.+Bisognoauthor=R.+G.+Pertwee&title=Cannabinoids.+Handbook+of+Experimental+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DThe%2520Biosynthesis%252C%2520Fate%2520and%2520Pharmacological%2520Properties%2520of%2520Endocannabinoids%26btitle%3DCannabinoids.%2520Handbook%2520of%2520Experimental%2520Pharmacology%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26pub%3DSpringer-Verlag%26date%3D2005%26volume%3D168%26spage%3D147%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Thakur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tichkule, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajaj, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makriyannis, A.</span><span> </span><span class="NLM_article-title">Latest advances in cannabinoid receptor agonists</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1647</span><span class="NLM_x">–</span> <span class="NLM_lpage">1673</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1517%2F13543770903436505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=19939187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WhtLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1647-1673&author=G.+A.+Thakurauthor=R.+Tichkuleauthor=S.+Bajajauthor=A.+Makriyannis&title=Latest+advances+in+cannabinoid+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Latest advances in cannabinoid receptor agonists</span></div><div class="casAuthors">Thakur, Ganesh A.; Tichkule, Ritesh; Bajaj, Shama; Makriyannis, Alexandros</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1647-1673</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Since the discovery of cannabinoid receptors and their endogenous ligands in early 1990s, the endocannabinoid system has been shown to play a vital role in several pathophysiol. processes.  It has been targeted for the treatment of several diseases including neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, Huntington's disease and MS), cancer, obesity, inflammatory bowel disease, neuropathic and inflammatory pain.  The last decade has witnessed remarkable advances in the development of cannabinergic ligands displaying high selectivity and potency towards two subtypes of cannabinoid receptors, namely CB1 and CB2.  Objective: In this review, we highlight the latest advances made in the development of cannabinoid agonists and summarize recently disclosed, novel chem. scaffolds as CB-selective agonists in patents that appeared during Jan. 2008 - June 2009.  Methods: Data presented here are obtained through the search of PubMed for research articles and reviews, and the website of European patents (http://ep.espacenet.com), SciFinder Scholar and US patents (www.uspto.gov).  Conclusions: Our anal. reveals prolific patenting activity mainly in the CB2 selective agonist area.  Limiting the BBB penetrability, thereby, leading to peripherally restricted CB1/CB2 agonists and enhancing CB2-selectivity emerge as likely prerequisites for avoidance of adverse central CB1 mediated side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6PLKU_aASWLVg90H21EOLACvtfcHk0ljJzroAlDis1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WhtLfP&md5=7b959b5b25908fef8fe45267aaa05334</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1517%2F13543770903436505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903436505%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DTichkule%26aufirst%3DR.%26aulast%3DBajaj%26aufirst%3DS.%26aulast%3DMakriyannis%26aufirst%3DA.%26atitle%3DLatest%2520advances%2520in%2520cannabinoid%2520receptor%2520agonists%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1647%26epage%3D1673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Cheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock, S. A.</span><span> </span><span class="NLM_article-title">Targeting cannabinoid agonists for inflammatory and neuropathic pain</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">951</span><span class="NLM_x">–</span> <span class="NLM_lpage">965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1517%2F13543784.16.7.951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=17594182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVOmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=951-965&author=Y.+Chengauthor=S.+A.+Hitchcock&title=Targeting+cannabinoid+agonists+for+inflammatory+and+neuropathic+pain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cannabinoid agonists for inflammatory and neuropathic pain</span></div><div class="casAuthors">Cheng, Yuan; Hitchcock, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">951-965</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The cannabinoid receptors CB1 and CB2 are class A G-protein-coupled receptors.  It is well known that cannabinoid receptor agonists produce relief of pain in a variety of animal models by interacting with cannabinoid receptors.  CB1 receptors are located centrally and peripherally, whereas CB2 receptors are expressed primarily on immune cells and tissues.  A large body of preclin. data supports the hypothesis that either CB2-selective agonists or CB1 agonists acting at peripheral sites, or with limited CNS exposure, will inhibit pain and neuroinflammation without side effects within the CNS.  There has been a growing interest in developing cannabinoid agonists.  Many new cannabinoid ligands have been synthesized and studied covering a wide variety of novel structural scaffolds.  This review focuses on the present development of cannabinoid agonists with an emphasis on selective CB2 agonists and peripherally restricted CB1 or CB1/CB2 dual agonists for treatment of inflammatory and neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprxE9ZXlueyrVg90H21EOLACvtfcHk0ljJzroAlDis1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVOmsbY%253D&md5=0728e81e6981449c3ec1551703caba03</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.7.951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.7.951%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26atitle%3DTargeting%2520cannabinoid%2520agonists%2520for%2520inflammatory%2520and%2520neuropathic%2520pain%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D951%26epage%3D965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Adam, J.; Cowley, P. M.; Kiyoi, T.; Morrison, A. J.; Mort, C. J. W.</span> <span class="citation_source-book">Progress in Medicinal Chemistry</span>; <span class="NLM_contrib-group">King, F. D.; Lawton, G.</span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">44</span>, p  <span class="NLM_fpage">207</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=207&author=J.+Adam&author=P.+M.+Cowley&author=T.+Kiyoi&author=A.+J.+Morrison&author=C.+J.+W.+Mortauthor=F.+D.+King&author=G.+Lawton&title=Progress+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAdam%26aufirst%3DJ.%26btitle%3DProgress%2520in%2520Medicinal%2520Chemistry%26aulast%3DKing%26aufirst%3DF.%2BD.%26pub%3DElsevier%26date%3D2006%26volume%3D44%26spage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Lehmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackshaw, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bränden, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nygren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smid, S. D.</span><span> </span><span class="NLM_article-title">Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">1129</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2002&pages=1129-1134&author=A.+Lehmannauthor=L.+A.+Blackshawauthor=L.+Br%C3%A4ndenauthor=A.+Carlssonauthor=J.+Jensenauthor=E.+Nygrenauthor=S.+D.+Smid&title=Cannabinoid+receptor+agonism+inhibits+transient+lower+esophageal+sphincter+relaxations+and+reflux+in+dogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DA.%26aulast%3DBlackshaw%26aufirst%3DL.%2BA.%26aulast%3DBr%25C3%25A4nden%26aufirst%3DL.%26aulast%3DCarlsson%26aufirst%3DA.%26aulast%3DJensen%26aufirst%3DJ.%26aulast%3DNygren%26aufirst%3DE.%26aulast%3DSmid%26aufirst%3DS.%2BD.%26atitle%3DCannabinoid%2520receptor%2520agonism%2520inhibits%2520transient%2520lower%2520esophageal%2520sphincter%2520relaxations%2520and%2520reflux%2520in%2520dogs%26jtitle%3DGastroenterology%26date%3D2002%26volume%3D123%26spage%3D1129%26epage%3D1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Beaumont, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckxstaens, G.</span><span> </span><span class="NLM_article-title">Effect of Δ<sup>9</sup>-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1111%2Fj.1476-5381.2008.00010.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=19068079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252Fmt1ymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2009&pages=153-162&author=H.+Beaumontauthor=J.+Jensenauthor=A.+Carlssonauthor=M.+Ruthauthor=A.+Lehmannauthor=G.+Boeckxstaens&title=Effect+of+%CE%949-tetrahydrocannabinol%2C+a+cannabinoid+receptor+agonist%2C+on+the+triggering+of+transient+lower+oesophageal+sphincter+relaxations+in+dogs+and+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans</span></div><div class="casAuthors">Beaumont H; Jensen J; Carlsson A; Ruth M; Lehmann A; Boeckxstaens Ge</div><div class="citationInfo"><span class="NLM_cas:title">British journal of pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">153-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Transient lower oesophageal sphincter relaxations (TLESRs) are the main mechanism underlying gastro-oesophageal reflux and are a potential pharmacological treatment target.  We evaluated the effect of the CB(1)/CB(2) receptor agonist delta(9)-tetrahydrocannabinol (delta(9)-THC) on TLESRs in dogs.  Based on these findings, the effect of delta(9)-THC was studied in healthy volunteers.  EXPERIMENTAL APPROACH:  In dogs, manometry was used to evaluate the effect of delta(9)-THC in the presence and absence of the CB(1) receptor antagonist SR141716A on TLESRs induced by gastric distension.  Secondly, the effect of 10 and 20 mg delta(9)-THC was studied in 18 healthy volunteers in a placebo-controlled study.  Manometry was performed before and for 3 h after meal ingestion on three occasions.  KEY RESULTS:  In dogs, delta(9)-THC dose-dependently inhibited TLESRs and reduced acid reflux rate.  SR141716A significantly reversed the effects of delta(9)-THC on TLESRs.  Similarly, in healthy volunteers, delta(9)-THC significantly reduced the number of TLESRs and caused a non-significant reduction of acid reflux episodes in the first postprandial hour.  In addition, lower oesophageal sphincter pressure and swallowing were significantly reduced by delta(9)-THC.  After intake of 20 mg, half of the subjects experienced nausea and vomiting leading to premature termination of the study.  Other side-effects were hypotension, tachycardia and central effects.  CONCLUSIONS AND IMPLICATIONS:  Delta(9)-THC significantly inhibited the increase in meal-induced TLESRs and reduced spontaneous swallowing in both dogs and humans.  In humans, delta(9)-THC significantly reduced basal lower oesophageal sphincter pressure.  These findings confirm previous observations in dogs and indicate that cannabinoid receptors are also involved in the triggering of TLESRs in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyUm43wSSQ3-3MPKNEWB5RfW6udTcc2eYe-pM_vrB7g7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252Fmt1ymtQ%253D%253D&md5=7235d6aff7533c64b9ffcf3df14f20e1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2008.00010.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2008.00010.x%26sid%3Dliteratum%253Aachs%26aulast%3DBeaumont%26aufirst%3DH.%26aulast%3DJensen%26aufirst%3DJ.%26aulast%3DCarlsson%26aufirst%3DA.%26aulast%3DRuth%26aufirst%3DM.%26aulast%3DLehmann%26aufirst%3DA.%26aulast%3DBoeckxstaens%26aufirst%3DG.%26atitle%3DEffect%2520of%2520%25CE%25949-tetrahydrocannabinol%252C%2520a%2520cannabinoid%2520receptor%2520agonist%252C%2520on%2520the%2520triggering%2520of%2520transient%2520lower%2520oesophageal%2520sphincter%2520relaxations%2520in%2520dogs%2520and%2520humans%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D156%26spage%3D153%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Mittal, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penagini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackshaw, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dent, J.</span><span> </span><span class="NLM_article-title">Transient lower esophageal sphincter relaxation</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">601</span><span class="NLM_x">–</span> <span class="NLM_lpage">610</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1995&pages=601-610&author=R.+K.+Mittalauthor=R.+H.+Hollowayauthor=R.+Penaginiauthor=L.+A.+Blackshawauthor=J.+Dent&title=Transient+lower+esophageal+sphincter+relaxation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMittal%26aufirst%3DR.%2BK.%26aulast%3DHolloway%26aufirst%3DR.%2BH.%26aulast%3DPenagini%26aufirst%3DR.%26aulast%3DBlackshaw%26aufirst%3DL.%2BA.%26aulast%3DDent%26aufirst%3DJ.%26atitle%3DTransient%2520lower%2520esophageal%2520sphincter%2520relaxation%26jtitle%3DGastroenterology%26date%3D1995%26volume%3D109%26spage%3D601%26epage%3D610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Rinaldi-Carmona, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Héaulme, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shire, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calandra, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruani, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Néliat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caput, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soubrié, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brelière, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Fur, G.</span><span> </span><span class="NLM_article-title">SR141716A, a potent and selective antagonist of the brain cannabinoid receptor</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1016%2F0014-5793%2894%2900773-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=8070571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVKjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=1994&pages=240-244&author=M.+Rinaldi-Carmonaauthor=F.+Barthauthor=M.+H%C3%A9aulmeauthor=D.+Shireauthor=B.+Calandraauthor=C.+Congyauthor=S.+Martinezauthor=J.+Maruaniauthor=G.+N%C3%A9liatauthor=D.+Caputauthor=P.+Ferraraauthor=P.+Soubri%C3%A9author=J.-C.+Breli%C3%A8reauthor=G.+Le+Fur&title=SR141716A%2C+a+potent+and+selective+antagonist+of+the+brain+cannabinoid+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">SR141716A, a potent and selective antagonist of the brain cannabinoid receptor</span></div><div class="casAuthors">Rinaldi-Carmona, Murielle; Barth, Francis; Heaulme, Michel; Shire, David; Calandra, Bernard; Congy, Christian; Martinez, Serge; Maruani, Jeanne; Neliat, Gervais; et al.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">240-4</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor.  This compd. displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor.  In vitro, SR141716A antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes.  After i.p. or oral administration, SR141716A antagonizes classical pharmacol. and behavioral effects of cannabinoid receptor agonists.  This compd. should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLJ59LaZb2cbVg90H21EOLACvtfcHk0ljwxbE_Sldlog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVKjsrw%253D&md5=1eebdfec28d2dde64729cddb859aa6c8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2894%2900773-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252894%252900773-X%26sid%3Dliteratum%253Aachs%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DH%25C3%25A9aulme%26aufirst%3DM.%26aulast%3DShire%26aufirst%3DD.%26aulast%3DCalandra%26aufirst%3DB.%26aulast%3DCongy%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DMaruani%26aufirst%3DJ.%26aulast%3DN%25C3%25A9liat%26aufirst%3DG.%26aulast%3DCaput%26aufirst%3DD.%26aulast%3DFerrara%26aufirst%3DP.%26aulast%3DSoubri%25C3%25A9%26aufirst%3DP.%26aulast%3DBreli%25C3%25A8re%26aufirst%3DJ.-C.%26aulast%3DLe%2BFur%26aufirst%3DG.%26atitle%3DSR141716A%252C%2520a%2520potent%2520and%2520selective%2520antagonist%2520of%2520the%2520brain%2520cannabinoid%2520receptor%26jtitle%3DFEBS%2520Lett.%26date%3D1994%26volume%3D350%26spage%3D240%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Rinaldi-Carmona., M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derocq, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casellas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oustric, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouaboula, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calandra, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shire, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brelière, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Fur, G.</span><span> </span><span class="NLM_article-title">SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">644</span><span class="NLM_x">–</span> <span class="NLM_lpage">650</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=9454810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADyaK1cXhtFWkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=1998&pages=644-650&author=M.+Rinaldi-Carmona.author=F.+Barthauthor=J.+Millanauthor=J.-M.+Derocqauthor=P.+Casellasauthor=C.+Congyauthor=D.+Oustricauthor=M.+Sarranauthor=M.+Bouaboulaauthor=B.+Calandraauthor=M.+Portierauthor=D.+Shireauthor=J.-C.+Breli%C3%A8reauthor=G.+Le+Fur&title=SR+144528%2C+the+first+potent+and+selective+antagonist+of+the+CB2+cannabinoid+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor</span></div><div class="casAuthors">Rinaldi-Carmona, Murielle; Barth, Francis; Millan, Jose; Derocq, Jean-Marie; Casellas, Pierre; Congy, Christian; Oustric, Didier; Sarran, Martine; Bouaboula, Monsif; Calandra, Bernard; Portier, Marielle; Shire, David; Breliere, Jean-Claude; Le Fur, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">644-650</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Based on both binding and functional data, this study introduces SR 144528 as the first, highly potent, selective and orally active antagonist for the CB2 receptor.  This compd. which displays subnanomolar affinity (Ki = 0.6 nM) for both the rat spleen and cloned human CB2 receptors has a 700-fold lower affinity (Ki = 400 nM) for both the rat brain and cloned human CB1 receptors.  Furthermore it shows no affinity for any of the more than 70 receptors, ion channels or enzymes investigated (IC50 > 10 μM).  In vitro, SR 144528 antagonizes the inhibitory effects of the cannabinoid receptor agonist CP 55,940 on forskolin-stimulated adenylyl cyclase activity in cell lines permanently expressing the h CB2 receptor (EC50 = 10 nM) but not in cells expressing the h CB1 (no effect at 10 μM).  Furthermore, SR 144528 is able to selectively block the mitogen-activated protein kinase activity induced by CP 55,940 in cell lines expressing h CB2 (IC50 = 39 nM) whereas in cells expressing h CB1 an IC50 value of more than 1 μM is found.  In addn., SR 144528 is shown to antagonize the stimulating effects of CP 55,940 on human tonsillar B-cell activation evoked by crosslinking of surface Igs (IC50 = 20 nM).  In vivo, after oral administration SR 144528 totally displaced the ex vivo [3H]-CP 55,940 binding to mouse spleen membranes (ED50 = 0.35 mg/kg) with a long duration of action.  In contrast, after the oral route it does not interact with the cannabinoid receptor expressed in the mouse brain (CB1).  It is expected that SR 144528 will provide a powerful tool to investigate the in vivo functions of the cannabinoid system in the immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLyEa8bHfntbVg90H21EOLACvtfcHk0ljwxbE_Sldlog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtFWkt78%253D&md5=c7ec1ad25da2567c186099934e0bb758</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRinaldi-Carmona.%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DMillan%26aufirst%3DJ.%26aulast%3DDerocq%26aufirst%3DJ.-M.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DCongy%26aufirst%3DC.%26aulast%3DOustric%26aufirst%3DD.%26aulast%3DSarran%26aufirst%3DM.%26aulast%3DBouaboula%26aufirst%3DM.%26aulast%3DCalandra%26aufirst%3DB.%26aulast%3DPortier%26aufirst%3DM.%26aulast%3DShire%26aufirst%3DD.%26aulast%3DBreli%25C3%25A8re%26aufirst%3DJ.-C.%26aulast%3DLe%2BFur%26aufirst%3DG.%26atitle%3DSR%2520144528%252C%2520the%2520first%2520potent%2520and%2520selective%2520antagonist%2520of%2520the%2520CB2%2520cannabinoid%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1998%26volume%3D284%26spage%3D644%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Lehmann, A.</span><span> </span><span class="NLM_article-title">Inhibitors of transient lower esophageal sphincter relaxations (“reflux inhibitors”) in the future treatment of GERD</span> <span class="citation_source-journal">Gastroenterol. Hepatol. Ann. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=109-117&author=A.+Lehmann&title=Inhibitors+of+transient+lower+esophageal+sphincter+relaxations+%28%E2%80%9Creflux+inhibitors%E2%80%9D%29+in+the+future+treatment+of+GERD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DA.%26atitle%3DInhibitors%2520of%2520transient%2520lower%2520esophageal%2520sphincter%2520relaxations%2520%2528%25E2%2580%259Creflux%2520inhibitors%25E2%2580%259D%2529%2520in%2520the%2520future%2520treatment%2520of%2520GERD%26jtitle%3DGastroenterol.%2520Hepatol.%2520Ann.%2520Rev.%26date%3D2006%26volume%3D1%26spage%3D109%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Rohof, W. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aronica, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troost, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckxstaens, G. E.</span><span> </span><span class="NLM_article-title">Localization of mGluR5, GABAB, GABAA, and cannabinoid receptors on the vago-vagal reflex pathway responsible for transient lower esophageal sphincter relaxation in humans: an immunohistochemical study</span> <span class="citation_source-journal">Neurogastroenterol. Motil.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">e173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1111%2Fj.1365-2982.2011.01868.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=22256945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVegsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=383-e173&author=W.+O.+Rohofauthor=E.+Aronicaauthor=H.+Beaumontauthor=D.+Troostauthor=G.+E.+Boeckxstaens&title=Localization+of+mGluR5%2C+GABAB%2C+GABAA%2C+and+cannabinoid+receptors+on+the+vago-vagal+reflex+pathway+responsible+for+transient+lower+esophageal+sphincter+relaxation+in+humans%3A+an+immunohistochemical+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of mGluR5, GABAB, GABAA, and cannabinoid receptors on the vago-vagal reflex pathway responsible for transient lower esophageal sphincter relaxation in humans: an immunohistochemical study</span></div><div class="casAuthors">Rohof, W. O.; Aronica, E.; Beaumont, H.; Troost, D.; Boeckxstaens, G. E.</div><div class="citationInfo"><span class="NLM_cas:title">Neurogastroenterology & Motility</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-391</span>CODEN:
                <span class="NLM_cas:coden">NMOTEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-1925</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background Transient lower esophageal sphincter relaxations (TLESRs) are the predominant mechanisms underlying gastro-esophageal reflux.  TLESRs are mediated by a vago-vagal reflex, which can be blocked by interaction with metabotropic Glutamate Receptor 5 (mGluR5), γ-aminobutyric acid type B (GABAB), γ-aminobutyric acid type A (GABAA), and cannabinoid (CB) receptors.  However, the distribution of these receptors in the neural pathway underlying the triggering of TLESRs has not been evaluated in humans.  Methods Using immunohistochem., we investigated the distribution of mGluR5, GABAA, GABAB, CB1, and CB2 receptors in the human nodose ganglion, the brain stem, and the myenteric plexus of the esophagus.  Key Results MGluR5, GABAB, CB1, and CB2 receptors are abundantly expressed in neurons of the myenteric plexus of the LES, nodose ganglion cell bodies and nerve fibers, the dorsal motor nucleus, and nucleus of the solitary tract in the brain stem.  GABAA receptors are expressed in the same regions except in the nodose ganglion and myenteric plexus of the LES.  Conclusions & Inferences Human mGluR5, GABAA,B, and CB1,2 receptors are abundantly expressed along the vago-vagal neural pathway and involved in the triggering of TLESRs.  These findings are not only in line with the central side effects obsd. during treatment with reflux inhibitors such as GABAB receptor agonists and mGluR5 antagonists, but also suggest that peripherally acting compds. may be effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC9PAQYJLZObVg90H21EOLACvtfcHk0lgk1Rh1IKMGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVegsbc%253D&md5=4d20eb59aafddd176939b585ac1badb3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2982.2011.01868.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2982.2011.01868.x%26sid%3Dliteratum%253Aachs%26aulast%3DRohof%26aufirst%3DW.%2BO.%26aulast%3DAronica%26aufirst%3DE.%26aulast%3DBeaumont%26aufirst%3DH.%26aulast%3DTroost%26aufirst%3DD.%26aulast%3DBoeckxstaens%26aufirst%3DG.%2BE.%26atitle%3DLocalization%2520of%2520mGluR5%252C%2520GABAB%252C%2520GABAA%252C%2520and%2520cannabinoid%2520receptors%2520on%2520the%2520vago-vagal%2520reflex%2520pathway%2520responsible%2520for%2520transient%2520lower%2520esophageal%2520sphincter%2520relaxation%2520in%2520humans%253A%2520an%2520immunohistochemical%2520study%26jtitle%3DNeurogastroenterol.%2520Motil.%26date%3D2012%26volume%3D24%26spage%3D383%26epage%3De173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Ameri, A.</span><span> </span><span class="NLM_article-title">The effects of cannabinoids on the brain</span> <span class="citation_source-journal">Prog. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1016%2FS0301-0082%2898%2900087-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=10368032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADyaK1MXjs1ejs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1999&pages=315-348&author=A.+Ameri&title=The+effects+of+cannabinoids+on+the+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of cannabinoids on the brain</span></div><div class="casAuthors">Ameri, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">315-348</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with many refs.  Cannabinoids have a long history of consumption for recreational and medical reasons.  The primary active constituent of the hemp plant Cannabis sativa is Δ9-tetrahydrocannabinol (Δ9-THC).  In humans, psychoactive cannabinoids produce euphoria, enhancement of sensory perception, tachycardia, antinociception, difficulties in concn. and impairment of memory.  The cognitive deficiencies seem to persist after withdrawal.  The toxicity of marijuana has been underestimated for a long time, since recent findings revealed Δ9-THC-induced cell death with shrinkage of neurons and DNA fragmentation in the hippocampus.  The acute effects of cannabinoids as well as the development of tolerance are mediated by G protein-coupled cannabinoid receptors.  The CB1 receptor and its splice variant CB1A, are found predominantly in the brain with highest densities in the hippocampus, cerebellum and striatum.  The CB2 receptor is found predominantly in the spleen and in hemopoietic cells and has only 44% overall nucleotide sequence identity with the CB1 receptor.  The existence of this receptor provided the mol. basis for the immunosuppressive actions of marijuana.  The CB1 receptor mediates inhibition of adenylate cyclase, inhibition of N- and P/Q-type calcium channels, stimulation of potassium channels, and activation of mitogen-activated protein kinase.  The CB2 receptor mediates inhibition of adenylate cyclase and activation of mitogen-activated protein kinase.  The discovery of endogenous cannabinoid receptor ligands, anandamide (N-arachidonylethanolamine) and 2-arachidonylglycerol made the notion of a central cannabinoid neuromodulatory system plausible.  Anandamide is released from neurons upon depolarization through a mechanism that requires calcium-dependent cleavage from a phospholipid precursor in neuronal membranes.  The release of anandamide is followed by rapid uptake into the plasma and hydrolysis by fatty-acid amidohydrolase.  The psychoactive cannabinoids increase the activity of dopaminergic neurons in the ventral tegmental area-mesolimbic pathway.  Since these dopaminergic circuits are known to play a pivotal role in mediating the reinforcing (rewarding) effects of the most drugs of abuse, the enhanced dopaminergic drive elicited by the cannabinoids is thought to underlie the reinforcing and abuse properties of marijuana.  Thus, cannabinoids share a final common neuronal action with other major drugs of abuse such as morphine, ethanol and nicotine in producing facilitation of the mesolimbic dopamine system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdPcJ7-vQg37Vg90H21EOLACvtfcHk0lgk1Rh1IKMGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjs1ejs7c%253D&md5=7ffe2ffb3c7604a4795f59aa240d260a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0301-0082%2898%2900087-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0301-0082%252898%252900087-2%26sid%3Dliteratum%253Aachs%26aulast%3DAmeri%26aufirst%3DA.%26atitle%3DThe%2520effects%2520of%2520cannabinoids%2520on%2520the%2520brain%26jtitle%3DProg.%2520Neurobiol.%26date%3D1999%26volume%3D58%26spage%3D315%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Dow, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpino, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautreau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadcock, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iredale, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly-Sullivan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lizano, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. M.</span><span> </span><span class="NLM_article-title">Design of a potent CB<sub>1</sub> receptor antagonist series: potential scaffold for peripherally-targeted agents</span> <span class="citation_source-journal">ACS Med. Chem. Lett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml3000325" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=397-401&author=R.+L.+Dowauthor=P.+A.+Carpinoauthor=D.+Gautreauauthor=J.+R.+Hadcockauthor=P.+A.+Iredaleauthor=D.+Kelly-Sullivanauthor=J.+S.+Lizanoauthor=R.+E.+O%E2%80%99Connorauthor=S.+R.+Schneiderauthor=D.+O.+Scottauthor=K.+M.+Ward&title=Design+of+a+potent+CB1+receptor+antagonist+series%3A+potential+scaffold+for+peripherally-targeted+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fml3000325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3000325%26sid%3Dliteratum%253Aachs%26aulast%3DDow%26aufirst%3DR.%2BL.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26aulast%3DGautreau%26aufirst%3DD.%26aulast%3DHadcock%26aufirst%3DJ.%2BR.%26aulast%3DIredale%26aufirst%3DP.%2BA.%26aulast%3DKelly-Sullivan%26aufirst%3DD.%26aulast%3DLizano%26aufirst%3DJ.%2BS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%2BE.%26aulast%3DSchneider%26aufirst%3DS.%2BR.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DWard%26aufirst%3DK.%2BM.%26atitle%3DDesign%2520of%2520a%2520potent%2520CB1%2520receptor%2520antagonist%2520series%253A%2520potential%2520scaffold%2520for%2520peripherally-targeted%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett%26date%3D2012%26volume%3D3%26spage%3D397%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Tam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vemuri, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bátkai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osei-Hyiaman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohnuma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambudkar, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makriyannis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">2953</span><span class="NLM_x">–</span> <span class="NLM_lpage">2966</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1172%2FJCI42551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=20664173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaiurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2010&pages=2953-2966&author=J.+Tamauthor=V.+K.+Vemuriauthor=J.+Liuauthor=S.+B%C3%A1tkaiauthor=B.+Mukhopadhyayauthor=G.+Godlewskiauthor=D.+Osei-Hyiamanauthor=S.+Ohnumaauthor=S.+V.+Ambudkarauthor=J.+Pickelauthor=A.+Makriyannisauthor=G.+Kunos&title=Peripheral+CB1+cannabinoid+receptor+blockade+improves+cardiometabolic+risk+in+mouse+models+of+obesity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity</span></div><div class="casAuthors">Tam, Joseph; Vemuri, V. Kiran; Liu, Jie; Batkai, Sandor; Mukhopadhyay, Bani; Godlewski, Grzegorz; Osei-Hyiaman, Douglas; Ohnuma, Shinobu; Ambudkar, Suresh V.; Pickel, James; Makriyannis, Alexandros; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2953-2966</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Obesity and its metabolic consequences are a major public health concern worldwide.  Obesity is assocd. with overactivity of the endocannabinoid system, which is involved in the regulation of appetite, lipogenesis, and insulin resistance.  Cannabinoid-1 receptor (CB1R) antagonists reduce body wt. and improve cardiometabolic abnormalities in exptl. and human obesity, but their therapeutic potential is limited by neuropsychiatric side effects.  Here we have demonstrated that a CB1R neutral antagonist largely restricted to the periphery does not affect behavioral responses mediated by CB1R in the brains of mice with genetic or diet-induced obesity, but it does cause wt.-independent improvements in glucose homeostasis, fatty liver, and plasma lipid profile.  These effects were due to blockade of CB1R in peripheral tissues, including the liver, as verified through the use of CB1R-deficient mice with or without transgenic expression of CB1R in the liver.  These results suggest that targeting peripheral CB1R has therapeutic potential for alleviating cardiometabolic risk in obese patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0VCuCx5tmorVg90H21EOLACvtfcHk0li9srXuQOErbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaiurzM&md5=ba383f0abb4642df9843f6ee5784ecb4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1172%2FJCI42551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI42551%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DVemuri%26aufirst%3DV.%2BK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DB%25C3%25A1tkai%26aufirst%3DS.%26aulast%3DMukhopadhyay%26aufirst%3DB.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DOsei-Hyiaman%26aufirst%3DD.%26aulast%3DOhnuma%26aufirst%3DS.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DPickel%26aufirst%3DJ.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DPeripheral%2520CB1%2520cannabinoid%2520receptor%2520blockade%2520improves%2520cardiometabolic%2520risk%2520in%2520mouse%2520models%2520of%2520obesity%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2010%26volume%3D120%26spage%3D2953%26epage%3D2966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wu, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, C.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Ly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M.-S.</span><span> </span><span class="NLM_article-title">A new perspective of cannabinoid 1 receptor. Antagonists: approaches toward peripheral CB1R blockers without crossing the blood–brain barrier</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1421</span><span class="NLM_x">–</span> <span class="NLM_lpage">1429</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.2174%2F156802611795860997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=21510837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1421-1429&author=Y.-K.+Wuauthor=C.-F.+Yehauthor=Ly%2C+T.+Weiauthor=M.-S.+Hung&title=A+new+perspective+of+cannabinoid+1+receptor.+Antagonists%3A+approaches+toward+peripheral+CB1R+blockers+without+crossing+the+blood%E2%80%93brain+barrier"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier</span></div><div class="casAuthors">Wu, Yen-Ku; Yeh, Ching-Fang; Ly, Tai Wei; Hung, Ming-Shiu</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1421-1429</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since Rimonabant was withdrawn in Europe in 2008 because of its substantial CNS risk factors including depression and anxiety, the development of anti-obesity drugs targeting CB1R in the brain was suspended and/or terminated globally.  Instead, developing peripherally restricted CB1R antagonists is actively pursued in the hope that not only could they eliminate any CNS adverse effects obsd. with Rimonabant, but also maintain therapeutic benefits in metabolic syndrome, including obesity, type 2 diabetes, and non-alc. fatty liver diseases.  In this review, we summarized the most recent advances that were made on this area, with particular emphasis on various synthetic approaches, whereby the increase in polarity, water soly. and polar surface area were centralized on, toward potential peripheralacting CB1 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnL4kEb4kxBbVg90H21EOLACvtfcHk0lj39SrF49w5VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOrtb0%253D&md5=18dec0238d7bec427e408904b69d484e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F156802611795860997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795860997%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-K.%26aulast%3DYeh%26aufirst%3DC.-F.%26aulast%3DWei%26aufirst%3DLy%252C%2BT.%26aulast%3DHung%26aufirst%3DM.-S.%26atitle%3DA%2520new%2520perspective%2520of%2520cannabinoid%25201%2520receptor.%2520Antagonists%253A%2520approaches%2520toward%2520peripheral%2520CB1R%2520blockers%2520without%2520crossing%2520the%2520blood%25E2%2580%2593brain%2520barrier%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D1421%26epage%3D1429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Fulp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortoff, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seltzman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathews, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitra, R.</span><span> </span><span class="NLM_article-title">Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2820</span><span class="NLM_x">–</span> <span class="NLM_lpage">2834</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201731z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2820-2834&author=A.+Fulpauthor=K.+Bortoffauthor=H.+Seltzmanauthor=Y.+Zhangauthor=J.+Mathewsauthor=R.+Snyderauthor=T.+Fennellauthor=R.+Maitra&title=Design+and+synthesis+of+cannabinoid+receptor+1+antagonists+for+peripheral+selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm201731z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201731z%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMathews%26aufirst%3DJ.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DFennell%26aufirst%3DT.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520cannabinoid%2520receptor%25201%2520antagonists%2520for%2520peripheral%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2820%26epage%3D2834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Cheng, Y.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pourashraf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walpole, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salois, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St-Onge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payza, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lessard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomaszewski, M. J.</span><span> </span><span class="NLM_article-title">γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1624</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1619-1624&author=Y.-X.+Chengauthor=M.+Pourashrafauthor=X.+Luoauthor=S.+Srivastavaauthor=C.+Walpoleauthor=D.+Saloisauthor=S.+St-Ongeauthor=K.+Payzaauthor=E.+Lessardauthor=X.-H.+Yuauthor=M.+J.+Tomaszewski&title=%CE%B3-Carbolines%3A+a+novel+class+of+cannabinoid+agonists+with+high+aqueous+solubility+and+restricted+CNS+penetration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.-X.%26aulast%3DPourashraf%26aufirst%3DM.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DWalpole%26aufirst%3DC.%26aulast%3DSalois%26aufirst%3DD.%26aulast%3DSt-Onge%26aufirst%3DS.%26aulast%3DPayza%26aufirst%3DK.%26aulast%3DLessard%26aufirst%3DE.%26aulast%3DYu%26aufirst%3DX.-H.%26aulast%3DTomaszewski%26aufirst%3DM.%2BJ.%26atitle%3D%25CE%25B3-Carbolines%253A%2520a%2520novel%2520class%2520of%2520cannabinoid%2520agonists%2520with%2520high%2520aqueous%2520solubility%2520and%2520restricted%2520CNS%2520penetration%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1619%26epage%3D1624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lj39SrF49w5VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, E. H.</span><span> </span><span class="NLM_article-title">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">–</span> <span class="NLM_lpage">939</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1038%2Fnrd3287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=21119731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=929-939&author=D.+A.+Smithauthor=L.+Diauthor=E.+H.+Kerns&title=The+effect+of+plasma+protein+binding+on+in+vivo+efficacy%3A+misconceptions+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span></div><div class="casAuthors">Smith, Dennis A.; Di, Li; Kerns, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">929-939</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Data from in vitro plasma protein binding expts. that det. the fraction of protein-bound drug are frequently used in drug discovery to guide structure design and to prioritize compds. for in vivo studies.  However, we consider that these practices are usually misleading, because in vivo efficacy is detd. by the free (unbound) drug concn. surrounding the therapeutic target, not by the free drug fraction.  These practices yield no enhancement of the in vivo free drug concn.  So, decisions based on free drug fraction could result in the wrong compds. being advanced through drug discovery programs.  This Perspective provides guidance on the application of plasma protein binding information in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOa3ippodhGbVg90H21EOLACvtfcHk0lj39SrF49w5VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI&md5=a45d00f68ab44580fa38a6acef49493a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd3287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3287%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DThe%2520effect%2520of%2520plasma%2520protein%2520binding%2520on%2520in%2520vivo%2520efficacy%253A%2520misconceptions%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D929%26epage%3D939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span> </span><span class="NLM_article-title">Strategies to optimize brain penetration in drug discovery</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">–</span> <span class="NLM_lpage">512</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=505-512&author=X.+Liuauthor=C.+Chen&title=Strategies+to+optimize+brain+penetration+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DStrategies%2520to%2520optimize%2520brain%2520penetration%2520in%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2005%26volume%3D8%26spage%3D505%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span> </span><span class="NLM_article-title">Progress in brain penetration evaluation in drug discovery and development</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">325</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1124%2Fjpet.107.130294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=18203948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVOjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2008&pages=349-356&author=X.+Liuauthor=C.+Chenauthor=B.+J.+Smith&title=Progress+in+brain+penetration+evaluation+in+drug+discovery+and+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in brain penetration evaluation in drug discovery and development</span></div><div class="casAuthors">Liu, Xingrong; Chen, Cuiping; Smith, Bill J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">349-356</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  This review discusses strategies to optimize brain penetration from the perspective of drug discovery and development.  Brain penetration kinetics can be described by the extent and time to reach brain equil.  The extent is defined as the ratio of free brain concn. to free plasma concn. at steady state.  For all central nervous system (CNS) drug discovery programs, optimization of the extent of brain penetration should focus on designing and selecting compds. having low efflux transport at the blood-brain barrier (BBB).  The time to reach brain equil. is detd. by both BBB permeability and brain tissue binding.  Rapid brain penetration can be achieved by increasing passive permeability and reducing brain tissue binding.  Although many drug transporters have been identified at the BBB, the available literature demonstrates only the in vivo functional importance of P-glycoprotein (P-gp) in limiting brain penetration of its substrates.  Drug-drug interactions mediated by P-gp at the BBB are possible due to inhibition or induction of P-gp.  For newly identified drug transporters at the BBB, more research is needed to reveal their in vivo significance.  We propose the following strategies for addressing drug transporters at the BBB.  (1) Drug discovery screens should be used to eliminate good P-gp substrates for CNS targets.  Special consideration could be given to moderate P-gp substrates as potential CNS drugs based on a high unmet medical need and the presence of a large safety margin.  (2) Selection of P-gp substrates as drug candidates for non-CNS targets can reduce their CNS-mediated side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQwQ371TauXLVg90H21EOLACvtfcHk0liifvebajjlqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVOjsL0%253D&md5=92da2a32a86934ff108d5df6e74ce99c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.130294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.130294%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26atitle%3DProgress%2520in%2520brain%2520penetration%2520evaluation%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D325%26spage%3D349%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Hammarlun-Udenaes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridén, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syvänen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span> </span><span class="NLM_article-title">On the rate and extent of drug delivery to the brain</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1737</span><span class="NLM_x">–</span> <span class="NLM_lpage">1750</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2008&pages=1737-1750&author=M.+Hammarlun-Udenaesauthor=M.+Frid%C3%A9nauthor=S.+Syv%C3%A4nenauthor=A.+Gupta&title=On+the+rate+and+extent+of+drug+delivery+to+the+brain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHammarlun-Udenaes%26aufirst%3DM.%26aulast%3DFrid%25C3%25A9n%26aufirst%3DM.%26aulast%3DSyv%25C3%25A4nen%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DA.%26atitle%3DOn%2520the%2520rate%2520and%2520extent%2520of%2520drug%2520delivery%2520to%2520the%2520brain%26jtitle%3DPharm.%2520Res.%26date%3D2008%26volume%3D25%26spage%3D1737%26epage%3D1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edward, H., K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guy, T., C.</span><span> </span><span class="NLM_article-title">Strategies to assess blood–brain barrier penetration</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">677</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=677-687&issue=6&author=D.+Liauthor=H.%2C+K.+Edwardauthor=T.%2C+C.+Guy&title=Strategies+to+assess+blood%E2%80%93brain+barrier+penetration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DEdward%26aufirst%3DH.%252C%2BK.%26aulast%3DGuy%26aufirst%3DT.%252C%2BC.%26atitle%3DStrategies%2520to%2520assess%2520blood%25E2%2580%2593brain%2520barrier%2520penetration%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26issue%3D6%26spage%3D677%26epage%3D687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Hitchcock, S. A.</span><span> </span><span class="NLM_article-title">Structural modifications that alter the p-glycoprotein efflux properties of compounds</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4877</span><span class="NLM_x">–</span> <span class="NLM_lpage">4895</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201136z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4877-4895&author=S.+A.+Hitchcock&title=Structural+modifications+that+alter+the+p-glycoprotein+efflux+properties+of+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm201136z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201136z%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26atitle%3DStructural%2520modifications%2520that%2520alter%2520the%2520p-glycoprotein%2520efflux%2520properties%2520of%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4877%26epage%3D4895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Aller, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chittaboina, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinh, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbatsch, I. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, G.</span><span> </span><span class="NLM_article-title">Structure of p-glycoprotein reveals a molecular basis for poly-specific drug binding</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">1718</span><span class="NLM_x">–</span> <span class="NLM_lpage">1722</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1126%2Fscience.1168750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=19325113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Kgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2009&pages=1718-1722&author=S.+G.+Allerauthor=J.+Yuauthor=A.+Wardauthor=Y.+Wengauthor=S.+Chittaboinaauthor=R.+Zhuoauthor=P.+M.+Harrellauthor=Y.+T.+Trinhauthor=Q.+Zhangauthor=I.+L.+Urbatschauthor=G.+Chang&title=Structure+of+p-glycoprotein+reveals+a+molecular+basis+for+poly-specific+drug+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding</span></div><div class="casAuthors">Aller, Stephen G.; Yu, Jodie; Ward, Andrew; Weng, Yue; Chittaboina, Srinivas; Zhuo, Rupeng; Harrell, Patina M.; Trinh, Yenphuong T.; Zhang, Qinghai; Urbatsch, Ina L.; Chang, Geoffrey</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">5922</span>),
    <span class="NLM_cas:pages">1718-1722</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">P-glycoprotein (P-gp) detoxifies cells by exporting hundreds of chem. unrelated toxins but has been implicated in multidrug resistance (MDR) in the treatment of cancers.  Substrate promiscuity is a hallmark of P-gp activity, thus a structural description of poly-specific drug-binding is important for the rational design of anticancer drugs and MDR inhibitors.  The x-ray structure of apo P-gp at 3.8 angstroms reveals an internal cavity of ~6000 angstroms cubed with a 30 angstrom sepn. of the two nucleotide-binding domains.  Two addnl. P-gp structures with cyclic peptide inhibitors demonstrate distinct drug-binding sites in the internal cavity capable of stereoselectivity that is based on hydrophobic and arom. interactions.  Apo and drug-bound P-gp structures have portals open to the cytoplasm and the inner leaflet of the lipid bilayer for drug entry.  The inward-facing conformation represents an initial stage of the transport cycle that is competent for drug binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2EUmR-iQyaLVg90H21EOLACvtfcHk0liifvebajjlqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Kgtro%253D&md5=66c7398b0257e6c05161a1afbecdafb1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1126%2Fscience.1168750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1168750%26sid%3Dliteratum%253Aachs%26aulast%3DAller%26aufirst%3DS.%2BG.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DWard%26aufirst%3DA.%26aulast%3DWeng%26aufirst%3DY.%26aulast%3DChittaboina%26aufirst%3DS.%26aulast%3DZhuo%26aufirst%3DR.%26aulast%3DHarrell%26aufirst%3DP.%2BM.%26aulast%3DTrinh%26aufirst%3DY.%2BT.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DUrbatsch%26aufirst%3DI.%2BL.%26aulast%3DChang%26aufirst%3DG.%26atitle%3DStructure%2520of%2520p-glycoprotein%2520reveals%2520a%2520molecular%2520basis%2520for%2520poly-specific%2520drug%2520binding%26jtitle%3DScience%26date%3D2009%26volume%3D323%26spage%3D1718%26epage%3D1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Uchida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsukura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terasaki, T.</span><span> </span><span class="NLM_article-title">Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">345</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1111%2Fj.1471-4159.2011.07208.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=21291474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFGhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=333-345&author=Y.+Uchidaauthor=S.+Ohtsukiauthor=Y.+Katsukuraauthor=C.+Ikedaauthor=T.+Suzukiauthor=J.+Kamiieauthor=T.+Terasaki&title=Quantitative+targeted+absolute+proteomics+of+human+blood%E2%80%93brain+barrier+transporters+and+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors</span></div><div class="casAuthors">Uchida, Yasuo; Ohtsuki, Sumio; Katsukura, Yuki; Ikeda, Chiemi; Suzuki, Takashi; Kamiie, Junichi; Terasaki, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">333-345</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We have obtained, for the first time, a quant. protein expression profile of membrane transporters and receptors in human brain microvessels, i.e., the blood-brain barrier (BBB).  Brain microvessels were isolated from brain cortexes of seven males (16-77 years old) and protein expression of 114 membrane proteins was detd. by means of a liq. chromatog.-tandem mass spectrometric quantification method using recently established in-silico peptide selection criteria.  Among drug transporters, breast cancer resistance protein showed the most abundant protein expression (8.14 fmol/μg protein), and its expression level was 1.85-fold greater in humans than in mice.  By contrast, the expression level of P-glycoprotein in humans (6.06 fmol/μg protein) was 2.33-fold smaller than that of mdr1a in mice.  The org. anion transporters reported in rodent BBB, i.e., multidrug resistance-assocd. protein, org. anion transporter and org. anion-transporting polypeptide family members, were under limit of quantification in humans, except multidrug resistance-assocd. protein 4 (0.195 fmol/μg protein).  Among detected transporters and receptors for endogenous substances, the glucose transporter 1 level was similar to that of mouse, while the L-type amino acid transporter 1 level was fivefold smaller than that of mouse.  These findings should be useful for understanding human BBB function and its differences from that in mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_2KX6pHt5F7Vg90H21EOLACvtfcHk0lijhv52JLs7Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFGhsr0%253D&md5=8b278a28401bea36b1ed683c205161bb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2011.07208.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2011.07208.x%26sid%3Dliteratum%253Aachs%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DOhtsuki%26aufirst%3DS.%26aulast%3DKatsukura%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DC.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DKamiie%26aufirst%3DJ.%26aulast%3DTerasaki%26aufirst%3DT.%26atitle%3DQuantitative%2520targeted%2520absolute%2520proteomics%2520of%2520human%2520blood%25E2%2580%2593brain%2520barrier%2520transporters%2520and%2520receptors%26jtitle%3DJ.%2520Neurochem.%26date%3D2011%26volume%3D117%26spage%3D333%26epage%3D345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Yee, S.</span><span> </span><span class="NLM_article-title">In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man—fact or myth</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">763</span><span class="NLM_x">–</span> <span class="NLM_lpage">766</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=763-766&author=S.+Yee&title=In+vitro+permeability+across+Caco-2+cells+%28colonic%29+can+predict+in+vivo+%28small+intestinal%29+absorption+in+man%E2%80%94fact+or+myth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYee%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520permeability%2520across%2520Caco-2%2520cells%2520%2528colonic%2529%2520can%2520predict%2520in%2520vivo%2520%2528small%2520intestinal%2529%2520absorption%2520in%2520man%25E2%2580%2594fact%2520or%2520myth%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26spage%3D763%26epage%3D766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Hilgendorf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahlin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seithel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artursson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ungell, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, J.</span><span> </span><span class="NLM_article-title">Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1340</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1124%2Fdmd.107.014902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=17496207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVKqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=1333-1340&author=C.+Hilgendorfauthor=G.+Ahlinauthor=A.+Seithelauthor=P.+Arturssonauthor=A.-L.+Ungellauthor=J.+Karlsson&title=Expression+of+thirty-six+drug+transporter+genes+in+human+intestine%2C+liver%2C+kidney%2C+and+organotypic+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines</span></div><div class="casAuthors">Hilgendorf, Constanze; Ahlin, Gustav; Seithel, Annick; Artursson, Per; Ungell, Anna-Lena; Karlsson, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1333-1340</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study was designed to quant. assess the mRNA expression of 36 important drug transporters in human jejunum, colon, liver, and kidney.  Expression of these transporters in human organs was compared with expression in commonly used cell lines (Caco-2, HepG2, and Caki-1) originating from these organs to assess their value as in vitro transporter system models, and was also compared with data obtained from the literature on expression in rat tissues to assess species differences.  Transporters that were highly expressed in the intestine included HPT1, PEPT1, BCRP, MRP2, and MDR1, whereas, in the liver, OCT1, MRP2, OATP-C, NTCP and BSEP were the main transporters.  In the kidney, OAT1 was expressed at the highest levels, followed by OAT3, OAT4, MCT5, MDR1, MRP2, OCT2, and OCTN2.  The best agreement between human tissue and the representative cell line was obsd. for human jejunum and Caco-2 cells.  Expression in liver and kidney orthol. cell lines was not correlated with that in the assocd. tissue.  Comparisons with rat transporter gene expression revealed significant species differences.  Our results allowed a comprehensive quant. comparison of drug transporter expression in human intestine, liver, and kidney.  We suggest that it would be beneficial for predictive pharmacokinetic research to focus on the most highly expressed transporters.  We hope that our comparison of rat and human tissue will help to explain the obsd. species differences in in vivo models, increase understanding of the impact of active transport processes on pharmacokinetics and distribution, and improve the quality of predictions from animal studies to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC3qvmG8tTf7Vg90H21EOLACvtfcHk0lijhv52JLs7Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVKqtbg%253D&md5=edfef89a8c422dbdcc0a097425b2ad2e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.014902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.014902%26sid%3Dliteratum%253Aachs%26aulast%3DHilgendorf%26aufirst%3DC.%26aulast%3DAhlin%26aufirst%3DG.%26aulast%3DSeithel%26aufirst%3DA.%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DUngell%26aufirst%3DA.-L.%26aulast%3DKarlsson%26aufirst%3DJ.%26atitle%3DExpression%2520of%2520thirty-six%2520drug%2520transporter%2520genes%2520in%2520human%2520intestine%252C%2520liver%252C%2520kidney%252C%2520and%2520organotypic%2520cell%2520lines%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D1333%26epage%3D1340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Fridén, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winiwarter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerndal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengtsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredberg, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarlund-Udenaes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonsson, M.</span><span> </span><span class="NLM_article-title">Structure–brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6233</span><span class="NLM_x">–</span> <span class="NLM_lpage">6243</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901036q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6233-6243&author=M.+Frid%C3%A9nauthor=S.+Winiwarterauthor=G.+Jerndalauthor=O.+Bengtssonauthor=H.+Wanauthor=U.+Bredbergauthor=M.+Hammarlund-Udenaesauthor=M.+Antonsson&title=Structure%E2%80%93brain+exposure+relationships+in+rat+and+human+using+a+novel+data+set+of+unbound+drug+concentrations+in+brain+interstitial+and+cerebrospinal+fluids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm901036q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901036q%26sid%3Dliteratum%253Aachs%26aulast%3DFrid%25C3%25A9n%26aufirst%3DM.%26aulast%3DWiniwarter%26aufirst%3DS.%26aulast%3DJerndal%26aufirst%3DG.%26aulast%3DBengtsson%26aufirst%3DO.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DBredberg%26aufirst%3DU.%26aulast%3DHammarlund-Udenaes%26aufirst%3DM.%26aulast%3DAntonsson%26aufirst%3DM.%26atitle%3DStructure%25E2%2580%2593brain%2520exposure%2520relationships%2520in%2520rat%2520and%2520human%2520using%2520a%2520novel%2520data%2520set%2520of%2520unbound%2520drug%2520concentrations%2520in%2520brain%2520interstitial%2520and%2520cerebrospinal%2520fluids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6233%26epage%3D6243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winiwarter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engkvist, O.</span><span> </span><span class="NLM_article-title">In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms</span> <span class="citation_source-journal">J. Mol. Graphics Modell.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">985</span><span class="NLM_x">–</span> <span class="NLM_lpage">995</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1016%2Fj.jmgm.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=21571561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2jtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=985-995&author=H.+Chenauthor=S.+Winiwarterauthor=M.+Fridenauthor=M.+Antonssonauthor=O.+Engkvist&title=In+silico+prediction+of+unbound+brain-to-plasma+concentration+ratio+using+machine+learning+algorithms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms</span></div><div class="casAuthors">Chen, Hongming; Winiwarter, Susanne; Friden, Markus; Antonsson, Madeleine; Engkvist, Ola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">985-995</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Distribution over the blood-brain barrier (BBB) is an important parameter to consider for compds. that will be synthesized in a drug discovery project.  Drugs that aim at targets in the central nervous system (CNS) must pass the BBB.  In contrast, drugs that act peripherally are often optimized to minimize the risk of CNS side effects by restricting their potential to reach the brain.  Historically, most prediction methods have focused on the total compd. distribution between the blood plasma and the brain.  However, recently it has been proposed that the unbound brain-to-plasma concn. ratio (Kp,uu,brain) is more relevant.  In the current study, quant. Kp,uu,brain prediction models have been built on a set of 173 inhouse compds. by using various machine learning algorithms.  The best model was shown to be reasonably predictive for the test set of 73 compds. (R2 = 0.58).  When used for qual. prediction the model shows an accuracy of 0.85 (Kappa = 0.68).  An addnl. external test set contg. 111 marketed CNS active drugs was also classified with the model and 89% of these drugs were correctly predicted as having high brain exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHnHw2ZkiO87Vg90H21EOLACvtfcHk0ljQgqAiHyUBtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2jtLY%253D&md5=097b3d766973588dd589704ca7b428d2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.jmgm.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmgm.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWiniwarter%26aufirst%3DS.%26aulast%3DFriden%26aufirst%3DM.%26aulast%3DAntonsson%26aufirst%3DM.%26aulast%3DEngkvist%26aufirst%3DO.%26atitle%3DIn%2520silico%2520prediction%2520of%2520unbound%2520brain-to-plasma%2520concentration%2520ratio%2520using%2520machine%2520learning%2520algorithms%26jtitle%3DJ.%2520Mol.%2520Graphics%2520Modell.%26date%3D2011%26volume%3D29%26spage%3D985%26epage%3D995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Hann, M. M.</span><span> </span><span class="NLM_article-title">Molecular obesity, potency and other addictions in drug discovery</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1039%2Fc1md00017a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Kht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=349-355&author=M.+M.+Hann&title=Molecular+obesity%2C+potency+and+other+addictions+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular obesity, potency and other addictions in drug discovery</span></div><div class="casAuthors">Hann, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-355</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Despite the increase in global biol. and chem. knowledge the discovery of effective and safe new drugs seems to become harder rather than easier.  Some of this challenge is due to increasing demands for safety and novelty, but some of the risk involved in this should be controllable if we had more effectively learned from our failures.  This perspective reflects on some of the learnings of recent years in relation to the causes of attrition.  The term Mol. Obesity is introduced to describe our tendency to build potency into mols. by the inappropriate use of lipophilicity which leads to the premature demise of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSlF7TPy6fHLVg90H21EOLACvtfcHk0ljQgqAiHyUBtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Kht7g%253D&md5=954870db4b1d9e846612c3bb256582f7</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fc1md00017a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1md00017a%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520obesity%252C%2520potency%2520and%2520other%2520addictions%2520in%2520drug%2520discovery%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2011%26volume%3D2%26spage%3D349%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Wager, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalobos, A.</span><span> </span><span class="NLM_article-title">Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">449</span></span><div class="citationLinks">[<a href="/doi/10.1021/cn100008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-449&author=T.+T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Moving+beyond+rules%3A+the+development+of+a+central+nervous+system+multiparameter+optimization+%28CNS+MPO%29+approach+to+enable+alignment+of+druglike+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">435-449</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The interplay among commonly used physicochem. properties in drug design was examd. and utilized to create a prospective design tool focused on the alignment of key druglike attributes.  Using a set of six physicochem. parameters ((a) lipophilicity, calcd. partition coeff. (ClogP); (b) calcd. distribution coeff. at pH = 7.4 (ClogD); (c) mol. wt. (MW); (d) topol. polar surface area (TPSA); (e) no. of hydrogen bond donors (HBD); (f) most basic center (pKa)), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compds. (N = 11 303).  The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates.  This anal. suggests that this algorithm could potentially be used to identify compds. with a higher probability of successfully testing hypotheses in the clinic.  In addn., a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set.  The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chem. design space through a holistic assessment approach.  Based on six physicochem. properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compds. with increased probability of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3Mvkgm_X5bVg90H21EOLACvtfcHk0ljQgqAiHyUBtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D&md5=e94998f65a420be6ee4dec4a987cb983</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fcn100008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100008c%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DMoving%2520beyond%2520rules%253A%2520the%2520development%2520of%2520a%2520central%2520nervous%2520system%2520multiparameter%2520optimization%2520%2528CNS%2520MPO%2529%2520approach%2520to%2520enable%2520alignment%2520of%2520druglike%2520properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Yu, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martino, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puma, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morinville, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St-Onge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lessard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, J. M.</span><span> </span><span class="NLM_article-title">A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain</span> <span class="citation_source-journal">Pain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">151</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">344</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2010&pages=337-344&author=X.+H.+Yuauthor=C.+Q.+Caoauthor=G.+Martinoauthor=C.+Pumaauthor=A.+Morinvilleauthor=S.+St-Ongeauthor=E.+Lessardauthor=M.+N.+Perkinsauthor=J.+M.+Laird&title=A+peripherally+restricted+cannabinoid+receptor+agonist+produces+robust+anti-nociceptive+effects+in+rodent+models+of+inflammatory+and+neuropathic+pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DX.%2BH.%26aulast%3DCao%26aufirst%3DC.%2BQ.%26aulast%3DMartino%26aufirst%3DG.%26aulast%3DPuma%26aufirst%3DC.%26aulast%3DMorinville%26aufirst%3DA.%26aulast%3DSt-Onge%26aufirst%3DS.%26aulast%3DLessard%26aufirst%3DE.%26aulast%3DPerkins%26aufirst%3DM.%2BN.%26aulast%3DLaird%26aufirst%3DJ.%2BM.%26atitle%3DA%2520peripherally%2520restricted%2520cannabinoid%2520receptor%2520agonist%2520produces%2520robust%2520anti-nociceptive%2520effects%2520in%2520rodent%2520models%2520of%2520inflammatory%2520and%2520neuropathic%2520pain%26jtitle%3DPain%26date%3D2010%26volume%3D151%26spage%3D337%26epage%3D344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Bylund, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toews, M. L.</span><span> </span><span class="NLM_article-title">Radioligand binding methods: practical guide and tips</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">L421</span><span class="NLM_x">–</span> <span class="NLM_lpage">L429</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1993&pages=L421-L429&author=D.+B.+Bylundauthor=M.+L.+Toews&title=Radioligand+binding+methods%3A+practical+guide+and+tips"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBylund%26aufirst%3DD.%2BB.%26aulast%3DToews%26aufirst%3DM.%2BL.%26atitle%3DRadioligand%2520binding%2520methods%253A%2520practical%2520guide%2520and%2520tips%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1993%26volume%3D265%26spage%3DL421%26epage%3DL429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Strange, P.</span><span> </span><span class="NLM_article-title">Use of the GTPγS ([<sup>35</sup>S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">1238</span><span class="NLM_x">–</span> <span class="NLM_lpage">1249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1111%2Fj.1476-5381.2010.00963.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=20662841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWhsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=1238-1249&author=P.+Strange&title=Use+of+the+GTP%CE%B3S+%28%5B35S%5DGTP%CE%B3S+and+Eu-GTP%CE%B3S%29+binding+assay+for+analysis+of+ligand+potency+and+efficacy+at+G+protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors</span></div><div class="casAuthors">Strange, Philip G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1238-1249</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  In this review I consider assays for G protein-coupled receptor (GPCR) activity based on the binding of labeled analogs of GTPγS ([35S]GTPγS or Eu-GTPγS) to G proteins in tissues (GTPγS binding assays).  Such assays provide convenient measures of GPCR activity close to the receptor in the signaling cascade.  In order to set up a GTPγS binding assay, the requirements of the assay must be considered.  These are tissue source, GTPγS analog, G protein, GDP, Mg2+/Na+ ions, saponin, incubation time.  The assay, once optimized, can be used to generate concn./response curves for GPCRs signaling via Gi/o proteins (or to other G proteins with a modified assay) and actions of agonists, inverse agonists and antagonists may, in principle, be assessed.  For agonists and inverse agonists, data for the maximal agonist effect, the concn. of ligand giving a half-maximal response and the Hill coeff. may be derived.  For antagonists, data for the equil. dissocn. const. can be obtained.  The mechanistic basis of the assay is considered.  Although the assay can be used to profile ligands, under the conditions it is used, it may not be measuring the same event that dets. GPCR action in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonpFh81URvabVg90H21EOLACvtfcHk0lgukAfMQLoAuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWhsr3K&md5=8fa11a4e869eec381bae3880f4051dc2</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00963.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00963.x%26sid%3Dliteratum%253Aachs%26aulast%3DStrange%26aufirst%3DP.%26atitle%3DUse%2520of%2520the%2520GTP%25CE%25B3S%2520%2528%255B35S%255DGTP%25CE%25B3S%2520and%2520Eu-GTP%25CE%25B3S%2529%2520binding%2520assay%2520for%2520analysis%2520of%2520ligand%2520potency%2520and%2520efficacy%2520at%2520G%2520protein-coupled%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D1238%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Valkó, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bevan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D.</span><span> </span><span class="NLM_article-title">Chromatographic hydrophobicity index by fast-gradient RP-HPLC: a high-throughput alternative to log <i>P</i>/log <i>D</i></span> <span class="citation_source-journal">Anal. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">2022</span><span class="NLM_x">–</span> <span class="NLM_lpage">2029</span></span><div class="citationLinks">[<a href="/doi/10.1021/ac961242d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1997&pages=2022-2029&author=K.+Valk%C3%B3author=C.+Bevanauthor=D.+Reynolds&title=Chromatographic+hydrophobicity+index+by+fast-gradient+RP-HPLC%3A+a+high-throughput+alternative+to+log%C2%A0P%2Flog%C2%A0D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fac961242d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac961242d%26sid%3Dliteratum%253Aachs%26aulast%3DValk%25C3%25B3%26aufirst%3DK.%26aulast%3DBevan%26aufirst%3DC.%26aulast%3DReynolds%26aufirst%3DD.%26atitle%3DChromatographic%2520hydrophobicity%2520index%2520by%2520fast-gradient%2520RP-HPLC%253A%2520a%2520high-throughput%2520alternative%2520to%2520log%25C2%25A0P%252Flog%25C2%25A0D%26jtitle%3DAnal.%2520Chem.%26date%3D1997%26volume%3D69%26spage%3D2022%26epage%3D2029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Besly, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, A. A.</span><span> </span><span class="NLM_article-title">Antimalarial 2-alkoxy-6-chloro-9-dialkylaminoalkylamino-1: 10-diaza-anthracenes</span> <span class="citation_source-journal">J. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1954</span><span class="NLM_x">, </span> <span class="NLM_fpage">2448</span><span class="NLM_x">–</span> <span class="NLM_lpage">2455</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1954&pages=2448-2455&author=D.+M.+Beslyauthor=A.+A.+Goldberg&title=Antimalarial+2-alkoxy-6-chloro-9-dialkylaminoalkylamino-1%3A+10-diaza-anthracenes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBesly%26aufirst%3DD.%2BM.%26aulast%3DGoldberg%26aufirst%3DA.%2BA.%26atitle%3DAntimalarial%25202-alkoxy-6-chloro-9-dialkylaminoalkylamino-1%253A%252010-diaza-anthracenes%26jtitle%3DJ.%2520Chem.%2520Soc.%26date%3D1954%26spage%3D2448%26epage%3D2455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Mitsunobu, O.</span><span> </span><span class="NLM_article-title">The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1055%2Fs-1981-29317" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1981&pages=1-28&author=O.+Mitsunobu&title=The+use+of+diethyl+azodicarboxylate+and+triphenylphosphine+in+synthesis+and+transformation+of+natural+products"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1055%2Fs-1981-29317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1981-29317%26sid%3Dliteratum%253Aachs%26aulast%3DMitsunobu%26aufirst%3DO.%26atitle%3DThe%2520use%2520of%2520diethyl%2520azodicarboxylate%2520and%2520triphenylphosphine%2520in%2520synthesis%2520and%2520transformation%2520of%2520natural%2520products%26jtitle%3DSynthesis%26date%3D1981%26volume%3D1%26spage%3D1%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Madsen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plewe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sams, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidelmann, U. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ynddal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brand, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teston, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, J.</span><span> </span><span class="NLM_article-title">Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1<i>H</i>-indol-4-ylmethylene]hydrazide</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">5755</span><span class="NLM_x">–</span> <span class="NLM_lpage">5775</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0208572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=5755-5775&author=P.+Madsenauthor=A.+Lingauthor=M.+Pleweauthor=C.+K.+Samsauthor=L.+B.+Knudsenauthor=U.+G.+Sidelmannauthor=L.+Ynddalauthor=C.+L.+Brandauthor=B.+Andersenauthor=D.+Murphyauthor=M.+Tengauthor=L.+Truesdaleauthor=D.+Kielauthor=J.+Mayauthor=A.+Kukiauthor=S.+Shiauthor=M.+D.+Johnsonauthor=K.+A.+Testonauthor=J.+Fengauthor=J.+Lakisauthor=K.+Anderesauthor=V.+Gregorauthor=J.+Lau&title=Optimization+of+alkylidene+hydrazide+based+human+glucagon+receptor+antagonists.+Discovery+of+the+highly+potent+and+orally+available+3-cyano-4-hydroxybenzoic+acid+%5B1-%282%2C3%2C5%2C6-tetramethylbenzyl%29-1H-indol-4-ylmethylene%5Dhydrazide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm0208572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0208572%26sid%3Dliteratum%253Aachs%26aulast%3DMadsen%26aufirst%3DP.%26aulast%3DLing%26aufirst%3DA.%26aulast%3DPlewe%26aufirst%3DM.%26aulast%3DSams%26aufirst%3DC.%2BK.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DSidelmann%26aufirst%3DU.%2BG.%26aulast%3DYnddal%26aufirst%3DL.%26aulast%3DBrand%26aufirst%3DC.%2BL.%26aulast%3DAndersen%26aufirst%3DB.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DTeng%26aufirst%3DM.%26aulast%3DTruesdale%26aufirst%3DL.%26aulast%3DKiel%26aufirst%3DD.%26aulast%3DMay%26aufirst%3DJ.%26aulast%3DKuki%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DM.%2BD.%26aulast%3DTeston%26aufirst%3DK.%2BA.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DLakis%26aufirst%3DJ.%26aulast%3DAnderes%26aufirst%3DK.%26aulast%3DGregor%26aufirst%3DV.%26aulast%3DLau%26aufirst%3DJ.%26atitle%3DOptimization%2520of%2520alkylidene%2520hydrazide%2520based%2520human%2520glucagon%2520receptor%2520antagonists.%2520Discovery%2520of%2520the%2520highly%2520potent%2520and%2520orally%2520available%25203-cyano-4-hydroxybenzoic%2520acid%2520%255B1-%25282%252C3%252C5%252C6-tetramethylbenzyl%2529-1H-indol-4-ylmethylene%255Dhydrazide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D5755%26epage%3D5775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Mente, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span> </span><span class="NLM_article-title">A recursive-partitioning model for blood–brain barrier permeation</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">481</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=465-481&author=S.+R.+Menteauthor=F.+Lombardo&title=A+recursive-partitioning+model+for+blood%E2%80%93brain+barrier+permeation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMente%26aufirst%3DS.%2BR.%26aulast%3DLombardo%26aufirst%3DF.%26atitle%3DA%2520recursive-partitioning%2520model%2520for%2520blood%25E2%2580%2593brain%2520barrier%2520permeation%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2005%26volume%3D19%26spage%3D465%26epage%3D481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Mauler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittendorf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horváth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vry, J.</span><span> </span><span class="NLM_article-title">Characterization of the diarylether sulfonylester (−)-(<i>R</i>)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1124%2Fjpet.302.1.359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=12065738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1SnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2002&pages=359-368&author=F.+Maulerauthor=J.+Mittendorfauthor=E.+Horv%C3%A1thauthor=J.+de+Vry&title=Characterization+of+the+diarylether+sulfonylester+%28%E2%88%92%29-%28R%29-3-%282-hydroxymethylindanyl-4-oxy%29phenyl-4%2C4%2C4-trifluoro-1-sulfonate+%28BAY+38-7271%29+as+a+potent+cannabinoid+receptor+agonist+with+neuroprotective+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties</span></div><div class="casAuthors">Mauler, Frank; Mittendorf, Joachim; Horvath, Ervin; De Vry, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">359-368</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) is a new high-affinity cannabinoid receptor subtype 1 (CB1 receptor) ligand (Ki = 0.46-1.85 nM; rat brain, human cortex, or recombinant human CB1 receptor), structurally unrelated to any cannabinoid receptor ligand known so far.  BAY 38-7271 was characterized as a CB1 receptor agonist in 5-[γ35S]-thiophosphate triethylammonium salt binding assays using rat or human CB1 receptors.  In the rat hypothermia assay, BAY 38-7271 induced a dose-dependent redn. in body temp. (minimal ED = 6 μg/kg, i.v.); whereas in rats trained to discriminate the CB1/CB2 receptor agonist (-)-cis-3-[2-hydroxy-4(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol (CP 55,940; 0.03 mg/kg, i.p.) from vehicle, BAY 38-7271 induced complete generalization (3 μg/kg, i.v.).  In both in vivo models, a specific CB1 receptor-mediated mechanism was confirmed by demonstrating that the effects of CP 55,940 and BAY 38-7271 were blocked by pretreatment with the selective CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride.  In the rat traumatic brain injury model, BAY 38-7271 demonstrated highly potent and efficient neuroprotective properties when administered as a 4-h infusion immediately after induction of subdural hematoma (70% infarct vol. redn. at 100 ng/kg/h).  Even when applied with a 3-h delay, a significant neuroprotective efficacy could be obsd. (59% infarct vol. redn. at 300 ng/kg/h).  The neuroprotective potential of BAY 38-7271 was confirmed in a rat model of focal cerebral ischemia induced by permanent occlusion of the middle cerebral artery.  It is concluded that the CB1/CB2 receptor agonist BAY 38-7271 shows pronounced neuroprotective properties that do not result from drug-induced hypothermia and that occur in a dose range devoid of typical cannabinoid-like side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrldnCfbQNSJrVg90H21EOLACvtfcHk0ljl7gfJx65-4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1SnsLs%253D&md5=cc492955592c81dc0d71f7c8ece9ac7b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fjpet.302.1.359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.302.1.359%26sid%3Dliteratum%253Aachs%26aulast%3DMauler%26aufirst%3DF.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DHorv%25C3%25A1th%26aufirst%3DE.%26aulast%3Dde%2BVry%26aufirst%3DJ.%26atitle%3DCharacterization%2520of%2520the%2520diarylether%2520sulfonylester%2520%2528%25E2%2588%2592%2529-%2528R%2529-3-%25282-hydroxymethylindanyl-4-oxy%2529phenyl-4%252C4%252C4-trifluoro-1-sulfonate%2520%2528BAY%252038-7271%2529%2520as%2520a%2520potent%2520cannabinoid%2520receptor%2520agonist%2520with%2520neuroprotective%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D302%26spage%3D359%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Fridén, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ljungqvist, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredberg, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarlund-Udenaes, M.</span><span> </span><span class="NLM_article-title">Improved measurement of drug exposure in brain using drug-specific correction for residual blood</span> <span class="citation_source-journal">J. Cereb. Blood Flow Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">150</span><span class="NLM_x">–</span> <span class="NLM_lpage">161</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1038%2Fjcbfm.2009.200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=19756019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Sg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=150-161&author=M.+Frid%C3%A9nauthor=H.+Ljungqvistauthor=B.+Middletonauthor=U.+Bredbergauthor=M.+Hammarlund-Udenaes&title=Improved+measurement+of+drug+exposure+in+brain+using+drug-specific+correction+for+residual+blood"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Improved measurement of drug exposure in the brain using drug-specific correction for residual blood</span></div><div class="casAuthors">Friden, Markus; Ljungqvist, Helena; Middleton, Brian; Bredberg, Ulf; Hammarlund-Udenaes, Margareta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cerebral Blood Flow & Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">150-161</span>CODEN:
                <span class="NLM_cas:coden">JCBMDN</span>;
        ISSN:<span class="NLM_cas:issn">0271-678X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A major challenge assocd. with the detn. of the unbound brain-to-plasma concn. ratio of a drug (Kp,uu,brain), is the error assocd. with correction for the drug in various vascular spaces of the brain, i.e., in residual blood.  The apparent brain vascular spaces of plasma water (Vwater, 10.3 μL/g brain), plasma proteins (Vprotein, 7.99 μL/g brain), and the vol. of erythrocytes (Ver, 2.13 μL/g brain) were detd. and incorporated into a novel, drug-specific correction model that took the drug-unbound fraction in the plasma (fu,p) into account.  The correction model was successfully applied for the detn. of Kp,uu,brain for indomethacin, loperamide, and moxalactam, which had potential problems assocd. with correction.  The influence on correction of the drug assocd. with erythrocytes was shown to be minimal.  Therefore, it is proposed that correction for residual blood can be performed using an effective plasma space in the brain (Veff), which is calcd. from the measured fu,p of the particular drug as well as from the ests. of Vwater and Vprotein, which are provided in this study.  Furthermore, the results highlight the value of detg. Kp,uu,brain with statistical precision to enable appropriate interpretation of brain exposure for drugs that appear to be restricted to the brain vascular spaces.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdAwudBZex47Vg90H21EOLACvtfcHk0ljl7gfJx65-4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Sg&md5=e55b0e2ec8254fdd498061cf3a1dd015</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fjcbfm.2009.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjcbfm.2009.200%26sid%3Dliteratum%253Aachs%26aulast%3DFrid%25C3%25A9n%26aufirst%3DM.%26aulast%3DLjungqvist%26aufirst%3DH.%26aulast%3DMiddleton%26aufirst%3DB.%26aulast%3DBredberg%26aufirst%3DU.%26aulast%3DHammarlund-Udenaes%26aufirst%3DM.%26atitle%3DImproved%2520measurement%2520of%2520drug%2520exposure%2520in%2520brain%2520using%2520drug-specific%2520correction%2520for%2520residual%2520blood%26jtitle%3DJ.%2520Cereb.%2520Blood%2520Flow%2520Metab.%26date%3D2010%26volume%3D30%26spage%3D150%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Wan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, F.</span><span> </span><span class="NLM_article-title">High throughput screening of drug–protein binding in drug discovery</span> <span class="citation_source-journal">J. Liq. Chromatogr. Relat. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1080%2F10826070701190989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVOhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=681-700&author=H.+Wanauthor=F.+Bergstrom&title=High+throughput+screening+of+drug%E2%80%93protein+binding+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput screening of drug-protein binding in drug discovery</span></div><div class="casAuthors">Wan, Hong; Bergstroem, Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Liquid Chromatography & Related Technologies</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5-7</span>),
    <span class="NLM_cas:pages">681-700</span>CODEN:
                <span class="NLM_cas:coden">JLCTFC</span>;
        ISSN:<span class="NLM_cas:issn">1082-6076</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  Characterization of drug-protein binding is essential, since it has profound effects on pharmacokinetic and pharmacodynamic parameters of new chem. entities.  Although the traditional equil. dialysis method is well established and widely used for drug-protein binding measurement, this assay suffers from its low throughput.  Recent efforts were made in developing and implementing high throughput assays for drug-protein screening in drug discovery.  The present review highlights high-throughput assays, as well as potential new approaches for drug-protein binding screening in drug discovery.  These primarily include automated 96-well plate, sample pooling based equil. dialysis combined with LCMS, immobilized HSA column HPLC, and electrodriven techniques such as frontal anal. combined with capillary electrophoresis (FACE), and affinity capillary electrophoresis (ACE).  Fundamental drug-protein binding models are also discussed to (1) compare and discriminate HSA (human serum albumin) and AGP (alpha 1-acid glycoprotein) binding with regard to the whole plasma protein binding; and (2) elucidate the applicability of high throughput screening (HTS) from the viewpoint of a simplified binding model.  Some strategies and recommendations are proposed in dealing with applications of high throughput assays in different situations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_xre3PNsNMbVg90H21EOLACvtfcHk0ljl7gfJx65-4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVOhtbg%253D&md5=5eb753c9ec9142c2a3d89a3a266dfacf</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1080%2F10826070701190989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10826070701190989%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DH.%26aulast%3DBergstrom%26aufirst%3DF.%26atitle%3DHigh%2520throughput%2520screening%2520of%2520drug%25E2%2580%2593protein%2520binding%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Liq.%2520Chromatogr.%2520Relat.%2520Technol.%26date%3D2007%26volume%3D30%26spage%3D681%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Griffen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robb, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, D. J.</span><span> </span><span class="NLM_article-title">Matched molecular pairs as a medicinal chemistry tool</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7739</span><span class="NLM_x">–</span> <span class="NLM_lpage">7750</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200452d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Wks7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7739-7750&author=E.+Griffenauthor=A.+G.+Leachauthor=G.+R.+Robbauthor=D.+J.+Warner&title=Matched+molecular+pairs+as+a+medicinal+chemistry+tool"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Matched Molecular Pairs as a Medicinal Chemistry Tool</span></div><div class="casAuthors">Griffen, Ed; Leach, Andrew G.; Robb, Graeme R.; Warner, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7739-7750</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">At the very heart of the role of a medicinal chemist or drug designer is the ability to link chem. structure to mol. properties.  This is the structure-activity relationship(SAR) or structure-property relationship(SPR).  Drug discovery projects often discover that a particular structural change causes a change to a property of interest.  The authors of this paper have been involved in developing and implementing some variations on the original theme of MMPA (matched mol. pairs anal.) and felt this to be the time to highlight some of these and to point toward future developments.  All of them are involved in the process of drug design, and it is within this context that they will set their comments.  In outline, they introduce matched mol. pair anal. and highlight why it fits so well with the kind of problem solving that is required in the process of drug design.  This will be followed by some comments concerning when the application of the methodol. is appropriate.  Then in a section intended for those with more computational interests, the authors describe the various ways that have been devised for identifying such matched pairs.  Throughout the paper, the authors have elected to use a publicly available data set to illustrate some of the comments: the ChEMBL database of inhibitors of the epidermal growth factor receptor tyrosine kinase (EGFR).  This consists of 2899 measurements of an IC50 annotated as a binding measurement on 2348 unique compds.  These measurements are drawn from a no. of sources, having been abstracted from the scientific literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMGFfO8Flm5bVg90H21EOLACvtfcHk0lj5TJzsFhMgrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Wks7jK&md5=fab3344d790d1c0ae688ec65830d9143</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm200452d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200452d%26sid%3Dliteratum%253Aachs%26aulast%3DGriffen%26aufirst%3DE.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DRobb%26aufirst%3DG.%2BR.%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26atitle%3DMatched%2520molecular%2520pairs%2520as%2520a%2520medicinal%2520chemistry%2520tool%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7739%26epage%3D7750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Lehmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremner Danielsen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flärdh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansson-Bränden, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kärrber, L.</span><span> </span><span class="NLM_article-title">Activation of the GABAB receptor inhibits transient lower esophageal sphincter relaxations in dogs</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">1147</span><span class="NLM_x">–</span> <span class="NLM_lpage">1154</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=1999&pages=1147-1154&author=A.+Lehmannauthor=M.+Antonssonauthor=M.+Bremner+Danielsenauthor=M.+Fl%C3%A4rdhauthor=L.+Hansson-Br%C3%A4ndenauthor=L.+K%C3%A4rrber&title=Activation+of+the+GABAB+receptor+inhibits+transient+lower+esophageal+sphincter+relaxations+in+dogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DA.%26aulast%3DAntonsson%26aufirst%3DM.%26aulast%3DBremner%2BDanielsen%26aufirst%3DM.%26aulast%3DFl%25C3%25A4rdh%26aufirst%3DM.%26aulast%3DHansson-Br%25C3%25A4nden%26aufirst%3DL.%26aulast%3DK%25C3%25A4rrber%26aufirst%3DL.%26atitle%3DActivation%2520of%2520the%2520GABAB%2520receptor%2520inhibits%2520transient%2520lower%2520esophageal%2520sphincter%2520relaxations%2520in%2520dogs%26jtitle%3DGastroenterology%26date%3D1999%26volume%3D117%26spage%3D1147%26epage%3D1154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Lichtman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaVecchia, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neviaser, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, B. R.</span><span> </span><span class="NLM_article-title">Effects of SR 141716A after acute or chronic cannabinoid administration in dogs</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1016%2FS0014-2999%2898%2900558-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=9797029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADyaK1cXlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=1998&pages=139-148&author=A.+H.+Lichtmanauthor=J.+L.+Wileyauthor=K.+L.+LaVecchiaauthor=S.+T.+Neviaserauthor=D.+B.+Arthurauthor=D.+M.+Wilsonauthor=B.+R.+Martin&title=Effects+of+SR+141716A+after+acute+or+chronic+cannabinoid+administration+in+dogs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of SR 141716A after acute or chronic cannabinoid administration in dogs</span></div><div class="casAuthors">Lichtman, Aron H.; Wiley, Jenny L.; LaVecchia, Kari L.; Neviaser, Scott T.; Arthur, David B.; Wilson, David M.; Martin, Billy R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">139-148</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The effects of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR 141716A), a specific cannabinoid receptor antagonist, were assessed in the dog static ataxia test after either acute treatment with two cannabinoid receptor agonists, Δ9-tetrahydrocannabinol and arachidonylethanolamide (anandamide), or chronic treatment with Δ9-tetrahydrocannabinol.  As previously reported, acute i.v. injected Δ9-tetrahydrocannabinol produced dose-dependent cannabinoid effects, including marked static ataxia, prancing, loss of muscle tone, and incoordination.  The behavioral profile of anandamide was distinctly different in that it produced a loss of muscle tone and considerable sedation with little static ataxia, prancing, or incoordination.  Despite these qual. differences between the two agonists, SR 141716A blocked the acute behavioral effects of both drugs indicating a cannabinoid receptor mechanism of action.  Interestingly, SR 141716A was able to ppt. a withdrawal syndrome in Δ9-tetrahydrocannabinol-tolerant dogs, but failed to produce any observable effects in dogs receiving chronic vehicle injections.  Acute toxicity caused by anandamide, which was not blocked by SR 141716A, precluded conducting dependence studies with this drug.  The Δ9-tetrahydrocannabinol pptd. withdrawal syndrome included diarrhea, vomiting, excessive salivation, decreases in social behavior, and increases in restless behavior and trembling.  This is the first demonstration of a pptd. withdrawal syndrome in a non-rodent species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTW---kmkGsbVg90H21EOLACvtfcHk0lj5TJzsFhMgrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlvFeltLY%253D&md5=0d5d3f06374fb12936e3bc3e86fae755</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2898%2900558-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252898%252900558-5%26sid%3Dliteratum%253Aachs%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DLaVecchia%26aufirst%3DK.%2BL.%26aulast%3DNeviaser%26aufirst%3DS.%2BT.%26aulast%3DArthur%26aufirst%3DD.%2BB.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26atitle%3DEffects%2520of%2520SR%2520141716A%2520after%2520acute%2520or%2520chronic%2520cannabinoid%2520administration%2520in%2520dogs%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1998%26volume%3D357%26spage%3D139%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Shardlow, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Generaux, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLauchlin, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pons, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skordos, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloomer, J. C.</span><span> </span><span class="NLM_article-title">Utilizing drug–drug interaction prediction tools during drug development: enhanced decision making based on clinical risk</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2076</span><span class="NLM_x">–</span> <span class="NLM_lpage">2084</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2076-2084&author=C.+E.+Shardlowauthor=G.+T.+Generauxauthor=C.+C.+MacLauchlinauthor=N.+Ponsauthor=K.+W.+Skordosauthor=J.+C.+Bloomer&title=Utilizing+drug%E2%80%93drug+interaction+prediction+tools+during+drug+development%3A+enhanced+decision+making+based+on+clinical+risk"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShardlow%26aufirst%3DC.%2BE.%26aulast%3DGeneraux%26aufirst%3DG.%2BT.%26aulast%3DMacLauchlin%26aufirst%3DC.%2BC.%26aulast%3DPons%26aufirst%3DN.%26aulast%3DSkordos%26aufirst%3DK.%2BW.%26aulast%3DBloomer%26aufirst%3DJ.%2BC.%26atitle%3DUtilizing%2520drug%25E2%2580%2593drug%2520interaction%2520prediction%2520tools%2520during%2520drug%2520development%253A%2520enhanced%2520decision%2520making%2520based%2520on%2520clinical%2520risk%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2076%26epage%3D2084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Peter, H.</span><span> </span><span class="NLM_article-title">Functional interaction of nitrogenous organic bases with cytochrome P450: a critical assessment and update of substrate features and predicted key active-site elements steering the access, binding, and orientation of amines</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1764</span><span class="NLM_x">, </span> <span class="NLM_fpage">645</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1764&publication_year=2006&pages=645-670&author=H.+Peter&title=Functional+interaction+of+nitrogenous+organic+bases+with+cytochrome+P450%3A+a+critical+assessment+and+update+of+substrate+features+and+predicted+key+active-site+elements+steering+the+access%2C+binding%2C+and+orientation+of+amines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeter%26aufirst%3DH.%26atitle%3DFunctional%2520interaction%2520of%2520nitrogenous%2520organic%2520bases%2520with%2520cytochrome%2520P450%253A%2520a%2520critical%2520assessment%2520and%2520update%2520of%2520substrate%2520features%2520and%2520predicted%2520key%2520active-site%2520elements%2520steering%2520the%2520access%252C%2520binding%252C%2520and%2520orientation%2520of%2520amines%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2006%26volume%3D1764%26spage%3D645%26epage%3D670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Redfern, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palethorpe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P. K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strang, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camm, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, T. G.</span><span> </span><span class="NLM_article-title">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=12667944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&author=W.+S.+Redfernauthor=L.+Carlssonauthor=A.+S.+Davisauthor=W.+G.+Lynchauthor=I.+MacKenzieauthor=S.+Palethorpeauthor=P.+K.+S.+Sieglauthor=I.+Strangauthor=A.+T.+Sullivanauthor=R.+Wallisauthor=A.+J.+Cammauthor=T.+G.+Hammond&title=Relationships+between+preclinical+cardiac+electrophysiology%2C+clinical+QT+interval+prolongation+and+torsade+de+pointes+for+a+broad+range+of+drugs%3A+evidence+for+a+provisional+safety+margin+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span></div><div class="casAuthors">Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discussing attempts to det. the relative value of preclin. cardiac electrophysiol. data (in vitro and in vivo) for predicting risk of torsades de pointes (TdP) in clin. use.  Published data on human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG) (or IKr) activity, cardiac action potential duration (at 90% repolarization; APD90), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.  These data were set against the free plasma concns. attained during clin. use (effective therapeutic plasma concns.; ETPCunbound).  The drugs were divided into five categories: (1) Class Ia and III antiarrhythmics; (2) withdrawn from market due to TdP; (3) measurable incidence/numerous reports of TdP in humans; (4) isolated reports of TdP in humans; (5) no reports of TdP in humans.  Data from hERG (or IKr) assays in addn. to ETPCunbound data were available for 52 drugs.  For Category 1 drugs, data for hERG/IKr IC50, APD90, QTc in animals and QTc in humans were generally close to or superimposed on the ETPCunbound values.  This relationship was uncoupled in the other categories, with more complex relationships between the data.  In Category 1 (except amiodarone), the ratios between hERG/IKr IC50 and ETPCunbound (max) ranged 0.1-31-fold.  Similar ranges were obtained for drugs in Category 2 (0.31-13-fold) and Category 3 (0.03-35-fold).  A large spread was found for Category 4 drugs (0.13-35,700-fold); this category embraced an assortment of mechanisms ranging from drugs which may well be affecting IKr currents in clin. use (e.g., sparfloxacin) to others such as nifedipine (35,700-fold) where channel block is not involved.  Finally, for the majority of Category 5 drugs there was a >30-fold sepn. between hERG/IKr activity and ETPCunbound values, with the notable exception of verapamil (1.7-fold), which is free from QT prolongation in man; this is probably explained by its multiple interactions with cardiac ion channels.  The dataset confirms the widely held belief that most drugs assocd. with TdP in humans are also assocd. with hERG K+ channel block at concns. close to or superimposed upon the free plasma concns. found in clin. use.  A 30-fold margin between Cmax and hERG IC50 may suffice for drugs currently undergoing clin. evaluation, but for future drug discovery programs, pharmaceutical companies should consider increasing this margin, particularly for drugs aimed at nondebilitating diseases.  However, interactions with multiple cardiac ion channels can either mitigate or exacerbate the prolongation of APD and QT that would ensue from block of IKr currents alone, and delay of repolarization per se is not necessarily torsadogenic.  Clearly, an integrated assessment of in vitro and in vivo data is required in order to predict the torsadogenic risk of a new candidate drug in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkpRDUH0rhyrVg90H21EOLACvtfcHk0ljVJZobxwaA5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D&md5=a236c07febd2e05fe70e61604619bf2e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%2BS.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BS.%26aulast%3DLynch%26aufirst%3DW.%2BG.%26aulast%3DMacKenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%2BS.%26aulast%3DStrang%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DA.%2BT.%26aulast%3DWallis%26aufirst%3DR.%26aulast%3DCamm%26aufirst%3DA.%2BJ.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26atitle%3DRelationships%2520between%2520preclinical%2520cardiac%2520electrophysiology%252C%2520clinical%2520QT%2520interval%2520prolongation%2520and%2520torsade%2520de%2520pointes%2520for%2520a%2520broad%2520range%2520of%2520drugs%253A%2520evidence%2520for%2520a%2520provisional%2520safety%2520margin%2520in%2520drug%2520development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26spage%3D32%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Schroeder, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neagle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trezise, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worley, J.</span><span> </span><span class="NLM_article-title">IonWorks: a new high-throughput electrophysiology measurement platform</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1177%2F1087057102239667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=12854998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlSqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=50-64&author=K.+Schroederauthor=B.+Neagleauthor=D.+J.+Treziseauthor=J.+Worley&title=IonWorks%3A+a+new+high-throughput+electrophysiology+measurement+platform"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">IonWorks HT: A new high-throughput electrophysiology measurement platform</span></div><div class="casAuthors">Schroeder, Kirk; Neagle, Brad; Trezise, Derek J.; Worley, Jennings</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-64</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">To address the throughput restrictions of classical patch clamp electrophysiol., Essen Instruments has developed a plate-based electrophysiol. measurement platform.  The instrument is an integrated platform that consists of computer-controlled fluid handling, recording electronics, and processing tools capable of voltage clamp whole-cell recordings from thousands of individual cells per day.  To establish a recording, the system uses a planar, multi-well substrate (a PatchPlate).  The system effectively positions 1 cell into a hole sepg. 2 fluid compartments in each well of the substrate.  Voltage control and current recordings from the cell membrane are made subsequent to gaining access to the cell interior by applying a permeabilizing agent to the intracellular side.  Based on the multi-well design of the PatchPlate, voltage clamp recordings of up to 384 individual cells can be made in minutes and are comparable to measurements made using traditional electrophysiol. techniques.  An integrated pipetting system allows for up to 2 addns. of modulation agents.  Typical throughput, measurement fidelity, stability, and comparative pharmacol. of a recombinant voltage-dependent sodium channel (hNav1.3) and a voltage-gated potassium channel (hKv1.5) exogenously expressed in CHO cells are presented.  The IonWorks HT device can be used in biophys. and pharmacol. profiling of ion channels in an environment compatible with high-capacity screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr99MfVnFuXs7Vg90H21EOLACvtfcHk0ljVJZobxwaA5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlSqu70%253D&md5=3a161db49dbb3c39e1db2d74e46e6bfb</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1177%2F1087057102239667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057102239667%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DK.%26aulast%3DNeagle%26aufirst%3DB.%26aulast%3DTrezise%26aufirst%3DD.%2BJ.%26aulast%3DWorley%26aufirst%3DJ.%26atitle%3DIonWorks%253A%2520a%2520new%2520high-throughput%2520electrophysiology%2520measurement%2520platform%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2003%26volume%3D8%26spage%3D50%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Tachibana, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span> </span><span class="NLM_article-title">Prediction of nonlinear intestinal absorption of CYP3A4 and p-glycoprotein substrates from their in vitro Km values</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">–</span> <span class="NLM_lpage">668</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=651-668&author=T.+Tachibanaauthor=M.+Katoauthor=Y.+Sugiyama&title=Prediction+of+nonlinear+intestinal+absorption+of+CYP3A4+and+p-glycoprotein+substrates+from+their+in+vitro+Km+values"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTachibana%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DPrediction%2520of%2520nonlinear%2520intestinal%2520absorption%2520of%2520CYP3A4%2520and%2520p-glycoprotein%2520substrates%2520from%2520their%2520in%2520vitro%2520Km%2520values%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D651%26epage%3D668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Amin, K.; Broddefalk, J.; Desfosses, H.; Evertsson, E.; Liu, Z.; Milburn, C.; Nilsson, K.; Tremblay, M.; Walpole, C.; Wei, Z.; Yang, H.</span>, WO2005115986(A1),<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Amin%2C+K.%3B+Broddefalk%2C+J.%3B+Desfosses%2C+H.%3B+Evertsson%2C+E.%3B+Liu%2C+Z.%3B+Milburn%2C+C.%3B+Nilsson%2C+K.%3B+Tremblay%2C+M.%3B+Walpole%2C+C.%3B+Wei%2C+Z.%3B+Yang%2C+H.%2C+WO2005115986%28A1%29%2C+2005."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAmin%26aufirst%3DK.%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Magnus Munck af Rosenschöld, Petra Johannesson, Antonios Nikitidis, Christian Tyrchan, Hui-Fang Chang, Robert Rönn, Dave Chapman, Victoria Ullah, Grigorios Nikitidis, Pernilla Glader, Helena Käck, Britta Bonn, Fredrik Wågberg, Eva Björkstrand, Ulf Andersson, Linda Swedin, Mattias Rohman, Theresa Andreasson, Eva Lamm Bergström, Fanyi Jiang, Xiao-Hong Zhou, Anders J. Lundqvist, Anna Malmberg, Margareta Ek, Euan Gordon, Anna Pettersen, Lena Ripa, <span class="NLM_string-name hlFld-ContribAuthor">Andrew M. Davis</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (17)
                                     , 7769-7787. <a href="https://doi.org/10.1021/acs.jmedchem.9b00555" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00555</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00555%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthe%252BOral%252BLeukotriene%252BC4%252BSynthase%252BInhibitor%252B%2525281S%25252C2S%252529-2-%252528%25257B5-%25255B%2525285-Chloro-2%25252C4-difluorophenyl%252529%2525282-fluoro-2-methylpropyl%252529amino%25255D-3-methoxypyrazin-2-yl%25257Dcarbonyl%252529cyclopropanecarboxylic%252BAcid%252B%252528AZD9898%252529%252Bas%252Ba%252BNew%252BTreatment%252Bfor%252BAsthma%26aulast%3DMunck%2Baf%2BRosensch%25C3%25B6ld%26aufirst%3DMagnus%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30032019%26date%3D30082019%26date%3D15082019%26volume%3D62%26issue%3D17%26spage%3D7769%26epage%3D7787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan-Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Houfu  Liu</span>, <span class="hlFld-ContribAuthor ">Scott G.  Summerfield</span>, <span class="hlFld-ContribAuthor ">Christopher N.  Luscombe</span>, and <span class="hlFld-ContribAuthor ">Jasminder  Sahi</span>  . </span><span class="cited-content_cbyCitation_article-title">Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2016,</strong> <em>13 </em>
                                    (5)
                                     , 1540-1550. <a href="https://doi.org/10.1021/acs.molpharmaceut.6b00031" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.6b00031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.6b00031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.6b00031%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DIntegrating%252Bin%252BSilico%252Band%252Bin%252BVitro%252BApproaches%252BTo%252BPredict%252BDrug%252BAccessibility%252Bto%252Bthe%252BCentral%252BNervous%252BSystem%26aulast%3DZhang%26aufirst%3DYan-Yan%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D12012016%26date%3D25032016%26date%3D17032016%26date%3D04042016%26date%3D02052016%26date%3D25032016%26volume%3D13%26issue%3D5%26spage%3D1540%26epage%3D1550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Ai</span>, <span class="hlFld-ContribAuthor ">Yang  Hu</span>, <span class="hlFld-ContribAuthor ">Fenghua  Kang</span>, <span class="hlFld-ContribAuthor ">Yisheng  Lai</span>, <span class="hlFld-ContribAuthor ">Yanju  Jia</span>, <span class="hlFld-ContribAuthor ">Zhangjian  Huang</span>, <span class="hlFld-ContribAuthor ">Sixun  Peng</span>, <span class="hlFld-ContribAuthor ">Hui  Ji</span>, <span class="hlFld-ContribAuthor ">Jide  Tian</span>, and <span class="hlFld-ContribAuthor ">Yihua  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Novel Olean-28,13β-lactams as Potential Antiprostate Cancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (11)
                                     , 4506-4520. <a href="https://doi.org/10.1021/jm5020023" title="DOI URL">https://doi.org/10.1021/jm5020023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5020023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5020023%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BOlean-28%25252C13%2525CE%2525B2-lactams%252Bas%252BPotential%252BAntiprostate%252BCancer%252BAgents%26aulast%3DAi%26aufirst%3DYong%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D24122014%26date%3D02062015%26date%3D11062015%26date%3D20052015%26volume%3D58%26issue%3D11%26spage%3D4506%26epage%3D4520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guillermo  Moreno-Sanz</span>, <span class="hlFld-ContribAuthor ">Andrea  Duranti</span>, <span class="hlFld-ContribAuthor ">Laurin  Melzig</span>, <span class="hlFld-ContribAuthor ">Claudio  Fiorelli</span>, <span class="hlFld-ContribAuthor ">Gian Filippo  Ruda</span>, <span class="hlFld-ContribAuthor ">Giampiero  Colombano</span>, <span class="hlFld-ContribAuthor ">Paola  Mestichelli</span>, <span class="hlFld-ContribAuthor ">Silvano  Sanchini</span>, <span class="hlFld-ContribAuthor ">Andrea  Tontini</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Tiziano  Bandiera</span>, <span class="hlFld-ContribAuthor ">Rita  Scarpelli</span>, <span class="hlFld-ContribAuthor ">Giorgio  Tarzia</span>, and <span class="hlFld-ContribAuthor ">Daniele  Piomelli</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Structure–Activity Relationship Studies of O-Biphenyl-3-yl Carbamates as Peripherally Restricted Fatty Acid Amide Hydrolase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (14)
                                     , 5917-5930. <a href="https://doi.org/10.1021/jm4007017" title="DOI URL">https://doi.org/10.1021/jm4007017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4007017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4007017%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationship%252BStudies%252Bof%252BO-Biphenyl-3-yl%252BCarbamates%252Bas%252BPeripherally%252BRestricted%252BFatty%252BAcid%252BAmide%252BHydrolase%252BInhibitors%26aulast%3DMoreno-Sanz%26aufirst%3DGuillermo%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D10052013%26date%3D03072013%26date%3D25072013%26volume%3D56%26issue%3D14%26spage%3D5917%26epage%3D5930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michelle Kem Su  Hor</span>, <span class="hlFld-ContribAuthor ">Monica  Dzwonkowski</span>, <span class="hlFld-ContribAuthor ">Tesia  Kolodziejczyk</span>, <span class="hlFld-ContribAuthor ">Lorne  Muir</span>, <span class="hlFld-ContribAuthor ">Nazar  Dubchak</span>, <span class="hlFld-ContribAuthor ">Sabina  Hochroth</span>, <span class="hlFld-ContribAuthor ">Bhaktasharan  Patel</span>, <span class="hlFld-ContribAuthor ">Aaron  Wu</span>, <span class="hlFld-ContribAuthor ">Sean  Knight</span>, <span class="hlFld-ContribAuthor ">Garrett  Smith</span>, <span class="hlFld-ContribAuthor ">Uday  Patel</span>, <span class="hlFld-ContribAuthor ">Quentin  Remley</span>, <span class="hlFld-ContribAuthor ">Cicily  Hummer</span>. </span><span class="cited-content_cbyCitation_article-title">Cannabinoids in Gastrointestinal Disorders. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 415-451. <a href="https://doi.org/10.1007/978-3-030-45968-0_17" title="DOI URL">https://doi.org/10.1007/978-3-030-45968-0_17</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-45968-0_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-45968-0_17%26sid%3Dliteratum%253Aachs%26atitle%3DCannabinoids%252Bin%252BGastrointestinal%252BDisorders%26aulast%3DHor%26aufirst%3DMichelle%2BKem%2BSu%26date%3D2020%26date%3D2020%26spage%3D415%26epage%3D451%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCannabis%252Bin%252BMedicine%26aulast%3DFinn%26aufirst%3DKenneth%26date%3D2020%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pascale  Moreau</span>, <span class="hlFld-ContribAuthor ">Fabrice  Anizon</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 6-6 Systems: Other Four Heteroatoms 2/2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.14956-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14956-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14956-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14956-X%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B6-6%252BSystems%25253A%252BOther%252BFour%252BHeteroatoms%252B2%25252F2%26aulast%3DMoreau%26aufirst%3DPascale%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3Dvol.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">He  Song</span>, <span class="hlFld-ContribAuthor ">Xiaochong  Liu</span>, <span class="hlFld-ContribAuthor ">Chenglong  Wang</span>, <span class="hlFld-ContribAuthor ">Jingyi  Qiao</span>, <span class="hlFld-ContribAuthor ">Wenyi  Chu</span>, <span class="hlFld-ContribAuthor ">Zhizhong  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Cu(TFA)
              2
              -Catalyzed Picolinamido-Directed C(sp
              2
              )−H Cyanation of Naphthalenes by Using Benzoyl Cyanide as a Cyano Source. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>6 </em>
                                    (11)
                                     , 1693-1698. <a href="https://doi.org/10.1002/ajoc.201700418" title="DOI URL">https://doi.org/10.1002/ajoc.201700418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201700418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201700418%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCu%252528TFA%252529%252B2%252B-Catalyzed%252BPicolinamido-Directed%252BC%252528sp%252B2%252B%252529%2525E2%252588%252592H%252BCyanation%252Bof%252BNaphthalenes%252Bby%252BUsing%252BBenzoyl%252BCyanide%252Bas%252Ba%252BCyano%252BSource%26aulast%3DSong%26aufirst%3DHe%26date%3D2017%26date%3D2017%26volume%3D6%26issue%3D11%26spage%3D1693%26epage%3D1698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony C.  Johnson</span>, <span class="hlFld-ContribAuthor ">Beverley  Greenwood-Van Meerveld</span>. </span><span class="cited-content_cbyCitation_article-title">Critical Evaluation of Animal Models of Gastrointestinal Disorders. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 289-317. <a href="https://doi.org/10.1007/164_2016_120" title="DOI URL">https://doi.org/10.1007/164_2016_120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/164_2016_120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F164_2016_120%26sid%3Dliteratum%253Aachs%26atitle%3DCritical%252BEvaluation%252Bof%252BAnimal%252BModels%252Bof%252BGastrointestinal%252BDisorders%26aulast%3DJohnson%26aufirst%3DAnthony%2BC.%26date%3D2017%26date%3D2017%26spage%3D289%26epage%3D317%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DGastrointestinal%252BPharmacology%26aulast%3DGreenwood-Van%2BMeerveld%26aufirst%3DBeverley%26date%3D2017%26volume%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan  Gotfried</span>, <span class="hlFld-ContribAuthor ">Rahul  Kataria</span>, <span class="hlFld-ContribAuthor ">Ron  Schey</span>. </span><span class="cited-content_cbyCitation_article-title">Review: The Role of Cannabinoids on Esophageal Function—What We Know Thus Far. </span><span class="cited-content_cbyCitation_journal-name">Cannabis and Cannabinoid Research</span><span> <strong>2017,</strong> <em>2 </em>
                                    (1)
                                     , 252-258. <a href="https://doi.org/10.1089/can.2017.0031" title="DOI URL">https://doi.org/10.1089/can.2017.0031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/can.2017.0031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fcan.2017.0031%26sid%3Dliteratum%253Aachs%26jtitle%3DCannabis%2520and%2520Cannabinoid%2520Research%26atitle%3DReview%25253A%252BThe%252BRole%252Bof%252BCannabinoids%252Bon%252BEsophageal%252BFunction%2525E2%252580%252594What%252BWe%252BKnow%252BThus%252BFar%26aulast%3DGotfried%26aufirst%3DJonathan%26date%3D2017%26volume%3D2%26issue%3D1%26spage%3D252%26epage%3D258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Di</span>, <span class="hlFld-ContribAuthor ">Edward H.  Kerns</span>. </span><span class="cited-content_cbyCitation_article-title">Blood-Brain Barrier. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 141-159. <a href="https://doi.org/10.1016/B978-0-12-801076-1.00010-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-801076-1.00010-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-801076-1.00010-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-801076-1.00010-1%26sid%3Dliteratum%253Aachs%26atitle%3DBlood-Brain%252BBarrier%26aulast%3DDi%26aufirst%3DLi%26date%3D2016%26spage%3D141%26epage%3D159%26pub%3DElsevier%26atitle%3DDrug-Like%252BProperties%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongming  Chen</span>, <span class="hlFld-ContribAuthor ">Susanne  Winiwarter</span>, <span class="hlFld-ContribAuthor ">Ola  Engkvist</span>. </span><span class="cited-content_cbyCitation_article-title">In Silico
              Tools for Predicting Brain Exposure of Drugs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 167-187. <a href="https://doi.org/10.1002/9781118788523.ch9" title="DOI URL">https://doi.org/10.1002/9781118788523.ch9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118788523.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118788523.ch9%26sid%3Dliteratum%253Aachs%26atitle%3DIn%252BSilico%252BTools%252Bfor%252BPredicting%252BBrain%252BExposure%252Bof%252BDrugs%26aulast%3DChen%26aufirst%3DHongming%26date%3D2015%26date%3D2015%26spage%3D167%26epage%3D187%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DBlood-Brain%252BBarrier%252Bin%252BDrug%252BDiscovery%26aulast%3DDi%26aufirst%3DLi%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew L.  Hopkins</span>, <span class="hlFld-ContribAuthor ">György M.  Keserü</span>, <span class="hlFld-ContribAuthor ">Paul D.  Leeson</span>, <span class="hlFld-ContribAuthor ">David C.  Rees</span>, <span class="hlFld-ContribAuthor ">Charles H.  Reynolds</span>. </span><span class="cited-content_cbyCitation_article-title">The role of ligand efficiency metrics in drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2014,</strong> <em>13 </em>
                                    (2)
                                     , 105-121. <a href="https://doi.org/10.1038/nrd4163" title="DOI URL">https://doi.org/10.1038/nrd4163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd4163%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DThe%252Brole%252Bof%252Bligand%252Befficiency%252Bmetrics%252Bin%252Bdrug%252Bdiscovery%26aulast%3DHopkins%26aufirst%3DAndrew%2BL.%26date%3D2014%26date%3D2014%26volume%3D13%26issue%3D2%26spage%3D105%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Markus  Fridén</span>. </span><span class="cited-content_cbyCitation_article-title">Prediction of Drug Exposure in the Brain from the Chemical Structure. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 317-338. <a href="https://doi.org/10.1007/978-1-4614-9105-7_11" title="DOI URL">https://doi.org/10.1007/978-1-4614-9105-7_11</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4614-9105-7_11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4614-9105-7_11%26sid%3Dliteratum%253Aachs%26atitle%3DPrediction%252Bof%252BDrug%252BExposure%252Bin%252Bthe%252BBrain%252Bfrom%252Bthe%252BChemical%252BStructure%26aulast%3DFrid%25C3%25A9n%26aufirst%3DMarkus%26date%3D2014%26date%3D2013%26spage%3D317%26epage%3D338%26pub%3DSpringer%2520New%2520York%26atitle%3DDrug%252BDelivery%252Bto%252Bthe%252BBrain%26aulast%3DHammarlund-Udenaes%26aufirst%3DMargareta%26date%3D2014%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of CB1 receptor agonists: anandamide (<b>1</b>), WIN 55,212-2 (<b>2</b>), and Δ<sup>9</sup>-tetrahydrocannabinol (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Experimental data showing total (<i>C</i><sub>br</sub>/<i>C</i><sub>pl</sub>) versus unbound (<i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub>) ratios for 258 compounds from a variety of AstraZeneca projects and marketed drugs.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The coloring is based on experimental Caco-2 efflux data. The relevance of the efflux ratio is demonstrated by a clear shift in the plot where compounds with higher efflux generally have lower <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub> ratios.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Initial CB1 receptor agonist lead (<b>4</b>) identified from screening a set of targeted GPCR libraries (75 000 compounds).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Substituted Pyridine and Pyrazine Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) R<sup>3</sup>C(O)Cl, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), DMF, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (ii) DIPEA, HATU, 50 °C; (b) R<sup>2</sup>NH<sub>2</sub>, DIPEA, DMF; (c) R<sup>2</sup>NH<sub>2</sub>, HATU, DIPEA, DMF; (d) R<sup>3</sup>COOH, HATU, DIPEA, DMF; (e) (i) oxalyl chloride, DCE, 70 °C; (ii) NaBH<sub>4</sub>, I<sub>2</sub>; (f) CH<sub>3</sub>SO<sub>2</sub>Cl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (g) nucleophile (R<sup>4</sup>H) (e.g., pyrrole for <b>9c</b>), KI, DMF, 80 °C; (h) pyridine hydrochloride, 160 °C; (i) Ag<sub>2</sub>CO<sub>3</sub>, R<sup>5</sup>Cl, DMF, 130 °C or R<sup>5</sup>OH, diisopropyl azodicarboxylate, Ph<sub>3</sub>P, THF, 50 °C. The structures of R<sup>1</sup>–R<sup>5</sup> and the molecule cores are presented in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Triazole Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) 4-methyl-1-naphthalenecarbonyl chloride, DIPEA, DMF, 50 °C; (ii) MeI, K<sub>2</sub>CO<sub>3</sub>; (b) (i) NBS, benzoyl peroxide, CCl<sub>4</sub>; (ii) 1,2,3-triazole, DMF; (c) R<sup>2</sup>NH<sub>2</sub>, DMF, 80 °C; (d) pyridine hydrochloride, 160 °C; (e) Ag<sub>2</sub>CO<sub>3</sub>, R<sup>5</sup>Cl, DMF, 130 °C. The structures of R<sup>1</sup>, R<sup>2</sup>, and R<sup>5</sup> are presented in Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Sulfoxide Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HCl, MeOH; (b) 4-[(methylthio)methyl]-1-naphthoyl chloride, pyridine, DMAP, CHCl<sub>3</sub>, 50 °C; (c) R<sup>2</sup>NH<sub>2</sub>, DMF, 80 °C; (d) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (e) pyridine hydrochloride, 160 °C; (f) Ag<sub>2</sub>CO<sub>3</sub>, R<sup>5</sup>Cl, DMF, 130 °C. The structures of R<sup>1</sup>, R<sup>2</sup>, and R<sup>5</sup> are presented in Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/medium/jm-2012-01511h_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0014.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compounds <b>13c</b> and <b>14</b> produced dose-dependent inhibition of transient lower esophageal sphincter relaxations (TLESRs) in the dog in vivo.<a onclick="showRef(event, 'ref9 ref48'); return false;" href="javascript:void(0);" class="ref ref9 ref48">(9, 48)</a> The graphs show mean percentage inhibition and SEM (<i>n</i> = number of experiments for each dose).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-1/jm301511h/production/images/large/jm-2012-01511h_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301511h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i74">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87054" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87054" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 55 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Howlett, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabral, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casellas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devane, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herkenham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechoulam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1124%2Fpr.54.2.161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=12037135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=161-202&author=A.+C.+Howlettauthor=F.+Barthauthor=T.+I.+Bonnerauthor=G.+Cabralauthor=P.+Casellasauthor=W.+A.+Devaneauthor=C.+C.+Felderauthor=M.+Herkenhamauthor=K.+Mackieauthor=B.+R.+Martinauthor=R.+Mechoulamauthor=R.+G.+Pertwee&title=International+Union+of+Pharmacology.+XXVII.+Classification+of+cannabinoid+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span></div><div class="casAuthors">Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-202</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Two types of cannabinoid receptor have been discovered so far, CB1 (2.1: CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993.  Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type.  Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity.  Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase.  CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels.  These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release.  Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers.  CB2 receptors are present mainly on immune cells.  Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release.  Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether.  It is unclear whether these eicosanoid mols. are the only, or primary, endogenous agonists.  Hence, the authors consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacol. Committee on Receptor Nomenclature and Drug Classification.  Although pharmacol. evidence for the existence of addnl. types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeoe-6izzgsrVg90H21EOLACvtfcHk0lhYof2wOjDm8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D&md5=4a8345d34b5724ee3cd999b71956ab54</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.161%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26aulast%3DCabral%26aufirst%3DG.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DDevane%26aufirst%3DW.%2BA.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DHerkenham%26aufirst%3DM.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXVII.%2520Classification%2520of%2520cannabinoid%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D161%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Devane, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breuer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pertwee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandelbaum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etinger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechoulam, R.</span><span> </span><span class="NLM_article-title">Isolation and structure of a brain constituent that binds to the cannabinoid receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">258</span><span class="NLM_x">, </span> <span class="NLM_fpage">1946</span><span class="NLM_x">–</span> <span class="NLM_lpage">1949</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1126%2Fscience.1470919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=1470919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADyaK3sXpvVKntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=1992&pages=1946-1949&author=W.+Devaneauthor=L.+Hanusauthor=A.+Breuerauthor=R.+Pertweeauthor=L.+Stevensonauthor=G.+Griffinauthor=D.+Gibsonauthor=A.+Mandelbaumauthor=A.+Etingerauthor=R.+Mechoulam&title=Isolation+and+structure+of+a+brain+constituent+that+binds+to+the+cannabinoid+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and structure of a brain constituent that binds to the cannabinoid receptor</span></div><div class="casAuthors">Devane, William A.; Hanus, Lumir; Breuer, Aviva; Pertwee, Roger G.; Stevenson, Lesley A.; Griffin, Graeme; Gibson, Dan; Mandelbaum, Asher; Etinger, Alexander; Mechoulam, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">258</span>
        (<span class="NLM_cas:issue">5090</span>),
    <span class="NLM_cas:pages">1946-9</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Arachidonylethanolamide, an arachidonic acid deriv. in the porcine brain, was identified as an endogenous ligand for the cannabinoid receptor.  The structure of this compd., anandamide, was detd. by mass spectrometry and NMR spectroscopy and was confirmed by synthesis.  Anandamide inhibited the specific binding of a radiolabeled cannabinoid probe to synaptosomal membranes in a manner typical of competitive ligands and produced a concn.-dependent inhibition of the elec. evoked twitch responses of the mouse vas deferens, a characteristic effect of psychotropic cannabinoids.  Anandamide may function as a natural ligand for the cannabinoid receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXqh5E4vHczbVg90H21EOLACvtfcHk0lhYof2wOjDm8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXpvVKntg%253D%253D&md5=13c7aa7316cd687240779f7f192d086b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1470919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1470919%26sid%3Dliteratum%253Aachs%26aulast%3DDevane%26aufirst%3DW.%26aulast%3DHanus%26aufirst%3DL.%26aulast%3DBreuer%26aufirst%3DA.%26aulast%3DPertwee%26aufirst%3DR.%26aulast%3DStevenson%26aufirst%3DL.%26aulast%3DGriffin%26aufirst%3DG.%26aulast%3DGibson%26aufirst%3DD.%26aulast%3DMandelbaum%26aufirst%3DA.%26aulast%3DEtinger%26aufirst%3DA.%26aulast%3DMechoulam%26aufirst%3DR.%26atitle%3DIsolation%2520and%2520structure%2520of%2520a%2520brain%2520constituent%2520that%2520binds%2520to%2520the%2520cannabinoid%2520receptor%26jtitle%3DScience%26date%3D1992%26volume%3D258%26spage%3D1946%26epage%3D1949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">Emerging strategies for exploiting cannabinoid receptor agonists as medicines</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">411</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1111%2Fj.1476-5381.2008.00048.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=19226257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2009&pages=397-411&author=R.+G.+Pertwee&title=Emerging+strategies+for+exploiting+cannabinoid+receptor+agonists+as+medicines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging strategies for exploiting cannabinoid receptor agonists as medicines</span></div><div class="casAuthors">Pertwee, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-411</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Medicines that activate cannabinoid CB1 and CB2 receptor are already in the clinic.  These are Cesamet (nabilone), Marinol (dronabinol; Δ9-tetrahydrocannabinol) and Sativex (Δ9-tetrahydrocannabinol with cannabidiol).  The first two of these medicines can be prescribed to reduce chemotherapy-induced nausea and vomiting.  Marinol can also be prescribed to stimulate appetite, while Sativex is prescribed for the symptomatic relief of neuropathic pain in adults with multiple sclerosis and as an adjunctive analgesic treatment for adult patients with advanced cancer.  One challenge now is to identify addnl. therapeutic targets for cannabinoid receptor agonists, and a no. of potential clin. applications for such agonists are mentioned in this review.  A second challenge is to develop strategies that will improve the efficacy and/or the benefit-to-risk ratio of a cannabinoid receptor agonist.  This review focuses on five strategies that have the potential to meet either or both of these objectives.  These are strategies that involve: (i) targeting cannabinoid receptors located outside the blood-brain barrier; (ii) targeting cannabinoid receptors expressed by a particular tissue; (iii) targeting up-regulated cannabinoid receptors; (iv) targeting cannabinoid CB2 receptors; or (v) 'multi-targeting'.  Preclin. data that justify addnl. research directed at evaluating the clin. importance of each of these strategies are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyRcPADOyxJLVg90H21EOLACvtfcHk0lix-ezZ0UxUVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wlsrk%253D&md5=d38ff0563eedaf74879d56e148840cb1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2008.00048.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2008.00048.x%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DEmerging%2520strategies%2520for%2520exploiting%2520cannabinoid%2520receptor%2520agonists%2520as%2520medicines%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D156%26spage%3D397%26epage%3D411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Di Marzo, V.; De Petrocellis, L.; Bisogno, T.</span><span> </span><span class="NLM_article-title">The Biosynthesis, Fate and Pharmacological Properties of Endocannabinoids</span>. In  <span class="citation_source-book">Cannabinoids. Handbook of Experimental Pharmacology</span>; <span class="NLM_contrib-group">Pertwee, R. G.</span>, Ed.; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">Heidelberg, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">168</span>, pp  <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=147-185&author=V.+Di+Marzo&author=L.+De+Petrocellis&author=T.+Bisognoauthor=R.+G.+Pertwee&title=Cannabinoids.+Handbook+of+Experimental+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DThe%2520Biosynthesis%252C%2520Fate%2520and%2520Pharmacological%2520Properties%2520of%2520Endocannabinoids%26btitle%3DCannabinoids.%2520Handbook%2520of%2520Experimental%2520Pharmacology%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26pub%3DSpringer-Verlag%26date%3D2005%26volume%3D168%26spage%3D147%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Thakur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tichkule, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajaj, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makriyannis, A.</span><span> </span><span class="NLM_article-title">Latest advances in cannabinoid receptor agonists</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1647</span><span class="NLM_x">–</span> <span class="NLM_lpage">1673</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1517%2F13543770903436505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=19939187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WhtLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1647-1673&author=G.+A.+Thakurauthor=R.+Tichkuleauthor=S.+Bajajauthor=A.+Makriyannis&title=Latest+advances+in+cannabinoid+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Latest advances in cannabinoid receptor agonists</span></div><div class="casAuthors">Thakur, Ganesh A.; Tichkule, Ritesh; Bajaj, Shama; Makriyannis, Alexandros</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1647-1673</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Since the discovery of cannabinoid receptors and their endogenous ligands in early 1990s, the endocannabinoid system has been shown to play a vital role in several pathophysiol. processes.  It has been targeted for the treatment of several diseases including neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, Huntington's disease and MS), cancer, obesity, inflammatory bowel disease, neuropathic and inflammatory pain.  The last decade has witnessed remarkable advances in the development of cannabinergic ligands displaying high selectivity and potency towards two subtypes of cannabinoid receptors, namely CB1 and CB2.  Objective: In this review, we highlight the latest advances made in the development of cannabinoid agonists and summarize recently disclosed, novel chem. scaffolds as CB-selective agonists in patents that appeared during Jan. 2008 - June 2009.  Methods: Data presented here are obtained through the search of PubMed for research articles and reviews, and the website of European patents (http://ep.espacenet.com), SciFinder Scholar and US patents (www.uspto.gov).  Conclusions: Our anal. reveals prolific patenting activity mainly in the CB2 selective agonist area.  Limiting the BBB penetrability, thereby, leading to peripherally restricted CB1/CB2 agonists and enhancing CB2-selectivity emerge as likely prerequisites for avoidance of adverse central CB1 mediated side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6PLKU_aASWLVg90H21EOLACvtfcHk0lix-ezZ0UxUVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WhtLfP&md5=7b959b5b25908fef8fe45267aaa05334</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1517%2F13543770903436505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903436505%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DTichkule%26aufirst%3DR.%26aulast%3DBajaj%26aufirst%3DS.%26aulast%3DMakriyannis%26aufirst%3DA.%26atitle%3DLatest%2520advances%2520in%2520cannabinoid%2520receptor%2520agonists%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1647%26epage%3D1673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Cheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock, S. A.</span><span> </span><span class="NLM_article-title">Targeting cannabinoid agonists for inflammatory and neuropathic pain</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">951</span><span class="NLM_x">–</span> <span class="NLM_lpage">965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1517%2F13543784.16.7.951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=17594182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVOmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=951-965&author=Y.+Chengauthor=S.+A.+Hitchcock&title=Targeting+cannabinoid+agonists+for+inflammatory+and+neuropathic+pain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cannabinoid agonists for inflammatory and neuropathic pain</span></div><div class="casAuthors">Cheng, Yuan; Hitchcock, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">951-965</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The cannabinoid receptors CB1 and CB2 are class A G-protein-coupled receptors.  It is well known that cannabinoid receptor agonists produce relief of pain in a variety of animal models by interacting with cannabinoid receptors.  CB1 receptors are located centrally and peripherally, whereas CB2 receptors are expressed primarily on immune cells and tissues.  A large body of preclin. data supports the hypothesis that either CB2-selective agonists or CB1 agonists acting at peripheral sites, or with limited CNS exposure, will inhibit pain and neuroinflammation without side effects within the CNS.  There has been a growing interest in developing cannabinoid agonists.  Many new cannabinoid ligands have been synthesized and studied covering a wide variety of novel structural scaffolds.  This review focuses on the present development of cannabinoid agonists with an emphasis on selective CB2 agonists and peripherally restricted CB1 or CB1/CB2 dual agonists for treatment of inflammatory and neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprxE9ZXlueyrVg90H21EOLACvtfcHk0lix-ezZ0UxUVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVOmsbY%253D&md5=0728e81e6981449c3ec1551703caba03</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.7.951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.7.951%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26atitle%3DTargeting%2520cannabinoid%2520agonists%2520for%2520inflammatory%2520and%2520neuropathic%2520pain%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D951%26epage%3D965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Adam, J.; Cowley, P. M.; Kiyoi, T.; Morrison, A. J.; Mort, C. J. W.</span> <span class="citation_source-book">Progress in Medicinal Chemistry</span>; <span class="NLM_contrib-group">King, F. D.; Lawton, G.</span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">44</span>, p  <span class="NLM_fpage">207</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=207&author=J.+Adam&author=P.+M.+Cowley&author=T.+Kiyoi&author=A.+J.+Morrison&author=C.+J.+W.+Mortauthor=F.+D.+King&author=G.+Lawton&title=Progress+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAdam%26aufirst%3DJ.%26btitle%3DProgress%2520in%2520Medicinal%2520Chemistry%26aulast%3DKing%26aufirst%3DF.%2BD.%26pub%3DElsevier%26date%3D2006%26volume%3D44%26spage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Lehmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackshaw, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bränden, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nygren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smid, S. D.</span><span> </span><span class="NLM_article-title">Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">1129</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2002&pages=1129-1134&author=A.+Lehmannauthor=L.+A.+Blackshawauthor=L.+Br%C3%A4ndenauthor=A.+Carlssonauthor=J.+Jensenauthor=E.+Nygrenauthor=S.+D.+Smid&title=Cannabinoid+receptor+agonism+inhibits+transient+lower+esophageal+sphincter+relaxations+and+reflux+in+dogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DA.%26aulast%3DBlackshaw%26aufirst%3DL.%2BA.%26aulast%3DBr%25C3%25A4nden%26aufirst%3DL.%26aulast%3DCarlsson%26aufirst%3DA.%26aulast%3DJensen%26aufirst%3DJ.%26aulast%3DNygren%26aufirst%3DE.%26aulast%3DSmid%26aufirst%3DS.%2BD.%26atitle%3DCannabinoid%2520receptor%2520agonism%2520inhibits%2520transient%2520lower%2520esophageal%2520sphincter%2520relaxations%2520and%2520reflux%2520in%2520dogs%26jtitle%3DGastroenterology%26date%3D2002%26volume%3D123%26spage%3D1129%26epage%3D1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Beaumont, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckxstaens, G.</span><span> </span><span class="NLM_article-title">Effect of Δ<sup>9</sup>-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1111%2Fj.1476-5381.2008.00010.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=19068079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252Fmt1ymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2009&pages=153-162&author=H.+Beaumontauthor=J.+Jensenauthor=A.+Carlssonauthor=M.+Ruthauthor=A.+Lehmannauthor=G.+Boeckxstaens&title=Effect+of+%CE%949-tetrahydrocannabinol%2C+a+cannabinoid+receptor+agonist%2C+on+the+triggering+of+transient+lower+oesophageal+sphincter+relaxations+in+dogs+and+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans</span></div><div class="casAuthors">Beaumont H; Jensen J; Carlsson A; Ruth M; Lehmann A; Boeckxstaens Ge</div><div class="citationInfo"><span class="NLM_cas:title">British journal of pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">153-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Transient lower oesophageal sphincter relaxations (TLESRs) are the main mechanism underlying gastro-oesophageal reflux and are a potential pharmacological treatment target.  We evaluated the effect of the CB(1)/CB(2) receptor agonist delta(9)-tetrahydrocannabinol (delta(9)-THC) on TLESRs in dogs.  Based on these findings, the effect of delta(9)-THC was studied in healthy volunteers.  EXPERIMENTAL APPROACH:  In dogs, manometry was used to evaluate the effect of delta(9)-THC in the presence and absence of the CB(1) receptor antagonist SR141716A on TLESRs induced by gastric distension.  Secondly, the effect of 10 and 20 mg delta(9)-THC was studied in 18 healthy volunteers in a placebo-controlled study.  Manometry was performed before and for 3 h after meal ingestion on three occasions.  KEY RESULTS:  In dogs, delta(9)-THC dose-dependently inhibited TLESRs and reduced acid reflux rate.  SR141716A significantly reversed the effects of delta(9)-THC on TLESRs.  Similarly, in healthy volunteers, delta(9)-THC significantly reduced the number of TLESRs and caused a non-significant reduction of acid reflux episodes in the first postprandial hour.  In addition, lower oesophageal sphincter pressure and swallowing were significantly reduced by delta(9)-THC.  After intake of 20 mg, half of the subjects experienced nausea and vomiting leading to premature termination of the study.  Other side-effects were hypotension, tachycardia and central effects.  CONCLUSIONS AND IMPLICATIONS:  Delta(9)-THC significantly inhibited the increase in meal-induced TLESRs and reduced spontaneous swallowing in both dogs and humans.  In humans, delta(9)-THC significantly reduced basal lower oesophageal sphincter pressure.  These findings confirm previous observations in dogs and indicate that cannabinoid receptors are also involved in the triggering of TLESRs in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyUm43wSSQ3-3MPKNEWB5RfW6udTcc2eagltZmL_AtFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252Fmt1ymtQ%253D%253D&md5=7235d6aff7533c64b9ffcf3df14f20e1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2008.00010.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2008.00010.x%26sid%3Dliteratum%253Aachs%26aulast%3DBeaumont%26aufirst%3DH.%26aulast%3DJensen%26aufirst%3DJ.%26aulast%3DCarlsson%26aufirst%3DA.%26aulast%3DRuth%26aufirst%3DM.%26aulast%3DLehmann%26aufirst%3DA.%26aulast%3DBoeckxstaens%26aufirst%3DG.%26atitle%3DEffect%2520of%2520%25CE%25949-tetrahydrocannabinol%252C%2520a%2520cannabinoid%2520receptor%2520agonist%252C%2520on%2520the%2520triggering%2520of%2520transient%2520lower%2520oesophageal%2520sphincter%2520relaxations%2520in%2520dogs%2520and%2520humans%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D156%26spage%3D153%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Mittal, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penagini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackshaw, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dent, J.</span><span> </span><span class="NLM_article-title">Transient lower esophageal sphincter relaxation</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">601</span><span class="NLM_x">–</span> <span class="NLM_lpage">610</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1995&pages=601-610&author=R.+K.+Mittalauthor=R.+H.+Hollowayauthor=R.+Penaginiauthor=L.+A.+Blackshawauthor=J.+Dent&title=Transient+lower+esophageal+sphincter+relaxation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMittal%26aufirst%3DR.%2BK.%26aulast%3DHolloway%26aufirst%3DR.%2BH.%26aulast%3DPenagini%26aufirst%3DR.%26aulast%3DBlackshaw%26aufirst%3DL.%2BA.%26aulast%3DDent%26aufirst%3DJ.%26atitle%3DTransient%2520lower%2520esophageal%2520sphincter%2520relaxation%26jtitle%3DGastroenterology%26date%3D1995%26volume%3D109%26spage%3D601%26epage%3D610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Rinaldi-Carmona, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Héaulme, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shire, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calandra, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruani, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Néliat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caput, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soubrié, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brelière, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Fur, G.</span><span> </span><span class="NLM_article-title">SR141716A, a potent and selective antagonist of the brain cannabinoid receptor</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1016%2F0014-5793%2894%2900773-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=8070571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVKjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=1994&pages=240-244&author=M.+Rinaldi-Carmonaauthor=F.+Barthauthor=M.+H%C3%A9aulmeauthor=D.+Shireauthor=B.+Calandraauthor=C.+Congyauthor=S.+Martinezauthor=J.+Maruaniauthor=G.+N%C3%A9liatauthor=D.+Caputauthor=P.+Ferraraauthor=P.+Soubri%C3%A9author=J.-C.+Breli%C3%A8reauthor=G.+Le+Fur&title=SR141716A%2C+a+potent+and+selective+antagonist+of+the+brain+cannabinoid+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">SR141716A, a potent and selective antagonist of the brain cannabinoid receptor</span></div><div class="casAuthors">Rinaldi-Carmona, Murielle; Barth, Francis; Heaulme, Michel; Shire, David; Calandra, Bernard; Congy, Christian; Martinez, Serge; Maruani, Jeanne; Neliat, Gervais; et al.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">240-4</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor.  This compd. displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor.  In vitro, SR141716A antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes.  After i.p. or oral administration, SR141716A antagonizes classical pharmacol. and behavioral effects of cannabinoid receptor agonists.  This compd. should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLJ59LaZb2cbVg90H21EOLACvtfcHk0ljogopRN4gMhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVKjsrw%253D&md5=1eebdfec28d2dde64729cddb859aa6c8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2894%2900773-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252894%252900773-X%26sid%3Dliteratum%253Aachs%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DH%25C3%25A9aulme%26aufirst%3DM.%26aulast%3DShire%26aufirst%3DD.%26aulast%3DCalandra%26aufirst%3DB.%26aulast%3DCongy%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DMaruani%26aufirst%3DJ.%26aulast%3DN%25C3%25A9liat%26aufirst%3DG.%26aulast%3DCaput%26aufirst%3DD.%26aulast%3DFerrara%26aufirst%3DP.%26aulast%3DSoubri%25C3%25A9%26aufirst%3DP.%26aulast%3DBreli%25C3%25A8re%26aufirst%3DJ.-C.%26aulast%3DLe%2BFur%26aufirst%3DG.%26atitle%3DSR141716A%252C%2520a%2520potent%2520and%2520selective%2520antagonist%2520of%2520the%2520brain%2520cannabinoid%2520receptor%26jtitle%3DFEBS%2520Lett.%26date%3D1994%26volume%3D350%26spage%3D240%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Rinaldi-Carmona., M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derocq, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casellas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oustric, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouaboula, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calandra, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shire, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brelière, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Fur, G.</span><span> </span><span class="NLM_article-title">SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">644</span><span class="NLM_x">–</span> <span class="NLM_lpage">650</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=9454810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADyaK1cXhtFWkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=1998&pages=644-650&author=M.+Rinaldi-Carmona.author=F.+Barthauthor=J.+Millanauthor=J.-M.+Derocqauthor=P.+Casellasauthor=C.+Congyauthor=D.+Oustricauthor=M.+Sarranauthor=M.+Bouaboulaauthor=B.+Calandraauthor=M.+Portierauthor=D.+Shireauthor=J.-C.+Breli%C3%A8reauthor=G.+Le+Fur&title=SR+144528%2C+the+first+potent+and+selective+antagonist+of+the+CB2+cannabinoid+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor</span></div><div class="casAuthors">Rinaldi-Carmona, Murielle; Barth, Francis; Millan, Jose; Derocq, Jean-Marie; Casellas, Pierre; Congy, Christian; Oustric, Didier; Sarran, Martine; Bouaboula, Monsif; Calandra, Bernard; Portier, Marielle; Shire, David; Breliere, Jean-Claude; Le Fur, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">644-650</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Based on both binding and functional data, this study introduces SR 144528 as the first, highly potent, selective and orally active antagonist for the CB2 receptor.  This compd. which displays subnanomolar affinity (Ki = 0.6 nM) for both the rat spleen and cloned human CB2 receptors has a 700-fold lower affinity (Ki = 400 nM) for both the rat brain and cloned human CB1 receptors.  Furthermore it shows no affinity for any of the more than 70 receptors, ion channels or enzymes investigated (IC50 > 10 μM).  In vitro, SR 144528 antagonizes the inhibitory effects of the cannabinoid receptor agonist CP 55,940 on forskolin-stimulated adenylyl cyclase activity in cell lines permanently expressing the h CB2 receptor (EC50 = 10 nM) but not in cells expressing the h CB1 (no effect at 10 μM).  Furthermore, SR 144528 is able to selectively block the mitogen-activated protein kinase activity induced by CP 55,940 in cell lines expressing h CB2 (IC50 = 39 nM) whereas in cells expressing h CB1 an IC50 value of more than 1 μM is found.  In addn., SR 144528 is shown to antagonize the stimulating effects of CP 55,940 on human tonsillar B-cell activation evoked by crosslinking of surface Igs (IC50 = 20 nM).  In vivo, after oral administration SR 144528 totally displaced the ex vivo [3H]-CP 55,940 binding to mouse spleen membranes (ED50 = 0.35 mg/kg) with a long duration of action.  In contrast, after the oral route it does not interact with the cannabinoid receptor expressed in the mouse brain (CB1).  It is expected that SR 144528 will provide a powerful tool to investigate the in vivo functions of the cannabinoid system in the immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLyEa8bHfntbVg90H21EOLACvtfcHk0ljDOIdRRfyIew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtFWkt78%253D&md5=c7ec1ad25da2567c186099934e0bb758</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRinaldi-Carmona.%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DMillan%26aufirst%3DJ.%26aulast%3DDerocq%26aufirst%3DJ.-M.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DCongy%26aufirst%3DC.%26aulast%3DOustric%26aufirst%3DD.%26aulast%3DSarran%26aufirst%3DM.%26aulast%3DBouaboula%26aufirst%3DM.%26aulast%3DCalandra%26aufirst%3DB.%26aulast%3DPortier%26aufirst%3DM.%26aulast%3DShire%26aufirst%3DD.%26aulast%3DBreli%25C3%25A8re%26aufirst%3DJ.-C.%26aulast%3DLe%2BFur%26aufirst%3DG.%26atitle%3DSR%2520144528%252C%2520the%2520first%2520potent%2520and%2520selective%2520antagonist%2520of%2520the%2520CB2%2520cannabinoid%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1998%26volume%3D284%26spage%3D644%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Lehmann, A.</span><span> </span><span class="NLM_article-title">Inhibitors of transient lower esophageal sphincter relaxations (“reflux inhibitors”) in the future treatment of GERD</span> <span class="citation_source-journal">Gastroenterol. Hepatol. Ann. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=109-117&author=A.+Lehmann&title=Inhibitors+of+transient+lower+esophageal+sphincter+relaxations+%28%E2%80%9Creflux+inhibitors%E2%80%9D%29+in+the+future+treatment+of+GERD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DA.%26atitle%3DInhibitors%2520of%2520transient%2520lower%2520esophageal%2520sphincter%2520relaxations%2520%2528%25E2%2580%259Creflux%2520inhibitors%25E2%2580%259D%2529%2520in%2520the%2520future%2520treatment%2520of%2520GERD%26jtitle%3DGastroenterol.%2520Hepatol.%2520Ann.%2520Rev.%26date%3D2006%26volume%3D1%26spage%3D109%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Rohof, W. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aronica, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troost, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckxstaens, G. E.</span><span> </span><span class="NLM_article-title">Localization of mGluR5, GABAB, GABAA, and cannabinoid receptors on the vago-vagal reflex pathway responsible for transient lower esophageal sphincter relaxation in humans: an immunohistochemical study</span> <span class="citation_source-journal">Neurogastroenterol. Motil.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">e173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1111%2Fj.1365-2982.2011.01868.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=22256945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVegsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=383-e173&author=W.+O.+Rohofauthor=E.+Aronicaauthor=H.+Beaumontauthor=D.+Troostauthor=G.+E.+Boeckxstaens&title=Localization+of+mGluR5%2C+GABAB%2C+GABAA%2C+and+cannabinoid+receptors+on+the+vago-vagal+reflex+pathway+responsible+for+transient+lower+esophageal+sphincter+relaxation+in+humans%3A+an+immunohistochemical+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of mGluR5, GABAB, GABAA, and cannabinoid receptors on the vago-vagal reflex pathway responsible for transient lower esophageal sphincter relaxation in humans: an immunohistochemical study</span></div><div class="casAuthors">Rohof, W. O.; Aronica, E.; Beaumont, H.; Troost, D.; Boeckxstaens, G. E.</div><div class="citationInfo"><span class="NLM_cas:title">Neurogastroenterology & Motility</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-391</span>CODEN:
                <span class="NLM_cas:coden">NMOTEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-1925</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background Transient lower esophageal sphincter relaxations (TLESRs) are the predominant mechanisms underlying gastro-esophageal reflux.  TLESRs are mediated by a vago-vagal reflex, which can be blocked by interaction with metabotropic Glutamate Receptor 5 (mGluR5), γ-aminobutyric acid type B (GABAB), γ-aminobutyric acid type A (GABAA), and cannabinoid (CB) receptors.  However, the distribution of these receptors in the neural pathway underlying the triggering of TLESRs has not been evaluated in humans.  Methods Using immunohistochem., we investigated the distribution of mGluR5, GABAA, GABAB, CB1, and CB2 receptors in the human nodose ganglion, the brain stem, and the myenteric plexus of the esophagus.  Key Results MGluR5, GABAB, CB1, and CB2 receptors are abundantly expressed in neurons of the myenteric plexus of the LES, nodose ganglion cell bodies and nerve fibers, the dorsal motor nucleus, and nucleus of the solitary tract in the brain stem.  GABAA receptors are expressed in the same regions except in the nodose ganglion and myenteric plexus of the LES.  Conclusions & Inferences Human mGluR5, GABAA,B, and CB1,2 receptors are abundantly expressed along the vago-vagal neural pathway and involved in the triggering of TLESRs.  These findings are not only in line with the central side effects obsd. during treatment with reflux inhibitors such as GABAB receptor agonists and mGluR5 antagonists, but also suggest that peripherally acting compds. may be effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC9PAQYJLZObVg90H21EOLACvtfcHk0ljDOIdRRfyIew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVegsbc%253D&md5=4d20eb59aafddd176939b585ac1badb3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2982.2011.01868.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2982.2011.01868.x%26sid%3Dliteratum%253Aachs%26aulast%3DRohof%26aufirst%3DW.%2BO.%26aulast%3DAronica%26aufirst%3DE.%26aulast%3DBeaumont%26aufirst%3DH.%26aulast%3DTroost%26aufirst%3DD.%26aulast%3DBoeckxstaens%26aufirst%3DG.%2BE.%26atitle%3DLocalization%2520of%2520mGluR5%252C%2520GABAB%252C%2520GABAA%252C%2520and%2520cannabinoid%2520receptors%2520on%2520the%2520vago-vagal%2520reflex%2520pathway%2520responsible%2520for%2520transient%2520lower%2520esophageal%2520sphincter%2520relaxation%2520in%2520humans%253A%2520an%2520immunohistochemical%2520study%26jtitle%3DNeurogastroenterol.%2520Motil.%26date%3D2012%26volume%3D24%26spage%3D383%26epage%3De173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Ameri, A.</span><span> </span><span class="NLM_article-title">The effects of cannabinoids on the brain</span> <span class="citation_source-journal">Prog. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1016%2FS0301-0082%2898%2900087-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=10368032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADyaK1MXjs1ejs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1999&pages=315-348&author=A.+Ameri&title=The+effects+of+cannabinoids+on+the+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of cannabinoids on the brain</span></div><div class="casAuthors">Ameri, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">315-348</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with many refs.  Cannabinoids have a long history of consumption for recreational and medical reasons.  The primary active constituent of the hemp plant Cannabis sativa is Δ9-tetrahydrocannabinol (Δ9-THC).  In humans, psychoactive cannabinoids produce euphoria, enhancement of sensory perception, tachycardia, antinociception, difficulties in concn. and impairment of memory.  The cognitive deficiencies seem to persist after withdrawal.  The toxicity of marijuana has been underestimated for a long time, since recent findings revealed Δ9-THC-induced cell death with shrinkage of neurons and DNA fragmentation in the hippocampus.  The acute effects of cannabinoids as well as the development of tolerance are mediated by G protein-coupled cannabinoid receptors.  The CB1 receptor and its splice variant CB1A, are found predominantly in the brain with highest densities in the hippocampus, cerebellum and striatum.  The CB2 receptor is found predominantly in the spleen and in hemopoietic cells and has only 44% overall nucleotide sequence identity with the CB1 receptor.  The existence of this receptor provided the mol. basis for the immunosuppressive actions of marijuana.  The CB1 receptor mediates inhibition of adenylate cyclase, inhibition of N- and P/Q-type calcium channels, stimulation of potassium channels, and activation of mitogen-activated protein kinase.  The CB2 receptor mediates inhibition of adenylate cyclase and activation of mitogen-activated protein kinase.  The discovery of endogenous cannabinoid receptor ligands, anandamide (N-arachidonylethanolamine) and 2-arachidonylglycerol made the notion of a central cannabinoid neuromodulatory system plausible.  Anandamide is released from neurons upon depolarization through a mechanism that requires calcium-dependent cleavage from a phospholipid precursor in neuronal membranes.  The release of anandamide is followed by rapid uptake into the plasma and hydrolysis by fatty-acid amidohydrolase.  The psychoactive cannabinoids increase the activity of dopaminergic neurons in the ventral tegmental area-mesolimbic pathway.  Since these dopaminergic circuits are known to play a pivotal role in mediating the reinforcing (rewarding) effects of the most drugs of abuse, the enhanced dopaminergic drive elicited by the cannabinoids is thought to underlie the reinforcing and abuse properties of marijuana.  Thus, cannabinoids share a final common neuronal action with other major drugs of abuse such as morphine, ethanol and nicotine in producing facilitation of the mesolimbic dopamine system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdPcJ7-vQg37Vg90H21EOLACvtfcHk0lhRAr9-WC-bJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjs1ejs7c%253D&md5=7ffe2ffb3c7604a4795f59aa240d260a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0301-0082%2898%2900087-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0301-0082%252898%252900087-2%26sid%3Dliteratum%253Aachs%26aulast%3DAmeri%26aufirst%3DA.%26atitle%3DThe%2520effects%2520of%2520cannabinoids%2520on%2520the%2520brain%26jtitle%3DProg.%2520Neurobiol.%26date%3D1999%26volume%3D58%26spage%3D315%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Dow, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpino, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautreau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadcock, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iredale, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly-Sullivan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lizano, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. M.</span><span> </span><span class="NLM_article-title">Design of a potent CB<sub>1</sub> receptor antagonist series: potential scaffold for peripherally-targeted agents</span> <span class="citation_source-journal">ACS Med. Chem. Lett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml3000325" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=397-401&author=R.+L.+Dowauthor=P.+A.+Carpinoauthor=D.+Gautreauauthor=J.+R.+Hadcockauthor=P.+A.+Iredaleauthor=D.+Kelly-Sullivanauthor=J.+S.+Lizanoauthor=R.+E.+O%E2%80%99Connorauthor=S.+R.+Schneiderauthor=D.+O.+Scottauthor=K.+M.+Ward&title=Design+of+a+potent+CB1+receptor+antagonist+series%3A+potential+scaffold+for+peripherally-targeted+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fml3000325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3000325%26sid%3Dliteratum%253Aachs%26aulast%3DDow%26aufirst%3DR.%2BL.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26aulast%3DGautreau%26aufirst%3DD.%26aulast%3DHadcock%26aufirst%3DJ.%2BR.%26aulast%3DIredale%26aufirst%3DP.%2BA.%26aulast%3DKelly-Sullivan%26aufirst%3DD.%26aulast%3DLizano%26aufirst%3DJ.%2BS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%2BE.%26aulast%3DSchneider%26aufirst%3DS.%2BR.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DWard%26aufirst%3DK.%2BM.%26atitle%3DDesign%2520of%2520a%2520potent%2520CB1%2520receptor%2520antagonist%2520series%253A%2520potential%2520scaffold%2520for%2520peripherally-targeted%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett%26date%3D2012%26volume%3D3%26spage%3D397%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Tam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vemuri, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bátkai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osei-Hyiaman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohnuma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambudkar, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makriyannis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">2953</span><span class="NLM_x">–</span> <span class="NLM_lpage">2966</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1172%2FJCI42551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=20664173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaiurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2010&pages=2953-2966&author=J.+Tamauthor=V.+K.+Vemuriauthor=J.+Liuauthor=S.+B%C3%A1tkaiauthor=B.+Mukhopadhyayauthor=G.+Godlewskiauthor=D.+Osei-Hyiamanauthor=S.+Ohnumaauthor=S.+V.+Ambudkarauthor=J.+Pickelauthor=A.+Makriyannisauthor=G.+Kunos&title=Peripheral+CB1+cannabinoid+receptor+blockade+improves+cardiometabolic+risk+in+mouse+models+of+obesity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity</span></div><div class="casAuthors">Tam, Joseph; Vemuri, V. Kiran; Liu, Jie; Batkai, Sandor; Mukhopadhyay, Bani; Godlewski, Grzegorz; Osei-Hyiaman, Douglas; Ohnuma, Shinobu; Ambudkar, Suresh V.; Pickel, James; Makriyannis, Alexandros; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2953-2966</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Obesity and its metabolic consequences are a major public health concern worldwide.  Obesity is assocd. with overactivity of the endocannabinoid system, which is involved in the regulation of appetite, lipogenesis, and insulin resistance.  Cannabinoid-1 receptor (CB1R) antagonists reduce body wt. and improve cardiometabolic abnormalities in exptl. and human obesity, but their therapeutic potential is limited by neuropsychiatric side effects.  Here we have demonstrated that a CB1R neutral antagonist largely restricted to the periphery does not affect behavioral responses mediated by CB1R in the brains of mice with genetic or diet-induced obesity, but it does cause wt.-independent improvements in glucose homeostasis, fatty liver, and plasma lipid profile.  These effects were due to blockade of CB1R in peripheral tissues, including the liver, as verified through the use of CB1R-deficient mice with or without transgenic expression of CB1R in the liver.  These results suggest that targeting peripheral CB1R has therapeutic potential for alleviating cardiometabolic risk in obese patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0VCuCx5tmorVg90H21EOLACvtfcHk0lhRAr9-WC-bJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaiurzM&md5=ba383f0abb4642df9843f6ee5784ecb4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1172%2FJCI42551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI42551%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DVemuri%26aufirst%3DV.%2BK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DB%25C3%25A1tkai%26aufirst%3DS.%26aulast%3DMukhopadhyay%26aufirst%3DB.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DOsei-Hyiaman%26aufirst%3DD.%26aulast%3DOhnuma%26aufirst%3DS.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DPickel%26aufirst%3DJ.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DPeripheral%2520CB1%2520cannabinoid%2520receptor%2520blockade%2520improves%2520cardiometabolic%2520risk%2520in%2520mouse%2520models%2520of%2520obesity%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2010%26volume%3D120%26spage%3D2953%26epage%3D2966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wu, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, C.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Ly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M.-S.</span><span> </span><span class="NLM_article-title">A new perspective of cannabinoid 1 receptor. Antagonists: approaches toward peripheral CB1R blockers without crossing the blood–brain barrier</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1421</span><span class="NLM_x">–</span> <span class="NLM_lpage">1429</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.2174%2F156802611795860997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=21510837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1421-1429&author=Y.-K.+Wuauthor=C.-F.+Yehauthor=Ly%2C+T.+Weiauthor=M.-S.+Hung&title=A+new+perspective+of+cannabinoid+1+receptor.+Antagonists%3A+approaches+toward+peripheral+CB1R+blockers+without+crossing+the+blood%E2%80%93brain+barrier"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier</span></div><div class="casAuthors">Wu, Yen-Ku; Yeh, Ching-Fang; Ly, Tai Wei; Hung, Ming-Shiu</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1421-1429</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since Rimonabant was withdrawn in Europe in 2008 because of its substantial CNS risk factors including depression and anxiety, the development of anti-obesity drugs targeting CB1R in the brain was suspended and/or terminated globally.  Instead, developing peripherally restricted CB1R antagonists is actively pursued in the hope that not only could they eliminate any CNS adverse effects obsd. with Rimonabant, but also maintain therapeutic benefits in metabolic syndrome, including obesity, type 2 diabetes, and non-alc. fatty liver diseases.  In this review, we summarized the most recent advances that were made on this area, with particular emphasis on various synthetic approaches, whereby the increase in polarity, water soly. and polar surface area were centralized on, toward potential peripheralacting CB1 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnL4kEb4kxBbVg90H21EOLACvtfcHk0lhRJAYDQ538xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOrtb0%253D&md5=18dec0238d7bec427e408904b69d484e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F156802611795860997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795860997%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-K.%26aulast%3DYeh%26aufirst%3DC.-F.%26aulast%3DWei%26aufirst%3DLy%252C%2BT.%26aulast%3DHung%26aufirst%3DM.-S.%26atitle%3DA%2520new%2520perspective%2520of%2520cannabinoid%25201%2520receptor.%2520Antagonists%253A%2520approaches%2520toward%2520peripheral%2520CB1R%2520blockers%2520without%2520crossing%2520the%2520blood%25E2%2580%2593brain%2520barrier%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D1421%26epage%3D1429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Fulp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortoff, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seltzman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathews, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitra, R.</span><span> </span><span class="NLM_article-title">Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2820</span><span class="NLM_x">–</span> <span class="NLM_lpage">2834</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201731z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2820-2834&author=A.+Fulpauthor=K.+Bortoffauthor=H.+Seltzmanauthor=Y.+Zhangauthor=J.+Mathewsauthor=R.+Snyderauthor=T.+Fennellauthor=R.+Maitra&title=Design+and+synthesis+of+cannabinoid+receptor+1+antagonists+for+peripheral+selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm201731z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201731z%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMathews%26aufirst%3DJ.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DFennell%26aufirst%3DT.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520cannabinoid%2520receptor%25201%2520antagonists%2520for%2520peripheral%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2820%26epage%3D2834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Cheng, Y.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pourashraf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walpole, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salois, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St-Onge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payza, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lessard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomaszewski, M. J.</span><span> </span><span class="NLM_article-title">γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1624</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1619-1624&author=Y.-X.+Chengauthor=M.+Pourashrafauthor=X.+Luoauthor=S.+Srivastavaauthor=C.+Walpoleauthor=D.+Saloisauthor=S.+St-Ongeauthor=K.+Payzaauthor=E.+Lessardauthor=X.-H.+Yuauthor=M.+J.+Tomaszewski&title=%CE%B3-Carbolines%3A+a+novel+class+of+cannabinoid+agonists+with+high+aqueous+solubility+and+restricted+CNS+penetration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.-X.%26aulast%3DPourashraf%26aufirst%3DM.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DWalpole%26aufirst%3DC.%26aulast%3DSalois%26aufirst%3DD.%26aulast%3DSt-Onge%26aufirst%3DS.%26aulast%3DPayza%26aufirst%3DK.%26aulast%3DLessard%26aufirst%3DE.%26aulast%3DYu%26aufirst%3DX.-H.%26aulast%3DTomaszewski%26aufirst%3DM.%2BJ.%26atitle%3D%25CE%25B3-Carbolines%253A%2520a%2520novel%2520class%2520of%2520cannabinoid%2520agonists%2520with%2520high%2520aqueous%2520solubility%2520and%2520restricted%2520CNS%2520penetration%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1619%26epage%3D1624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lipf8AP2D8VbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, E. H.</span><span> </span><span class="NLM_article-title">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">–</span> <span class="NLM_lpage">939</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1038%2Fnrd3287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=21119731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=929-939&author=D.+A.+Smithauthor=L.+Diauthor=E.+H.+Kerns&title=The+effect+of+plasma+protein+binding+on+in+vivo+efficacy%3A+misconceptions+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span></div><div class="casAuthors">Smith, Dennis A.; Di, Li; Kerns, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">929-939</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Data from in vitro plasma protein binding expts. that det. the fraction of protein-bound drug are frequently used in drug discovery to guide structure design and to prioritize compds. for in vivo studies.  However, we consider that these practices are usually misleading, because in vivo efficacy is detd. by the free (unbound) drug concn. surrounding the therapeutic target, not by the free drug fraction.  These practices yield no enhancement of the in vivo free drug concn.  So, decisions based on free drug fraction could result in the wrong compds. being advanced through drug discovery programs.  This Perspective provides guidance on the application of plasma protein binding information in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOa3ippodhGbVg90H21EOLACvtfcHk0lipf8AP2D8VbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI&md5=a45d00f68ab44580fa38a6acef49493a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd3287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3287%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DThe%2520effect%2520of%2520plasma%2520protein%2520binding%2520on%2520in%2520vivo%2520efficacy%253A%2520misconceptions%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D929%26epage%3D939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span> </span><span class="NLM_article-title">Strategies to optimize brain penetration in drug discovery</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">–</span> <span class="NLM_lpage">512</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=505-512&author=X.+Liuauthor=C.+Chen&title=Strategies+to+optimize+brain+penetration+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DStrategies%2520to%2520optimize%2520brain%2520penetration%2520in%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2005%26volume%3D8%26spage%3D505%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span> </span><span class="NLM_article-title">Progress in brain penetration evaluation in drug discovery and development</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">325</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1124%2Fjpet.107.130294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=18203948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVOjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2008&pages=349-356&author=X.+Liuauthor=C.+Chenauthor=B.+J.+Smith&title=Progress+in+brain+penetration+evaluation+in+drug+discovery+and+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in brain penetration evaluation in drug discovery and development</span></div><div class="casAuthors">Liu, Xingrong; Chen, Cuiping; Smith, Bill J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">349-356</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  This review discusses strategies to optimize brain penetration from the perspective of drug discovery and development.  Brain penetration kinetics can be described by the extent and time to reach brain equil.  The extent is defined as the ratio of free brain concn. to free plasma concn. at steady state.  For all central nervous system (CNS) drug discovery programs, optimization of the extent of brain penetration should focus on designing and selecting compds. having low efflux transport at the blood-brain barrier (BBB).  The time to reach brain equil. is detd. by both BBB permeability and brain tissue binding.  Rapid brain penetration can be achieved by increasing passive permeability and reducing brain tissue binding.  Although many drug transporters have been identified at the BBB, the available literature demonstrates only the in vivo functional importance of P-glycoprotein (P-gp) in limiting brain penetration of its substrates.  Drug-drug interactions mediated by P-gp at the BBB are possible due to inhibition or induction of P-gp.  For newly identified drug transporters at the BBB, more research is needed to reveal their in vivo significance.  We propose the following strategies for addressing drug transporters at the BBB.  (1) Drug discovery screens should be used to eliminate good P-gp substrates for CNS targets.  Special consideration could be given to moderate P-gp substrates as potential CNS drugs based on a high unmet medical need and the presence of a large safety margin.  (2) Selection of P-gp substrates as drug candidates for non-CNS targets can reduce their CNS-mediated side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQwQ371TauXLVg90H21EOLACvtfcHk0lg3jJ9U1W-KjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVOjsL0%253D&md5=92da2a32a86934ff108d5df6e74ce99c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.130294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.130294%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26atitle%3DProgress%2520in%2520brain%2520penetration%2520evaluation%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D325%26spage%3D349%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Hammarlun-Udenaes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridén, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syvänen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span> </span><span class="NLM_article-title">On the rate and extent of drug delivery to the brain</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1737</span><span class="NLM_x">–</span> <span class="NLM_lpage">1750</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2008&pages=1737-1750&author=M.+Hammarlun-Udenaesauthor=M.+Frid%C3%A9nauthor=S.+Syv%C3%A4nenauthor=A.+Gupta&title=On+the+rate+and+extent+of+drug+delivery+to+the+brain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHammarlun-Udenaes%26aufirst%3DM.%26aulast%3DFrid%25C3%25A9n%26aufirst%3DM.%26aulast%3DSyv%25C3%25A4nen%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DA.%26atitle%3DOn%2520the%2520rate%2520and%2520extent%2520of%2520drug%2520delivery%2520to%2520the%2520brain%26jtitle%3DPharm.%2520Res.%26date%3D2008%26volume%3D25%26spage%3D1737%26epage%3D1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edward, H., K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guy, T., C.</span><span> </span><span class="NLM_article-title">Strategies to assess blood–brain barrier penetration</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">677</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=677-687&issue=6&author=D.+Liauthor=H.%2C+K.+Edwardauthor=T.%2C+C.+Guy&title=Strategies+to+assess+blood%E2%80%93brain+barrier+penetration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DEdward%26aufirst%3DH.%252C%2BK.%26aulast%3DGuy%26aufirst%3DT.%252C%2BC.%26atitle%3DStrategies%2520to%2520assess%2520blood%25E2%2580%2593brain%2520barrier%2520penetration%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26issue%3D6%26spage%3D677%26epage%3D687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Hitchcock, S. A.</span><span> </span><span class="NLM_article-title">Structural modifications that alter the p-glycoprotein efflux properties of compounds</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4877</span><span class="NLM_x">–</span> <span class="NLM_lpage">4895</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201136z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4877-4895&author=S.+A.+Hitchcock&title=Structural+modifications+that+alter+the+p-glycoprotein+efflux+properties+of+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm201136z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201136z%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26atitle%3DStructural%2520modifications%2520that%2520alter%2520the%2520p-glycoprotein%2520efflux%2520properties%2520of%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4877%26epage%3D4895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Aller, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chittaboina, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinh, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbatsch, I. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, G.</span><span> </span><span class="NLM_article-title">Structure of p-glycoprotein reveals a molecular basis for poly-specific drug binding</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">1718</span><span class="NLM_x">–</span> <span class="NLM_lpage">1722</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1126%2Fscience.1168750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=19325113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Kgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2009&pages=1718-1722&author=S.+G.+Allerauthor=J.+Yuauthor=A.+Wardauthor=Y.+Wengauthor=S.+Chittaboinaauthor=R.+Zhuoauthor=P.+M.+Harrellauthor=Y.+T.+Trinhauthor=Q.+Zhangauthor=I.+L.+Urbatschauthor=G.+Chang&title=Structure+of+p-glycoprotein+reveals+a+molecular+basis+for+poly-specific+drug+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding</span></div><div class="casAuthors">Aller, Stephen G.; Yu, Jodie; Ward, Andrew; Weng, Yue; Chittaboina, Srinivas; Zhuo, Rupeng; Harrell, Patina M.; Trinh, Yenphuong T.; Zhang, Qinghai; Urbatsch, Ina L.; Chang, Geoffrey</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">5922</span>),
    <span class="NLM_cas:pages">1718-1722</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">P-glycoprotein (P-gp) detoxifies cells by exporting hundreds of chem. unrelated toxins but has been implicated in multidrug resistance (MDR) in the treatment of cancers.  Substrate promiscuity is a hallmark of P-gp activity, thus a structural description of poly-specific drug-binding is important for the rational design of anticancer drugs and MDR inhibitors.  The x-ray structure of apo P-gp at 3.8 angstroms reveals an internal cavity of ~6000 angstroms cubed with a 30 angstrom sepn. of the two nucleotide-binding domains.  Two addnl. P-gp structures with cyclic peptide inhibitors demonstrate distinct drug-binding sites in the internal cavity capable of stereoselectivity that is based on hydrophobic and arom. interactions.  Apo and drug-bound P-gp structures have portals open to the cytoplasm and the inner leaflet of the lipid bilayer for drug entry.  The inward-facing conformation represents an initial stage of the transport cycle that is competent for drug binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2EUmR-iQyaLVg90H21EOLACvtfcHk0lg3jJ9U1W-KjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Kgtro%253D&md5=66c7398b0257e6c05161a1afbecdafb1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1126%2Fscience.1168750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1168750%26sid%3Dliteratum%253Aachs%26aulast%3DAller%26aufirst%3DS.%2BG.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DWard%26aufirst%3DA.%26aulast%3DWeng%26aufirst%3DY.%26aulast%3DChittaboina%26aufirst%3DS.%26aulast%3DZhuo%26aufirst%3DR.%26aulast%3DHarrell%26aufirst%3DP.%2BM.%26aulast%3DTrinh%26aufirst%3DY.%2BT.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DUrbatsch%26aufirst%3DI.%2BL.%26aulast%3DChang%26aufirst%3DG.%26atitle%3DStructure%2520of%2520p-glycoprotein%2520reveals%2520a%2520molecular%2520basis%2520for%2520poly-specific%2520drug%2520binding%26jtitle%3DScience%26date%3D2009%26volume%3D323%26spage%3D1718%26epage%3D1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Uchida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsukura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terasaki, T.</span><span> </span><span class="NLM_article-title">Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">345</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1111%2Fj.1471-4159.2011.07208.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=21291474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFGhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=333-345&author=Y.+Uchidaauthor=S.+Ohtsukiauthor=Y.+Katsukuraauthor=C.+Ikedaauthor=T.+Suzukiauthor=J.+Kamiieauthor=T.+Terasaki&title=Quantitative+targeted+absolute+proteomics+of+human+blood%E2%80%93brain+barrier+transporters+and+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors</span></div><div class="casAuthors">Uchida, Yasuo; Ohtsuki, Sumio; Katsukura, Yuki; Ikeda, Chiemi; Suzuki, Takashi; Kamiie, Junichi; Terasaki, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">333-345</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We have obtained, for the first time, a quant. protein expression profile of membrane transporters and receptors in human brain microvessels, i.e., the blood-brain barrier (BBB).  Brain microvessels were isolated from brain cortexes of seven males (16-77 years old) and protein expression of 114 membrane proteins was detd. by means of a liq. chromatog.-tandem mass spectrometric quantification method using recently established in-silico peptide selection criteria.  Among drug transporters, breast cancer resistance protein showed the most abundant protein expression (8.14 fmol/μg protein), and its expression level was 1.85-fold greater in humans than in mice.  By contrast, the expression level of P-glycoprotein in humans (6.06 fmol/μg protein) was 2.33-fold smaller than that of mdr1a in mice.  The org. anion transporters reported in rodent BBB, i.e., multidrug resistance-assocd. protein, org. anion transporter and org. anion-transporting polypeptide family members, were under limit of quantification in humans, except multidrug resistance-assocd. protein 4 (0.195 fmol/μg protein).  Among detected transporters and receptors for endogenous substances, the glucose transporter 1 level was similar to that of mouse, while the L-type amino acid transporter 1 level was fivefold smaller than that of mouse.  These findings should be useful for understanding human BBB function and its differences from that in mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_2KX6pHt5F7Vg90H21EOLACvtfcHk0lh6qRIA-YzUDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFGhsr0%253D&md5=8b278a28401bea36b1ed683c205161bb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2011.07208.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2011.07208.x%26sid%3Dliteratum%253Aachs%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DOhtsuki%26aufirst%3DS.%26aulast%3DKatsukura%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DC.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DKamiie%26aufirst%3DJ.%26aulast%3DTerasaki%26aufirst%3DT.%26atitle%3DQuantitative%2520targeted%2520absolute%2520proteomics%2520of%2520human%2520blood%25E2%2580%2593brain%2520barrier%2520transporters%2520and%2520receptors%26jtitle%3DJ.%2520Neurochem.%26date%3D2011%26volume%3D117%26spage%3D333%26epage%3D345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Yee, S.</span><span> </span><span class="NLM_article-title">In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man—fact or myth</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">763</span><span class="NLM_x">–</span> <span class="NLM_lpage">766</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=763-766&author=S.+Yee&title=In+vitro+permeability+across+Caco-2+cells+%28colonic%29+can+predict+in+vivo+%28small+intestinal%29+absorption+in+man%E2%80%94fact+or+myth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYee%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520permeability%2520across%2520Caco-2%2520cells%2520%2528colonic%2529%2520can%2520predict%2520in%2520vivo%2520%2528small%2520intestinal%2529%2520absorption%2520in%2520man%25E2%2580%2594fact%2520or%2520myth%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26spage%3D763%26epage%3D766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Hilgendorf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahlin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seithel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artursson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ungell, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, J.</span><span> </span><span class="NLM_article-title">Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1340</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1124%2Fdmd.107.014902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=17496207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVKqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=1333-1340&author=C.+Hilgendorfauthor=G.+Ahlinauthor=A.+Seithelauthor=P.+Arturssonauthor=A.-L.+Ungellauthor=J.+Karlsson&title=Expression+of+thirty-six+drug+transporter+genes+in+human+intestine%2C+liver%2C+kidney%2C+and+organotypic+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines</span></div><div class="casAuthors">Hilgendorf, Constanze; Ahlin, Gustav; Seithel, Annick; Artursson, Per; Ungell, Anna-Lena; Karlsson, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1333-1340</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study was designed to quant. assess the mRNA expression of 36 important drug transporters in human jejunum, colon, liver, and kidney.  Expression of these transporters in human organs was compared with expression in commonly used cell lines (Caco-2, HepG2, and Caki-1) originating from these organs to assess their value as in vitro transporter system models, and was also compared with data obtained from the literature on expression in rat tissues to assess species differences.  Transporters that were highly expressed in the intestine included HPT1, PEPT1, BCRP, MRP2, and MDR1, whereas, in the liver, OCT1, MRP2, OATP-C, NTCP and BSEP were the main transporters.  In the kidney, OAT1 was expressed at the highest levels, followed by OAT3, OAT4, MCT5, MDR1, MRP2, OCT2, and OCTN2.  The best agreement between human tissue and the representative cell line was obsd. for human jejunum and Caco-2 cells.  Expression in liver and kidney orthol. cell lines was not correlated with that in the assocd. tissue.  Comparisons with rat transporter gene expression revealed significant species differences.  Our results allowed a comprehensive quant. comparison of drug transporter expression in human intestine, liver, and kidney.  We suggest that it would be beneficial for predictive pharmacokinetic research to focus on the most highly expressed transporters.  We hope that our comparison of rat and human tissue will help to explain the obsd. species differences in in vivo models, increase understanding of the impact of active transport processes on pharmacokinetics and distribution, and improve the quality of predictions from animal studies to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC3qvmG8tTf7Vg90H21EOLACvtfcHk0lh6qRIA-YzUDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVKqtbg%253D&md5=edfef89a8c422dbdcc0a097425b2ad2e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.014902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.014902%26sid%3Dliteratum%253Aachs%26aulast%3DHilgendorf%26aufirst%3DC.%26aulast%3DAhlin%26aufirst%3DG.%26aulast%3DSeithel%26aufirst%3DA.%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DUngell%26aufirst%3DA.-L.%26aulast%3DKarlsson%26aufirst%3DJ.%26atitle%3DExpression%2520of%2520thirty-six%2520drug%2520transporter%2520genes%2520in%2520human%2520intestine%252C%2520liver%252C%2520kidney%252C%2520and%2520organotypic%2520cell%2520lines%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D1333%26epage%3D1340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Fridén, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winiwarter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerndal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengtsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredberg, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarlund-Udenaes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonsson, M.</span><span> </span><span class="NLM_article-title">Structure–brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6233</span><span class="NLM_x">–</span> <span class="NLM_lpage">6243</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901036q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6233-6243&author=M.+Frid%C3%A9nauthor=S.+Winiwarterauthor=G.+Jerndalauthor=O.+Bengtssonauthor=H.+Wanauthor=U.+Bredbergauthor=M.+Hammarlund-Udenaesauthor=M.+Antonsson&title=Structure%E2%80%93brain+exposure+relationships+in+rat+and+human+using+a+novel+data+set+of+unbound+drug+concentrations+in+brain+interstitial+and+cerebrospinal+fluids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm901036q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901036q%26sid%3Dliteratum%253Aachs%26aulast%3DFrid%25C3%25A9n%26aufirst%3DM.%26aulast%3DWiniwarter%26aufirst%3DS.%26aulast%3DJerndal%26aufirst%3DG.%26aulast%3DBengtsson%26aufirst%3DO.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DBredberg%26aufirst%3DU.%26aulast%3DHammarlund-Udenaes%26aufirst%3DM.%26aulast%3DAntonsson%26aufirst%3DM.%26atitle%3DStructure%25E2%2580%2593brain%2520exposure%2520relationships%2520in%2520rat%2520and%2520human%2520using%2520a%2520novel%2520data%2520set%2520of%2520unbound%2520drug%2520concentrations%2520in%2520brain%2520interstitial%2520and%2520cerebrospinal%2520fluids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6233%26epage%3D6243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winiwarter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engkvist, O.</span><span> </span><span class="NLM_article-title">In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms</span> <span class="citation_source-journal">J. Mol. Graphics Modell.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">985</span><span class="NLM_x">–</span> <span class="NLM_lpage">995</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1016%2Fj.jmgm.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=21571561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2jtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=985-995&author=H.+Chenauthor=S.+Winiwarterauthor=M.+Fridenauthor=M.+Antonssonauthor=O.+Engkvist&title=In+silico+prediction+of+unbound+brain-to-plasma+concentration+ratio+using+machine+learning+algorithms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms</span></div><div class="casAuthors">Chen, Hongming; Winiwarter, Susanne; Friden, Markus; Antonsson, Madeleine; Engkvist, Ola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">985-995</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Distribution over the blood-brain barrier (BBB) is an important parameter to consider for compds. that will be synthesized in a drug discovery project.  Drugs that aim at targets in the central nervous system (CNS) must pass the BBB.  In contrast, drugs that act peripherally are often optimized to minimize the risk of CNS side effects by restricting their potential to reach the brain.  Historically, most prediction methods have focused on the total compd. distribution between the blood plasma and the brain.  However, recently it has been proposed that the unbound brain-to-plasma concn. ratio (Kp,uu,brain) is more relevant.  In the current study, quant. Kp,uu,brain prediction models have been built on a set of 173 inhouse compds. by using various machine learning algorithms.  The best model was shown to be reasonably predictive for the test set of 73 compds. (R2 = 0.58).  When used for qual. prediction the model shows an accuracy of 0.85 (Kappa = 0.68).  An addnl. external test set contg. 111 marketed CNS active drugs was also classified with the model and 89% of these drugs were correctly predicted as having high brain exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHnHw2ZkiO87Vg90H21EOLACvtfcHk0ljRclUY9fgi5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2jtLY%253D&md5=097b3d766973588dd589704ca7b428d2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.jmgm.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmgm.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWiniwarter%26aufirst%3DS.%26aulast%3DFriden%26aufirst%3DM.%26aulast%3DAntonsson%26aufirst%3DM.%26aulast%3DEngkvist%26aufirst%3DO.%26atitle%3DIn%2520silico%2520prediction%2520of%2520unbound%2520brain-to-plasma%2520concentration%2520ratio%2520using%2520machine%2520learning%2520algorithms%26jtitle%3DJ.%2520Mol.%2520Graphics%2520Modell.%26date%3D2011%26volume%3D29%26spage%3D985%26epage%3D995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Hann, M. M.</span><span> </span><span class="NLM_article-title">Molecular obesity, potency and other addictions in drug discovery</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1039%2Fc1md00017a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Kht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=349-355&author=M.+M.+Hann&title=Molecular+obesity%2C+potency+and+other+addictions+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular obesity, potency and other addictions in drug discovery</span></div><div class="casAuthors">Hann, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-355</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Despite the increase in global biol. and chem. knowledge the discovery of effective and safe new drugs seems to become harder rather than easier.  Some of this challenge is due to increasing demands for safety and novelty, but some of the risk involved in this should be controllable if we had more effectively learned from our failures.  This perspective reflects on some of the learnings of recent years in relation to the causes of attrition.  The term Mol. Obesity is introduced to describe our tendency to build potency into mols. by the inappropriate use of lipophilicity which leads to the premature demise of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSlF7TPy6fHLVg90H21EOLACvtfcHk0ljRclUY9fgi5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Kht7g%253D&md5=954870db4b1d9e846612c3bb256582f7</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fc1md00017a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1md00017a%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520obesity%252C%2520potency%2520and%2520other%2520addictions%2520in%2520drug%2520discovery%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2011%26volume%3D2%26spage%3D349%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Wager, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalobos, A.</span><span> </span><span class="NLM_article-title">Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">449</span></span><div class="citationLinks">[<a href="/doi/10.1021/cn100008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-449&author=T.+T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Moving+beyond+rules%3A+the+development+of+a+central+nervous+system+multiparameter+optimization+%28CNS+MPO%29+approach+to+enable+alignment+of+druglike+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">435-449</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The interplay among commonly used physicochem. properties in drug design was examd. and utilized to create a prospective design tool focused on the alignment of key druglike attributes.  Using a set of six physicochem. parameters ((a) lipophilicity, calcd. partition coeff. (ClogP); (b) calcd. distribution coeff. at pH = 7.4 (ClogD); (c) mol. wt. (MW); (d) topol. polar surface area (TPSA); (e) no. of hydrogen bond donors (HBD); (f) most basic center (pKa)), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compds. (N = 11 303).  The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates.  This anal. suggests that this algorithm could potentially be used to identify compds. with a higher probability of successfully testing hypotheses in the clinic.  In addn., a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set.  The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chem. design space through a holistic assessment approach.  Based on six physicochem. properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compds. with increased probability of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3Mvkgm_X5bVg90H21EOLACvtfcHk0lgmOkte0cMuFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D&md5=e94998f65a420be6ee4dec4a987cb983</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fcn100008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100008c%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DMoving%2520beyond%2520rules%253A%2520the%2520development%2520of%2520a%2520central%2520nervous%2520system%2520multiparameter%2520optimization%2520%2528CNS%2520MPO%2529%2520approach%2520to%2520enable%2520alignment%2520of%2520druglike%2520properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Yu, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martino, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puma, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morinville, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St-Onge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lessard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, J. M.</span><span> </span><span class="NLM_article-title">A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain</span> <span class="citation_source-journal">Pain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">151</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">344</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2010&pages=337-344&author=X.+H.+Yuauthor=C.+Q.+Caoauthor=G.+Martinoauthor=C.+Pumaauthor=A.+Morinvilleauthor=S.+St-Ongeauthor=E.+Lessardauthor=M.+N.+Perkinsauthor=J.+M.+Laird&title=A+peripherally+restricted+cannabinoid+receptor+agonist+produces+robust+anti-nociceptive+effects+in+rodent+models+of+inflammatory+and+neuropathic+pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DX.%2BH.%26aulast%3DCao%26aufirst%3DC.%2BQ.%26aulast%3DMartino%26aufirst%3DG.%26aulast%3DPuma%26aufirst%3DC.%26aulast%3DMorinville%26aufirst%3DA.%26aulast%3DSt-Onge%26aufirst%3DS.%26aulast%3DLessard%26aufirst%3DE.%26aulast%3DPerkins%26aufirst%3DM.%2BN.%26aulast%3DLaird%26aufirst%3DJ.%2BM.%26atitle%3DA%2520peripherally%2520restricted%2520cannabinoid%2520receptor%2520agonist%2520produces%2520robust%2520anti-nociceptive%2520effects%2520in%2520rodent%2520models%2520of%2520inflammatory%2520and%2520neuropathic%2520pain%26jtitle%3DPain%26date%3D2010%26volume%3D151%26spage%3D337%26epage%3D344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Bylund, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toews, M. L.</span><span> </span><span class="NLM_article-title">Radioligand binding methods: practical guide and tips</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">L421</span><span class="NLM_x">–</span> <span class="NLM_lpage">L429</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1993&pages=L421-L429&author=D.+B.+Bylundauthor=M.+L.+Toews&title=Radioligand+binding+methods%3A+practical+guide+and+tips"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBylund%26aufirst%3DD.%2BB.%26aulast%3DToews%26aufirst%3DM.%2BL.%26atitle%3DRadioligand%2520binding%2520methods%253A%2520practical%2520guide%2520and%2520tips%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1993%26volume%3D265%26spage%3DL421%26epage%3DL429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Strange, P.</span><span> </span><span class="NLM_article-title">Use of the GTPγS ([<sup>35</sup>S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">1238</span><span class="NLM_x">–</span> <span class="NLM_lpage">1249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1111%2Fj.1476-5381.2010.00963.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=20662841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWhsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=1238-1249&author=P.+Strange&title=Use+of+the+GTP%CE%B3S+%28%5B35S%5DGTP%CE%B3S+and+Eu-GTP%CE%B3S%29+binding+assay+for+analysis+of+ligand+potency+and+efficacy+at+G+protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors</span></div><div class="casAuthors">Strange, Philip G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1238-1249</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  In this review I consider assays for G protein-coupled receptor (GPCR) activity based on the binding of labeled analogs of GTPγS ([35S]GTPγS or Eu-GTPγS) to G proteins in tissues (GTPγS binding assays).  Such assays provide convenient measures of GPCR activity close to the receptor in the signaling cascade.  In order to set up a GTPγS binding assay, the requirements of the assay must be considered.  These are tissue source, GTPγS analog, G protein, GDP, Mg2+/Na+ ions, saponin, incubation time.  The assay, once optimized, can be used to generate concn./response curves for GPCRs signaling via Gi/o proteins (or to other G proteins with a modified assay) and actions of agonists, inverse agonists and antagonists may, in principle, be assessed.  For agonists and inverse agonists, data for the maximal agonist effect, the concn. of ligand giving a half-maximal response and the Hill coeff. may be derived.  For antagonists, data for the equil. dissocn. const. can be obtained.  The mechanistic basis of the assay is considered.  Although the assay can be used to profile ligands, under the conditions it is used, it may not be measuring the same event that dets. GPCR action in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonpFh81URvabVg90H21EOLACvtfcHk0lgmOkte0cMuFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWhsr3K&md5=8fa11a4e869eec381bae3880f4051dc2</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00963.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00963.x%26sid%3Dliteratum%253Aachs%26aulast%3DStrange%26aufirst%3DP.%26atitle%3DUse%2520of%2520the%2520GTP%25CE%25B3S%2520%2528%255B35S%255DGTP%25CE%25B3S%2520and%2520Eu-GTP%25CE%25B3S%2529%2520binding%2520assay%2520for%2520analysis%2520of%2520ligand%2520potency%2520and%2520efficacy%2520at%2520G%2520protein-coupled%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D1238%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Valkó, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bevan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D.</span><span> </span><span class="NLM_article-title">Chromatographic hydrophobicity index by fast-gradient RP-HPLC: a high-throughput alternative to log <i>P</i>/log <i>D</i></span> <span class="citation_source-journal">Anal. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">2022</span><span class="NLM_x">–</span> <span class="NLM_lpage">2029</span></span><div class="citationLinks">[<a href="/doi/10.1021/ac961242d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1997&pages=2022-2029&author=K.+Valk%C3%B3author=C.+Bevanauthor=D.+Reynolds&title=Chromatographic+hydrophobicity+index+by+fast-gradient+RP-HPLC%3A+a+high-throughput+alternative+to+log%C2%A0P%2Flog%C2%A0D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fac961242d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac961242d%26sid%3Dliteratum%253Aachs%26aulast%3DValk%25C3%25B3%26aufirst%3DK.%26aulast%3DBevan%26aufirst%3DC.%26aulast%3DReynolds%26aufirst%3DD.%26atitle%3DChromatographic%2520hydrophobicity%2520index%2520by%2520fast-gradient%2520RP-HPLC%253A%2520a%2520high-throughput%2520alternative%2520to%2520log%25C2%25A0P%252Flog%25C2%25A0D%26jtitle%3DAnal.%2520Chem.%26date%3D1997%26volume%3D69%26spage%3D2022%26epage%3D2029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Besly, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, A. A.</span><span> </span><span class="NLM_article-title">Antimalarial 2-alkoxy-6-chloro-9-dialkylaminoalkylamino-1: 10-diaza-anthracenes</span> <span class="citation_source-journal">J. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1954</span><span class="NLM_x">, </span> <span class="NLM_fpage">2448</span><span class="NLM_x">–</span> <span class="NLM_lpage">2455</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1954&pages=2448-2455&author=D.+M.+Beslyauthor=A.+A.+Goldberg&title=Antimalarial+2-alkoxy-6-chloro-9-dialkylaminoalkylamino-1%3A+10-diaza-anthracenes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBesly%26aufirst%3DD.%2BM.%26aulast%3DGoldberg%26aufirst%3DA.%2BA.%26atitle%3DAntimalarial%25202-alkoxy-6-chloro-9-dialkylaminoalkylamino-1%253A%252010-diaza-anthracenes%26jtitle%3DJ.%2520Chem.%2520Soc.%26date%3D1954%26spage%3D2448%26epage%3D2455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Mitsunobu, O.</span><span> </span><span class="NLM_article-title">The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1055%2Fs-1981-29317" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1981&pages=1-28&author=O.+Mitsunobu&title=The+use+of+diethyl+azodicarboxylate+and+triphenylphosphine+in+synthesis+and+transformation+of+natural+products"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1055%2Fs-1981-29317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1981-29317%26sid%3Dliteratum%253Aachs%26aulast%3DMitsunobu%26aufirst%3DO.%26atitle%3DThe%2520use%2520of%2520diethyl%2520azodicarboxylate%2520and%2520triphenylphosphine%2520in%2520synthesis%2520and%2520transformation%2520of%2520natural%2520products%26jtitle%3DSynthesis%26date%3D1981%26volume%3D1%26spage%3D1%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Madsen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plewe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sams, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidelmann, U. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ynddal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brand, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teston, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, J.</span><span> </span><span class="NLM_article-title">Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1<i>H</i>-indol-4-ylmethylene]hydrazide</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">5755</span><span class="NLM_x">–</span> <span class="NLM_lpage">5775</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0208572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=5755-5775&author=P.+Madsenauthor=A.+Lingauthor=M.+Pleweauthor=C.+K.+Samsauthor=L.+B.+Knudsenauthor=U.+G.+Sidelmannauthor=L.+Ynddalauthor=C.+L.+Brandauthor=B.+Andersenauthor=D.+Murphyauthor=M.+Tengauthor=L.+Truesdaleauthor=D.+Kielauthor=J.+Mayauthor=A.+Kukiauthor=S.+Shiauthor=M.+D.+Johnsonauthor=K.+A.+Testonauthor=J.+Fengauthor=J.+Lakisauthor=K.+Anderesauthor=V.+Gregorauthor=J.+Lau&title=Optimization+of+alkylidene+hydrazide+based+human+glucagon+receptor+antagonists.+Discovery+of+the+highly+potent+and+orally+available+3-cyano-4-hydroxybenzoic+acid+%5B1-%282%2C3%2C5%2C6-tetramethylbenzyl%29-1H-indol-4-ylmethylene%5Dhydrazide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm0208572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0208572%26sid%3Dliteratum%253Aachs%26aulast%3DMadsen%26aufirst%3DP.%26aulast%3DLing%26aufirst%3DA.%26aulast%3DPlewe%26aufirst%3DM.%26aulast%3DSams%26aufirst%3DC.%2BK.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DSidelmann%26aufirst%3DU.%2BG.%26aulast%3DYnddal%26aufirst%3DL.%26aulast%3DBrand%26aufirst%3DC.%2BL.%26aulast%3DAndersen%26aufirst%3DB.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DTeng%26aufirst%3DM.%26aulast%3DTruesdale%26aufirst%3DL.%26aulast%3DKiel%26aufirst%3DD.%26aulast%3DMay%26aufirst%3DJ.%26aulast%3DKuki%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DM.%2BD.%26aulast%3DTeston%26aufirst%3DK.%2BA.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DLakis%26aufirst%3DJ.%26aulast%3DAnderes%26aufirst%3DK.%26aulast%3DGregor%26aufirst%3DV.%26aulast%3DLau%26aufirst%3DJ.%26atitle%3DOptimization%2520of%2520alkylidene%2520hydrazide%2520based%2520human%2520glucagon%2520receptor%2520antagonists.%2520Discovery%2520of%2520the%2520highly%2520potent%2520and%2520orally%2520available%25203-cyano-4-hydroxybenzoic%2520acid%2520%255B1-%25282%252C3%252C5%252C6-tetramethylbenzyl%2529-1H-indol-4-ylmethylene%255Dhydrazide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D5755%26epage%3D5775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Mente, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span> </span><span class="NLM_article-title">A recursive-partitioning model for blood–brain barrier permeation</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">481</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=465-481&author=S.+R.+Menteauthor=F.+Lombardo&title=A+recursive-partitioning+model+for+blood%E2%80%93brain+barrier+permeation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMente%26aufirst%3DS.%2BR.%26aulast%3DLombardo%26aufirst%3DF.%26atitle%3DA%2520recursive-partitioning%2520model%2520for%2520blood%25E2%2580%2593brain%2520barrier%2520permeation%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2005%26volume%3D19%26spage%3D465%26epage%3D481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Mauler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittendorf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horváth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vry, J.</span><span> </span><span class="NLM_article-title">Characterization of the diarylether sulfonylester (−)-(<i>R</i>)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1124%2Fjpet.302.1.359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=12065738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1SnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2002&pages=359-368&author=F.+Maulerauthor=J.+Mittendorfauthor=E.+Horv%C3%A1thauthor=J.+de+Vry&title=Characterization+of+the+diarylether+sulfonylester+%28%E2%88%92%29-%28R%29-3-%282-hydroxymethylindanyl-4-oxy%29phenyl-4%2C4%2C4-trifluoro-1-sulfonate+%28BAY+38-7271%29+as+a+potent+cannabinoid+receptor+agonist+with+neuroprotective+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties</span></div><div class="casAuthors">Mauler, Frank; Mittendorf, Joachim; Horvath, Ervin; De Vry, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">359-368</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) is a new high-affinity cannabinoid receptor subtype 1 (CB1 receptor) ligand (Ki = 0.46-1.85 nM; rat brain, human cortex, or recombinant human CB1 receptor), structurally unrelated to any cannabinoid receptor ligand known so far.  BAY 38-7271 was characterized as a CB1 receptor agonist in 5-[γ35S]-thiophosphate triethylammonium salt binding assays using rat or human CB1 receptors.  In the rat hypothermia assay, BAY 38-7271 induced a dose-dependent redn. in body temp. (minimal ED = 6 μg/kg, i.v.); whereas in rats trained to discriminate the CB1/CB2 receptor agonist (-)-cis-3-[2-hydroxy-4(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol (CP 55,940; 0.03 mg/kg, i.p.) from vehicle, BAY 38-7271 induced complete generalization (3 μg/kg, i.v.).  In both in vivo models, a specific CB1 receptor-mediated mechanism was confirmed by demonstrating that the effects of CP 55,940 and BAY 38-7271 were blocked by pretreatment with the selective CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride.  In the rat traumatic brain injury model, BAY 38-7271 demonstrated highly potent and efficient neuroprotective properties when administered as a 4-h infusion immediately after induction of subdural hematoma (70% infarct vol. redn. at 100 ng/kg/h).  Even when applied with a 3-h delay, a significant neuroprotective efficacy could be obsd. (59% infarct vol. redn. at 300 ng/kg/h).  The neuroprotective potential of BAY 38-7271 was confirmed in a rat model of focal cerebral ischemia induced by permanent occlusion of the middle cerebral artery.  It is concluded that the CB1/CB2 receptor agonist BAY 38-7271 shows pronounced neuroprotective properties that do not result from drug-induced hypothermia and that occur in a dose range devoid of typical cannabinoid-like side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrldnCfbQNSJrVg90H21EOLACvtfcHk0lj06LgugSV46g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1SnsLs%253D&md5=cc492955592c81dc0d71f7c8ece9ac7b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fjpet.302.1.359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.302.1.359%26sid%3Dliteratum%253Aachs%26aulast%3DMauler%26aufirst%3DF.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DHorv%25C3%25A1th%26aufirst%3DE.%26aulast%3Dde%2BVry%26aufirst%3DJ.%26atitle%3DCharacterization%2520of%2520the%2520diarylether%2520sulfonylester%2520%2528%25E2%2588%2592%2529-%2528R%2529-3-%25282-hydroxymethylindanyl-4-oxy%2529phenyl-4%252C4%252C4-trifluoro-1-sulfonate%2520%2528BAY%252038-7271%2529%2520as%2520a%2520potent%2520cannabinoid%2520receptor%2520agonist%2520with%2520neuroprotective%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D302%26spage%3D359%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Fridén, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ljungqvist, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredberg, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarlund-Udenaes, M.</span><span> </span><span class="NLM_article-title">Improved measurement of drug exposure in brain using drug-specific correction for residual blood</span> <span class="citation_source-journal">J. Cereb. Blood Flow Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">150</span><span class="NLM_x">–</span> <span class="NLM_lpage">161</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1038%2Fjcbfm.2009.200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=19756019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Sg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=150-161&author=M.+Frid%C3%A9nauthor=H.+Ljungqvistauthor=B.+Middletonauthor=U.+Bredbergauthor=M.+Hammarlund-Udenaes&title=Improved+measurement+of+drug+exposure+in+brain+using+drug-specific+correction+for+residual+blood"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Improved measurement of drug exposure in the brain using drug-specific correction for residual blood</span></div><div class="casAuthors">Friden, Markus; Ljungqvist, Helena; Middleton, Brian; Bredberg, Ulf; Hammarlund-Udenaes, Margareta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cerebral Blood Flow & Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">150-161</span>CODEN:
                <span class="NLM_cas:coden">JCBMDN</span>;
        ISSN:<span class="NLM_cas:issn">0271-678X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A major challenge assocd. with the detn. of the unbound brain-to-plasma concn. ratio of a drug (Kp,uu,brain), is the error assocd. with correction for the drug in various vascular spaces of the brain, i.e., in residual blood.  The apparent brain vascular spaces of plasma water (Vwater, 10.3 μL/g brain), plasma proteins (Vprotein, 7.99 μL/g brain), and the vol. of erythrocytes (Ver, 2.13 μL/g brain) were detd. and incorporated into a novel, drug-specific correction model that took the drug-unbound fraction in the plasma (fu,p) into account.  The correction model was successfully applied for the detn. of Kp,uu,brain for indomethacin, loperamide, and moxalactam, which had potential problems assocd. with correction.  The influence on correction of the drug assocd. with erythrocytes was shown to be minimal.  Therefore, it is proposed that correction for residual blood can be performed using an effective plasma space in the brain (Veff), which is calcd. from the measured fu,p of the particular drug as well as from the ests. of Vwater and Vprotein, which are provided in this study.  Furthermore, the results highlight the value of detg. Kp,uu,brain with statistical precision to enable appropriate interpretation of brain exposure for drugs that appear to be restricted to the brain vascular spaces.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdAwudBZex47Vg90H21EOLACvtfcHk0lizU7HqpN0Ziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Sg&md5=e55b0e2ec8254fdd498061cf3a1dd015</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fjcbfm.2009.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjcbfm.2009.200%26sid%3Dliteratum%253Aachs%26aulast%3DFrid%25C3%25A9n%26aufirst%3DM.%26aulast%3DLjungqvist%26aufirst%3DH.%26aulast%3DMiddleton%26aufirst%3DB.%26aulast%3DBredberg%26aufirst%3DU.%26aulast%3DHammarlund-Udenaes%26aufirst%3DM.%26atitle%3DImproved%2520measurement%2520of%2520drug%2520exposure%2520in%2520brain%2520using%2520drug-specific%2520correction%2520for%2520residual%2520blood%26jtitle%3DJ.%2520Cereb.%2520Blood%2520Flow%2520Metab.%26date%3D2010%26volume%3D30%26spage%3D150%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Wan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, F.</span><span> </span><span class="NLM_article-title">High throughput screening of drug–protein binding in drug discovery</span> <span class="citation_source-journal">J. Liq. Chromatogr. Relat. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1080%2F10826070701190989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVOhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=681-700&author=H.+Wanauthor=F.+Bergstrom&title=High+throughput+screening+of+drug%E2%80%93protein+binding+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput screening of drug-protein binding in drug discovery</span></div><div class="casAuthors">Wan, Hong; Bergstroem, Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Liquid Chromatography & Related Technologies</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5-7</span>),
    <span class="NLM_cas:pages">681-700</span>CODEN:
                <span class="NLM_cas:coden">JLCTFC</span>;
        ISSN:<span class="NLM_cas:issn">1082-6076</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  Characterization of drug-protein binding is essential, since it has profound effects on pharmacokinetic and pharmacodynamic parameters of new chem. entities.  Although the traditional equil. dialysis method is well established and widely used for drug-protein binding measurement, this assay suffers from its low throughput.  Recent efforts were made in developing and implementing high throughput assays for drug-protein screening in drug discovery.  The present review highlights high-throughput assays, as well as potential new approaches for drug-protein binding screening in drug discovery.  These primarily include automated 96-well plate, sample pooling based equil. dialysis combined with LCMS, immobilized HSA column HPLC, and electrodriven techniques such as frontal anal. combined with capillary electrophoresis (FACE), and affinity capillary electrophoresis (ACE).  Fundamental drug-protein binding models are also discussed to (1) compare and discriminate HSA (human serum albumin) and AGP (alpha 1-acid glycoprotein) binding with regard to the whole plasma protein binding; and (2) elucidate the applicability of high throughput screening (HTS) from the viewpoint of a simplified binding model.  Some strategies and recommendations are proposed in dealing with applications of high throughput assays in different situations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_xre3PNsNMbVg90H21EOLACvtfcHk0lizU7HqpN0Ziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVOhtbg%253D&md5=5eb753c9ec9142c2a3d89a3a266dfacf</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1080%2F10826070701190989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10826070701190989%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DH.%26aulast%3DBergstrom%26aufirst%3DF.%26atitle%3DHigh%2520throughput%2520screening%2520of%2520drug%25E2%2580%2593protein%2520binding%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Liq.%2520Chromatogr.%2520Relat.%2520Technol.%26date%3D2007%26volume%3D30%26spage%3D681%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Griffen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robb, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, D. J.</span><span> </span><span class="NLM_article-title">Matched molecular pairs as a medicinal chemistry tool</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7739</span><span class="NLM_x">–</span> <span class="NLM_lpage">7750</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200452d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Wks7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7739-7750&author=E.+Griffenauthor=A.+G.+Leachauthor=G.+R.+Robbauthor=D.+J.+Warner&title=Matched+molecular+pairs+as+a+medicinal+chemistry+tool"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Matched Molecular Pairs as a Medicinal Chemistry Tool</span></div><div class="casAuthors">Griffen, Ed; Leach, Andrew G.; Robb, Graeme R.; Warner, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7739-7750</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">At the very heart of the role of a medicinal chemist or drug designer is the ability to link chem. structure to mol. properties.  This is the structure-activity relationship(SAR) or structure-property relationship(SPR).  Drug discovery projects often discover that a particular structural change causes a change to a property of interest.  The authors of this paper have been involved in developing and implementing some variations on the original theme of MMPA (matched mol. pairs anal.) and felt this to be the time to highlight some of these and to point toward future developments.  All of them are involved in the process of drug design, and it is within this context that they will set their comments.  In outline, they introduce matched mol. pair anal. and highlight why it fits so well with the kind of problem solving that is required in the process of drug design.  This will be followed by some comments concerning when the application of the methodol. is appropriate.  Then in a section intended for those with more computational interests, the authors describe the various ways that have been devised for identifying such matched pairs.  Throughout the paper, the authors have elected to use a publicly available data set to illustrate some of the comments: the ChEMBL database of inhibitors of the epidermal growth factor receptor tyrosine kinase (EGFR).  This consists of 2899 measurements of an IC50 annotated as a binding measurement on 2348 unique compds.  These measurements are drawn from a no. of sources, having been abstracted from the scientific literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMGFfO8Flm5bVg90H21EOLACvtfcHk0lizU7HqpN0Ziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Wks7jK&md5=fab3344d790d1c0ae688ec65830d9143</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm200452d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200452d%26sid%3Dliteratum%253Aachs%26aulast%3DGriffen%26aufirst%3DE.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DRobb%26aufirst%3DG.%2BR.%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26atitle%3DMatched%2520molecular%2520pairs%2520as%2520a%2520medicinal%2520chemistry%2520tool%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7739%26epage%3D7750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Lehmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremner Danielsen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flärdh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansson-Bränden, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kärrber, L.</span><span> </span><span class="NLM_article-title">Activation of the GABAB receptor inhibits transient lower esophageal sphincter relaxations in dogs</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">1147</span><span class="NLM_x">–</span> <span class="NLM_lpage">1154</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=1999&pages=1147-1154&author=A.+Lehmannauthor=M.+Antonssonauthor=M.+Bremner+Danielsenauthor=M.+Fl%C3%A4rdhauthor=L.+Hansson-Br%C3%A4ndenauthor=L.+K%C3%A4rrber&title=Activation+of+the+GABAB+receptor+inhibits+transient+lower+esophageal+sphincter+relaxations+in+dogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DA.%26aulast%3DAntonsson%26aufirst%3DM.%26aulast%3DBremner%2BDanielsen%26aufirst%3DM.%26aulast%3DFl%25C3%25A4rdh%26aufirst%3DM.%26aulast%3DHansson-Br%25C3%25A4nden%26aufirst%3DL.%26aulast%3DK%25C3%25A4rrber%26aufirst%3DL.%26atitle%3DActivation%2520of%2520the%2520GABAB%2520receptor%2520inhibits%2520transient%2520lower%2520esophageal%2520sphincter%2520relaxations%2520in%2520dogs%26jtitle%3DGastroenterology%26date%3D1999%26volume%3D117%26spage%3D1147%26epage%3D1154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Lichtman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaVecchia, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neviaser, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, B. R.</span><span> </span><span class="NLM_article-title">Effects of SR 141716A after acute or chronic cannabinoid administration in dogs</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1016%2FS0014-2999%2898%2900558-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=9797029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADyaK1cXlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=1998&pages=139-148&author=A.+H.+Lichtmanauthor=J.+L.+Wileyauthor=K.+L.+LaVecchiaauthor=S.+T.+Neviaserauthor=D.+B.+Arthurauthor=D.+M.+Wilsonauthor=B.+R.+Martin&title=Effects+of+SR+141716A+after+acute+or+chronic+cannabinoid+administration+in+dogs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of SR 141716A after acute or chronic cannabinoid administration in dogs</span></div><div class="casAuthors">Lichtman, Aron H.; Wiley, Jenny L.; LaVecchia, Kari L.; Neviaser, Scott T.; Arthur, David B.; Wilson, David M.; Martin, Billy R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">139-148</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The effects of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR 141716A), a specific cannabinoid receptor antagonist, were assessed in the dog static ataxia test after either acute treatment with two cannabinoid receptor agonists, Δ9-tetrahydrocannabinol and arachidonylethanolamide (anandamide), or chronic treatment with Δ9-tetrahydrocannabinol.  As previously reported, acute i.v. injected Δ9-tetrahydrocannabinol produced dose-dependent cannabinoid effects, including marked static ataxia, prancing, loss of muscle tone, and incoordination.  The behavioral profile of anandamide was distinctly different in that it produced a loss of muscle tone and considerable sedation with little static ataxia, prancing, or incoordination.  Despite these qual. differences between the two agonists, SR 141716A blocked the acute behavioral effects of both drugs indicating a cannabinoid receptor mechanism of action.  Interestingly, SR 141716A was able to ppt. a withdrawal syndrome in Δ9-tetrahydrocannabinol-tolerant dogs, but failed to produce any observable effects in dogs receiving chronic vehicle injections.  Acute toxicity caused by anandamide, which was not blocked by SR 141716A, precluded conducting dependence studies with this drug.  The Δ9-tetrahydrocannabinol pptd. withdrawal syndrome included diarrhea, vomiting, excessive salivation, decreases in social behavior, and increases in restless behavior and trembling.  This is the first demonstration of a pptd. withdrawal syndrome in a non-rodent species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTW---kmkGsbVg90H21EOLACvtfcHk0ljAZqmpUtjC5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlvFeltLY%253D&md5=0d5d3f06374fb12936e3bc3e86fae755</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2898%2900558-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252898%252900558-5%26sid%3Dliteratum%253Aachs%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DLaVecchia%26aufirst%3DK.%2BL.%26aulast%3DNeviaser%26aufirst%3DS.%2BT.%26aulast%3DArthur%26aufirst%3DD.%2BB.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26atitle%3DEffects%2520of%2520SR%2520141716A%2520after%2520acute%2520or%2520chronic%2520cannabinoid%2520administration%2520in%2520dogs%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1998%26volume%3D357%26spage%3D139%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Shardlow, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Generaux, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLauchlin, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pons, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skordos, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloomer, J. C.</span><span> </span><span class="NLM_article-title">Utilizing drug–drug interaction prediction tools during drug development: enhanced decision making based on clinical risk</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2076</span><span class="NLM_x">–</span> <span class="NLM_lpage">2084</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2076-2084&author=C.+E.+Shardlowauthor=G.+T.+Generauxauthor=C.+C.+MacLauchlinauthor=N.+Ponsauthor=K.+W.+Skordosauthor=J.+C.+Bloomer&title=Utilizing+drug%E2%80%93drug+interaction+prediction+tools+during+drug+development%3A+enhanced+decision+making+based+on+clinical+risk"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShardlow%26aufirst%3DC.%2BE.%26aulast%3DGeneraux%26aufirst%3DG.%2BT.%26aulast%3DMacLauchlin%26aufirst%3DC.%2BC.%26aulast%3DPons%26aufirst%3DN.%26aulast%3DSkordos%26aufirst%3DK.%2BW.%26aulast%3DBloomer%26aufirst%3DJ.%2BC.%26atitle%3DUtilizing%2520drug%25E2%2580%2593drug%2520interaction%2520prediction%2520tools%2520during%2520drug%2520development%253A%2520enhanced%2520decision%2520making%2520based%2520on%2520clinical%2520risk%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2076%26epage%3D2084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Peter, H.</span><span> </span><span class="NLM_article-title">Functional interaction of nitrogenous organic bases with cytochrome P450: a critical assessment and update of substrate features and predicted key active-site elements steering the access, binding, and orientation of amines</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1764</span><span class="NLM_x">, </span> <span class="NLM_fpage">645</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1764&publication_year=2006&pages=645-670&author=H.+Peter&title=Functional+interaction+of+nitrogenous+organic+bases+with+cytochrome+P450%3A+a+critical+assessment+and+update+of+substrate+features+and+predicted+key+active-site+elements+steering+the+access%2C+binding%2C+and+orientation+of+amines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeter%26aufirst%3DH.%26atitle%3DFunctional%2520interaction%2520of%2520nitrogenous%2520organic%2520bases%2520with%2520cytochrome%2520P450%253A%2520a%2520critical%2520assessment%2520and%2520update%2520of%2520substrate%2520features%2520and%2520predicted%2520key%2520active-site%2520elements%2520steering%2520the%2520access%252C%2520binding%252C%2520and%2520orientation%2520of%2520amines%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2006%26volume%3D1764%26spage%3D645%26epage%3D670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Redfern, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palethorpe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P. K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strang, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camm, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, T. G.</span><span> </span><span class="NLM_article-title">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=12667944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&author=W.+S.+Redfernauthor=L.+Carlssonauthor=A.+S.+Davisauthor=W.+G.+Lynchauthor=I.+MacKenzieauthor=S.+Palethorpeauthor=P.+K.+S.+Sieglauthor=I.+Strangauthor=A.+T.+Sullivanauthor=R.+Wallisauthor=A.+J.+Cammauthor=T.+G.+Hammond&title=Relationships+between+preclinical+cardiac+electrophysiology%2C+clinical+QT+interval+prolongation+and+torsade+de+pointes+for+a+broad+range+of+drugs%3A+evidence+for+a+provisional+safety+margin+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span></div><div class="casAuthors">Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discussing attempts to det. the relative value of preclin. cardiac electrophysiol. data (in vitro and in vivo) for predicting risk of torsades de pointes (TdP) in clin. use.  Published data on human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG) (or IKr) activity, cardiac action potential duration (at 90% repolarization; APD90), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.  These data were set against the free plasma concns. attained during clin. use (effective therapeutic plasma concns.; ETPCunbound).  The drugs were divided into five categories: (1) Class Ia and III antiarrhythmics; (2) withdrawn from market due to TdP; (3) measurable incidence/numerous reports of TdP in humans; (4) isolated reports of TdP in humans; (5) no reports of TdP in humans.  Data from hERG (or IKr) assays in addn. to ETPCunbound data were available for 52 drugs.  For Category 1 drugs, data for hERG/IKr IC50, APD90, QTc in animals and QTc in humans were generally close to or superimposed on the ETPCunbound values.  This relationship was uncoupled in the other categories, with more complex relationships between the data.  In Category 1 (except amiodarone), the ratios between hERG/IKr IC50 and ETPCunbound (max) ranged 0.1-31-fold.  Similar ranges were obtained for drugs in Category 2 (0.31-13-fold) and Category 3 (0.03-35-fold).  A large spread was found for Category 4 drugs (0.13-35,700-fold); this category embraced an assortment of mechanisms ranging from drugs which may well be affecting IKr currents in clin. use (e.g., sparfloxacin) to others such as nifedipine (35,700-fold) where channel block is not involved.  Finally, for the majority of Category 5 drugs there was a >30-fold sepn. between hERG/IKr activity and ETPCunbound values, with the notable exception of verapamil (1.7-fold), which is free from QT prolongation in man; this is probably explained by its multiple interactions with cardiac ion channels.  The dataset confirms the widely held belief that most drugs assocd. with TdP in humans are also assocd. with hERG K+ channel block at concns. close to or superimposed upon the free plasma concns. found in clin. use.  A 30-fold margin between Cmax and hERG IC50 may suffice for drugs currently undergoing clin. evaluation, but for future drug discovery programs, pharmaceutical companies should consider increasing this margin, particularly for drugs aimed at nondebilitating diseases.  However, interactions with multiple cardiac ion channels can either mitigate or exacerbate the prolongation of APD and QT that would ensue from block of IKr currents alone, and delay of repolarization per se is not necessarily torsadogenic.  Clearly, an integrated assessment of in vitro and in vivo data is required in order to predict the torsadogenic risk of a new candidate drug in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkpRDUH0rhyrVg90H21EOLACvtfcHk0ljAZqmpUtjC5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D&md5=a236c07febd2e05fe70e61604619bf2e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%2BS.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BS.%26aulast%3DLynch%26aufirst%3DW.%2BG.%26aulast%3DMacKenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%2BS.%26aulast%3DStrang%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DA.%2BT.%26aulast%3DWallis%26aufirst%3DR.%26aulast%3DCamm%26aufirst%3DA.%2BJ.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26atitle%3DRelationships%2520between%2520preclinical%2520cardiac%2520electrophysiology%252C%2520clinical%2520QT%2520interval%2520prolongation%2520and%2520torsade%2520de%2520pointes%2520for%2520a%2520broad%2520range%2520of%2520drugs%253A%2520evidence%2520for%2520a%2520provisional%2520safety%2520margin%2520in%2520drug%2520development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26spage%3D32%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Schroeder, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neagle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trezise, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worley, J.</span><span> </span><span class="NLM_article-title">IonWorks: a new high-throughput electrophysiology measurement platform</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm301511h&amp;key=10.1177%2F1087057102239667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm301511h&amp;key=12854998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm301511h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlSqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=50-64&author=K.+Schroederauthor=B.+Neagleauthor=D.+J.+Treziseauthor=J.+Worley&title=IonWorks%3A+a+new+high-throughput+electrophysiology+measurement+platform"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">IonWorks HT: A new high-throughput electrophysiology measurement platform</span></div><div class="casAuthors">Schroeder, Kirk; Neagle, Brad; Trezise, Derek J.; Worley, Jennings</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-64</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">To address the throughput restrictions of classical patch clamp electrophysiol., Essen Instruments has developed a plate-based electrophysiol. measurement platform.  The instrument is an integrated platform that consists of computer-controlled fluid handling, recording electronics, and processing tools capable of voltage clamp whole-cell recordings from thousands of individual cells per day.  To establish a recording, the system uses a planar, multi-well substrate (a PatchPlate).  The system effectively positions 1 cell into a hole sepg. 2 fluid compartments in each well of the substrate.  Voltage control and current recordings from the cell membrane are made subsequent to gaining access to the cell interior by applying a permeabilizing agent to the intracellular side.  Based on the multi-well design of the PatchPlate, voltage clamp recordings of up to 384 individual cells can be made in minutes and are comparable to measurements made using traditional electrophysiol. techniques.  An integrated pipetting system allows for up to 2 addns. of modulation agents.  Typical throughput, measurement fidelity, stability, and comparative pharmacol. of a recombinant voltage-dependent sodium channel (hNav1.3) and a voltage-gated potassium channel (hKv1.5) exogenously expressed in CHO cells are presented.  The IonWorks HT device can be used in biophys. and pharmacol. profiling of ion channels in an environment compatible with high-capacity screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr99MfVnFuXs7Vg90H21EOLACvtfcHk0lgDPkzWx_nB8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlSqu70%253D&md5=3a161db49dbb3c39e1db2d74e46e6bfb</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1177%2F1087057102239667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057102239667%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DK.%26aulast%3DNeagle%26aufirst%3DB.%26aulast%3DTrezise%26aufirst%3DD.%2BJ.%26aulast%3DWorley%26aufirst%3DJ.%26atitle%3DIonWorks%253A%2520a%2520new%2520high-throughput%2520electrophysiology%2520measurement%2520platform%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2003%26volume%3D8%26spage%3D50%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Tachibana, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span> </span><span class="NLM_article-title">Prediction of nonlinear intestinal absorption of CYP3A4 and p-glycoprotein substrates from their in vitro Km values</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">–</span> <span class="NLM_lpage">668</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=651-668&author=T.+Tachibanaauthor=M.+Katoauthor=Y.+Sugiyama&title=Prediction+of+nonlinear+intestinal+absorption+of+CYP3A4+and+p-glycoprotein+substrates+from+their+in+vitro+Km+values"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTachibana%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DPrediction%2520of%2520nonlinear%2520intestinal%2520absorption%2520of%2520CYP3A4%2520and%2520p-glycoprotein%2520substrates%2520from%2520their%2520in%2520vitro%2520Km%2520values%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D651%26epage%3D668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Amin, K.; Broddefalk, J.; Desfosses, H.; Evertsson, E.; Liu, Z.; Milburn, C.; Nilsson, K.; Tremblay, M.; Walpole, C.; Wei, Z.; Yang, H.</span>, WO2005115986(A1),<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Amin%2C+K.%3B+Broddefalk%2C+J.%3B+Desfosses%2C+H.%3B+Evertsson%2C+E.%3B+Liu%2C+Z.%3B+Milburn%2C+C.%3B+Nilsson%2C+K.%3B+Tremblay%2C+M.%3B+Walpole%2C+C.%3B+Wei%2C+Z.%3B+Yang%2C+H.%2C+WO2005115986%28A1%29%2C+2005."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAmin%26aufirst%3DK.%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i70"><a href="/doi/suppl/10.1021/jm301511h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_48021"></div></div></div></div></div><hr /></hr><p class="last">Experimental methods used to determine dog behavior, solubility, Caco-2 transport and efflux ratios, CYP enzyme inhibition, measurement of unbound brain exposure in the rat, <i>C</i><sub>u,br</sub>/<i>C</i><sub>u,pl</sub>, and hERG inhibition. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301511h/suppl_file/jm301511h_si_001.pdf">jm301511h_si_001.pdf (108.37 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm301511h&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-1%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm301511h" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm301511h" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799bdda38cc3c2e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
